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Dexamethasone therapy has been the backbone of myeloma treatment for the 
last few decades. Despite advances in chemotherapy, myeloma continues to 
be incurable and all patients eventually relapse with progressive disease. Cell 
adhesion mediated drug resistance and a permissive bone marrow 
microenvironment facilitates myeloma cell survival. Upto 90% of myeloma 
patients present with bone disease of varying degrees, which is a result of 
enhanced osteoclastic activity and reduced osteoblast differentiation and 
function. Dasatinib, a multi-targeted tyrosine kinase inhibitor, inhibits the Src 
family kinases, Abl kinase, c- kit and PDGFR. I hypothesised, combining 
Dasatinib with a cytotoxic agent dexamethasone; through direct antimyeloma 
effect, disruption of osteoclast cytoskeleton and adhesion of plasma cells to 
the bone marrow microenvironment, would enhance tumour sensitivity to 
steroids. 
In plasma cells, combination of Dasatinib and dexamethasone at clinically 
relevant concentrations induced apoptosis of human myeloma cell lines and 
exhibited synergy. Cell cycle analysis showed reduction in the proliferative 
compartment (G2/M) and increase in the non-viable (SubG0) population 
indicating cell death by apoptosis also confirmed by Annexin V staining. 
Dasatinib and Dexamethasone combination inhibited secretion of IL-6 in 
cocultures of fibroblastic stromal cells and plasma cells but not MIP – 1 α in 
myeloma cells.  
Dasatinib inhibited adhesion of plasma cells on Fibronectin (FN) despite 
integrin activation. This effect correlated with down regulation of Src and Abl 





stromal cells and osteoclasts. Dasatinib disrupted the organisation of actin 
cytoskeleton in osteoclasts and blocked osteoclast maturation. Similar effect 
was observed with PP2 a Src inhibitor, confirming that the effects were 
mediated at least in part through Src inhibition. This effect resulted in impaired 
osteoclast function, evidenced by reduced in vitro bone resorption. A novel in 
vitro coculture system comprising eGFP expressing MM cell lines was 
designed and validated with available methods to screen drugs when plasma 
cells were cocultured with accessory cells in the microenvironment. Using this 
system, I found the combination of dasatinib with dexamethasone overcomes 
the protective effect of fibroblastic stromal cells and osteoclasts and induces 
apoptosis of myeloma cells. I conclude that Dasatinib would overcome 
resistance of myeloma cells to dexamethasone in the presence of stromal 
cells and osteoclasts. These findings warrant exploring this drug combination 
in steroid resistant myeloma patients with extensive skeletal disease in a 


























Myeloma is an incurable neoplasm characterised by the accumulation of 
clonal plasma cells in the bone marrow accounting for approximately 1% of all 
cancers (10-15% of haematological malignancies). In the year 2000, the 
annual age-standardised incidence in South East Thames region was 7.8 per 
100,000 of the population. With a median age of onset of 73 years, Myeloma 
is predominantly a disease of the elderly 1. It was estimated that 
approximately 11,000 patients currently suffer from multiple myeloma in the 
UK, with approximately 3,000 new cases and 2,000 deaths from the disease 
each year. The recent data released by office of national statistics has 
reported 4040 new patients in the year 2007 with an annual age standardised 
incidence ( European) rate  per 100,000 population of 4.8 ( 4.7 -5.0) 2. The 
age standardised mortality rate in the year 2008 for myeloma was 2.8 (2.7-
3.0). The 5 yr overall survival (OS) rate of 33.1% (32.1 -35.0) between 2003 
and 2007, with a survival improvement of 3.5% over a one year period 3.The 
survival advantage is at least partly explained by availability of novel agents 
for treatment of myeloma which have direct cytotoxic effect on the neoplastic 
plasma cells and effects on the bone marrow microenvironment, which is 
permissive for the plasma cells to proliferate and survive. Smouldering 
myeloma is an asymptomatic plasma cell disorder associated with a high risk 
of progression to symptomatic multiple myeloma or amyloidosis. By definition 
these patients have more than 10% plasma cells in their bone marrow with no 
evidence of end organ damage.  Disease progression occurs in up to 73% of 





that the risk of progression was related to the levels of monoclonal protein and 
number of plasma cells in the bone marrow 4. Overall risk of progression 
decreases with time, 10% per year for the first 5 years, approximately 3% per  
year for the next 5 years, and 1% per year for the last 10 years in a 20 yr 
follow up period. Monoclonal gammopathy of undetermined significance 
(MGUS) is a benign pre neoplastic stage with bone marrow plasmacytosis 
less than 10% with no evidence of end organ damage. The rate of 
progression from MGUS to myeloma is 1% per year and higher in patients 
with non IgG paraproteinaemia with a high level of monoclonal protein at 
presentation and abnormal serum free light chain ratio between kappa and 
lambda light chains 5,6. Until recently, most patients were thought to present 
with denovo myeloma and a small proportion progressed from a MGUS. 
Recently, Landgren et al studied 71 myeloma patients among 77476 adults 
enrolled in prospective cancer screening trial 7. Serum protein electrophoresis, 
immunofixation, and serum Free light chain (sFLC) assays were performed on 
stored samples to determine the prevalence of MGUS. All the 71 patients who 
had developed MM had a preceding MGUS, with 3/4th of patients with a 
detectable monoclonal protein up to 8 or more years prior to the diagnosis of 
MM. Fifty percent of patients showed a longitudinal increase in monoclonal 
protein prior to the diagnosis of myeloma. Weiss and colleagues also studied 
30 patients with MM where there was serum available stored by the US 
Department of Defence Serum Repository. A preceding monoclonal 
gammopathy was detected in 27/30 patients with serial increase in 
monoclonal paraprotein and light chains in some of the patients where 





secretory myeloma where a serum or urine paraprotein was not detected has 
been significantly reduced since the availability of serum free light chain 
assay. This test has a very high sensitivity and specificity to detect differential 
monoclonal rise in light chains (normal ratio kappa: lambda – 0.26 - 1.65) as a 
marker of clonal lymphoproliferative disorder. Dispenzieri and colleagues 
described a new entity of light chain MGUS where there is absence of a IgH 
expression8. In their study, the prevalence rate of light chain MGUS was 0.8% 
with a risk of progression to myeloma of 0.3% per 100 person-years. Despite 
the risk of progression of myeloma the other significant co morbid feature is 
the development of renal disease in 23% of patients with light chain MGUS 8. 
There are no defined therapies for MGUS or smouldering myeloma which 
would arrest disease progression. On an ethical and practical note such 
therapeutic trials will be difficult to justify particularly as patients are 
asymptomatic and the primary end point of disease progression and survival 
could take several years to detect significant difference. San Miguel and 
colleagues have started treating high risk smouldering myeloma patients with 
lenalidomide and Dexamethasone in a clinical trial. Although early the drug 
has been well tolerated with some complete responses observed 9. Since the 
widespread use of recently licensed therapies thalidomide, bortezomib and 
lenalidomide, the median overall survival of patients treated upfront or at 
relapse has significantly increased 10. In the total therapy 3 protocol which is a 
dose intense protocol with thalidomide and bortezomib induction followed by 
tandem autologous transplantation, complete response rates at 24 months in 
excess of 90% were observed 11. But despite this impressive advance in 





relapsed myeloma remains an area of active investigation. There is no clear 
consensus on induction or relapse therapy, among the treating physicians. 
Majority of physicians favour the sequential use of active therapeutic agents 
with consolidation with high dose therapy. But there are trials combining active 
agents together for front line use such as Bortezomib, lenalidomide and 
dexamethasone (RVD)12 and bortezomib, lenalidomide, thalidomide and 
dexamethasone (EVOLUTION trial)13, which have yielded VGPR rates of 67% 
in a highly selected group of patients confirming significant clinical activity.  
But it remains to be seen if the responses are durable and whether these 
patients are salvaged when they progress. In the UK, where PCT funding is 
guided by NICE appraisal process, by default bortezomib is used for treatment 
of myeloma patients in first relapse and lenalidomide for subsequent relapses, 
with almost all patients treated upfront with thalidomide based therapy. 
Currently there are more than 30 agents in Phase I/II trials either alone or in 
combination for treatment of relapsed/refractory myeloma. These agents 
induce modest direct cytotoxic effect on plasma cells in vitro. Although the 
effects of these newer agents on the microenvironment are poorly delineated, 
the high response rates clearly indicate that the modulation of the marrow 
microenvironment, which supports the survival and proliferation of the 
neoplastic plasma cell clone, plays an important role. Recently clonal 
evolution resulting in drug resistance to therapies has been proposed. This is 
currently an active area of research. If this were to be proven, this would drive 
further requirement of improved therapies as the median survival of myeloma 






2.1 Evolution of disease and role of the marrow microenvironment 
Research on the role of bone marrow microenvironment in disease 
progression from MGUS/Smouldering myeloma to symptomatic myeloma is 
focussed on several major themes. Genetic events, progressive angiogenesis, 
bone disease and release of soluble factors, adhesion leading to drug 
resistance and breakdown of immune surveillance are the main areas. For 
purposes of description in this thesis, the bone marrow microenvironment 
encompasses haematopoietic and non haematopoietic cells, extracellular 







Figure 1: Description of Bone marrow compartments. The bone marrow is 
divided into cellular, non cellular and liquid compartments as listed above. 
Within the cellular compartments both cells of haemopoietic lineage and non 
haemopoietic lineage are present. The non haemopoietic cellular 
compartment is loosely termed as marrow accessory cells or cells in the 
microenvironment. Bone marrow plasma contains the cytokines listed in the 
liquid compartment of the bone marrow. CEP – circulating endothelial 
progenitors, HSC – haemopoietic stem cell, ECM- extracellular matrix, PG – 
proteoglycan, GSG – glycosaminoglycans. Adapted from Podar et al 






2.1.1 Acquired chromosomal changes and gene expression in plasma 
cells 
Progression from MGUS and asymptomatic myeloma to symptomatic 
myeloma has been an intense subject of research over the last decade. One 
of the largest cytogenetics studies, where fluorescence in situ hybridisation 
(FISH) analysis was carried out in purified bone marrow plasma cells of 1064 
patients recruited in IFM99 trials demonstrated an acquired genomic 
aberration in 90% of patients14. Kuehl and Bergsagel described the oncogenic 
events during transformation from MGUS to Myeloma. Hyperdiploidy and 
translocations causing activation of cyclin D1, cyclin D2 or cyclin D3 and 
deletion 13 are early oncogenic events. In the cells harbouring the 
translocations with activated cyclins, cyclin dysregulation makes the cells 
susceptible to proliferative stimuli and enhances interaction with stromal cells. 
Myc translocation is rare event in MGUS but more frequent in early and 
advanced myeloma with almost all human myeloma cell lines (HMCL) 
harbouring this feature (Fig.2). This observation confirms the hypothesis that 
these are secondary events. Other events such as activating mutations of  
NRAS, KRAS, FGFR3 and mutations or deletions in TP53 are secondary 
events occurring during disease progression 15.   Gene expression studies 
performed in CD138 enriched plasma cells by Shaughnessy et al, in 245 
newly diagnosed myeloma patients, identified 7 distinct subsets (Fig 3) 16. 
They are hyperdiploid sub group, proliferative signature, Low bone disease 
group, MMSET group, MAF sub group, CCND1 activation and CCND3 





expression they have classified 7 cohorts of patients, with some genomic 
subsets having significantly better event free and overall survival compared to 
others. Gene expression studies comparing normal plasma cells, MGUS and 
Myeloma plasma cells shows differential expression of genes. The Genes 
involved in cell signalling (NFkB), oncogenes (RB1), developmental genes 
(Wnt pathway) and transcription factor genes were significantly different 17. 
Although the level of cyclin expression observed in neoplastic plasma cells is 
similar to dividing B cells, myeloma cells which are fully differentiated B cells 
have a very low proliferative rate. The role of the marrow microenvironment 
providing the matrix and soluble factors necessary to drive the proliferation of 
these cells within the bone marrow and giving them a survival advantage is 
key to disease progression.  Taken together, acquired chromosomal changes 
leading to differential expression of genes is involved in progression of 






Fig 2: Genomic changes leading to disease progression: This is a model 
of sequential genomic events leading to disease progression from MGUS to 
myeloma. TLC – translocation. Adapted from Bergsagel, P. L. et al. J Clin 














Fig 3: Gene expression profiling in myeloma plasma cells: Gene 
expression analysis was performed from mRNA extracted from CD138 
selected plasma cells from 256 newly diagnosed myeloma patients. The 
image shows a two-dimensional unsupervised hierarchic cluster analysis of 
1559 highly variable genes (rows) in 256 cases (columns). Red and green 
indicate overexpressed and underexpressed genes, respectively. The sample 
dendrogram at the top and gene dendrogram to the side reflect the 
relatedness of the samples. Note that the dendrogram branches are strongly 
influenced by noticeable clusters of overexpressed genes. Subgroups G1 to 
G7, from left to right, are indicated under the dendrogram. Adapted from 









2.1.2 Increased Angiogenesis and the angiogenic switch 
Angiogenesis in the bone marrow of myeloma patients is mediated by plasma 
cells, stromal cells and endothelial cells in the microenvironment. The impact 
of angiogenesis was evidently observed when bone marrow biopsies of 
MGUS, early and advanced myeloma were stained with FVIII, a coagulation 
factor, showing significantly increased microvascular density in relapsed 
myeloma18. Vascular endothelial growth factor (VEGF) secreted by plasma 
cells acts on cognate receptors on stromal cells thereby releasing soluble 
factors driving plasma cell proliferation in  a paracrine manner 19. VEGF also 
directly acts on endothelial cells inducing proliferation and therefore 
angiogenesis. This results in enhanced survival, endothelial cell permeability 
and endothelial cell migration. A similar mechanism is suggested in 
Angiopoietin -1 and Tie -2 receptor interaction 20. Endothelial cells from 
myeloma patients cultured for long periods (MMEC) show upregulation of 
angiogenic genes and receptors, inducing an intense angiogenic response in 
chick embryo chorioallantoic membrane, in comparison to endothelial cells 
from MGUS patients 21. The process of an angiogenic switch causing 
progression from a relatively avascular phase to a vascular phase is preceded 
by losing CD45 expression on plasma cells and secretion of high levels of 
VEGF 22. It is also hypothesised that there is loss of inhibition of angiogenesis 
resulting in observed increase in microvascular density (Fig 4).  
Tumour associated macrophages secrete proangiogenic cytokines and growth 
factors and angiogenesis modulating enzymes such as metalloproteinases 23. 





plasmacytomas as has been described before24. Vacca et al have also shown 
that these macrophages in the presence of growth factors such as VEGF, 
FGF-2 can transform into phenotypic and functional endothelial cells.  
Vanderkerken et al demonstrated the importance a hypoxic bone marrow 
environment to enhance engraftment and angiogenesis. They used a hypoxia 
prodrug as proof of principle which induced apoptosis of syngeneic bone 
marrow plasma cells in 5T33 mice with reduction of tumour load 25. Finally, 
thalidomide an antiangiogenic drug significantly reduced microvascular 
density in bone marrows of responding patients, but no reduction in 
angiogenesis was observed in non responding patients 26.  In summary, 
angiogenesis is an active process linked to disease progression in myeloma. 














Fig 4: Correlation of angiogenesis with disease progression – 
Hypothesis: Increased angiogenesis is observed in marrow pf patients with 
disease progression. This image depicts the changes which lead to 
angiogenic switch from avascular to a vascular phase. VEGF- vascular 
endothelial growth factor, FGF – fibroblast growth factor , HGF – hepatocyte 
growth factor, Ang-1 – Angiopoietin -1, BMSC – bone marrow stromal cell. 














2.1.3 Breakdown of Immune surveillance in the microenvironment 
Antigenic targets of spontaneous immunity have been shown to be altered 
from MGUS to myeloma. MGUS patients mount a humoral and cellular 
immune response against SOX2 gene which is important for embryonal cell 
renewal27. Both CD4 and CD8 T cell responses were present in patients with 
MGUS but not in patients with myeloma. SOX2 expression was found in a 
CD138 neg CD19 neg compartment of bone marrow cells, and patients with 
SOX2 specific T cells had a significantly lower rate of disease progression 
compared to patients lacking the T cell response. The Idiotype protein is a 
myeloma restricted antigen but idiotype vaccinations have not induced 
significant clinical responses in myeloma patients28. Humoral and cellular 
immune response against OFD1 a centrosome related protein, which plays a 
role in Wnt and Hedgehog signalling pathway in myeloma patients, was 
detected in both MGUS and myeloma patient samples. Downregulation of 
OFD1 using siRNA in MM1S cells downregulated the proteins involved in the 
pathway29. Cancer Testis antigens are also aberrantly expressed by myeloma 
cells and are a potential immunotherapeutic target. CD4+ T cell immunity and 
cytotoxicity was observed more in MGUS than in MM patients against 
melanoma associated antigen (MAGE) positive myeloma cell lines. CD8+ 
memory T cell responses were seen exclusively in myeloma patients but 
these cells were poorly recruited into the bone marrow30.  
Increased frequency of naturally occurring functional 
CD4(+)CD25(+)FoxP3(+) T(Reg) cells in patients with MM as well as MGUS 





mechanisms through which they modulate the immune function in myeloma 
and whether they play a role in disease progression, remains unclear31. 
Expression of MIC-A and NKG2D in NK cells of myeloma patients were lower 
in comparison to MGUS patients and these findings could potentially be linked 
to disease progression32. Recent studies looking at aberrant antigen 
processing machinery in myeloma patients demonstrated reduction in 
expression of proteasome subunits and peptide transporters. RT-PCR 
experiments showed changes in antigen processing machinery at the 
transcriptional level. These results allude to antigen processing aberration as 
one of the mechanisms of impaired immune surveillance in myeloma 
patients33.  
On a more clinically relevant basis, thalidomide and lenalidomide induce 
natural killer (NK) cell activation. IMiDs induce IL-2 transcription and secretion 
by activation of PI3kinase activation which induces NK cell proliferation and 
activation34. Dhodapkar et al showed lenalidomide and dexamethasone in 
combination induced natural killer T cell (NKT) expansion and activation in 
vitro and in vivo in myeloma patients in the presence of NKT ligand. This 
serves as an alternative mechanism for NK activation 35. These observations 
and experiments show a defective immune response and defective immune 
surveillance in myeloma patients. Some of the early therapeutic results are 
encouraging and could potentially lead to immunotherapy trials either with cell 







2.2 Evolution of myeloma therapy 
The malignant plasma cells in myeloma, build up through a combination of 
increased proliferation and abnormal cell survival. Inhibition of normal cell 
death can occur in response to both intracellular and extracellular signals and 
is mediated by a complex series of cellular processes in the plasma cells. 
Conventional chemotherapy agents interfere with the synthesis of DNA or the 
process of cell division. Alkylating agents, anthracyclines and corticosteroids 
have been the mainstay of myeloma therapy until the start of this decade. 
Melphalan was the first chemotherapy agent to be used to treat myeloma and 
cyclophosphamide, a non-cross resistant alkylating agent, has also been 
shown to be effective and has the added benefit of being less myelotoxic. This 
is particularly advantageous in treating patients who have received previous 
chemotherapy and in elderly patients with reduced bone marrow reserve. 
Anthracyclines have significant cardiotoxic and myelosuppressive effects and 
were commonly used in combination with corticosteroids. The poor responses 
reported with chemotherapy are primarily due to the increased incidence of 
drug resistance that occurs with successive lines of therapy and also because 
of cumulative myelotoxicity and organ toxicity, which restricts the intensity of 
drug delivery. Dexamethasone remains an effective agent in the newly 
diagnosed and relapsed settings because it is not excreted by the kidney and 
so can be given in the face of renal impairment.  However, responses are 
short lived with a median of only 4 to 6 months in most studies.  Long term 







2.2.1 Thalidomide and its analogues (IMiDs) 
Over the last five years, three novel agents have been licensed to treat this 
disease. Thalidomide, Bortezomib and Lenalidomide were licensed on the 
back of Phase III trials recruiting significant number of patients. Thalidomide 
and its analogues and proteasomal inhibitors represent new classes of active 
drugs against myeloma in over two decades. Thalidomide role as an 
antiangiogenic agent was identified in 1994 and its activity in myeloma was 




.  Thalidomide has antiproliferative, 
proapoptotic effects on myeloma cell lines and primary cells from myeloma 
patients38. These effects were enhanced and synergistic with addition of 
dexamethasone to the cultures. Thalidomide apart from being antiangiogenic 
possesses a strong anti-inflammatory property with significant reduction in 
TNFα levels in vitro. Thalidomide also has an immunomodulatory role by 
enhancing T cell proliferation and NK cell cytolytic activity in vitro39. A large 
phase III study in newly diagnosed patients confirmed the results obtained in 
smaller phase II studies, and further demonstrated a durable response with 
improved time to disease progression40. IMiDs, thalidomide analogues with 
potent in vitro and in vivo activity, of which Lenalidomide (Revlimid®, Celgene 
Corporation) and pomalidomide (Actimid®, Celgene Corporation) are 
extensively studied and are in clinical use for myeloma. Hideshima et al and 
Davies et al in their experiments clearly demonstrated that these analogues 
have much more potent antiproliferative, proapoptotic and immunomodulatory 
effects with activation of T cell and NK cell response 38,39. Thalidomide 
analogues are also several thousand fold potent than thalidomide in reduction 





resistant myeloma cell lines in vitro, the effects on the microenvironment 
underpins its clinical activity (Fig.5). Two large Lenalidomide and 
dexamethasone (Len- Dex) trials at a median follow-up from randomisation of 
17.1 months (MM-009) and 16.5 months (MM-010), showed a significant 
improvement with Len-Dex compared to Dexamethasone in overall response 
(MM-009: 61% vs 20.5%, p<. 001; MM-010: 59.1% vs. 24%, p<. 001, 
respectively) and time to progression (TTP) (MM-009: 11.1months vs. 
4.7months, p<. 001;
 
MM-010: 11.3months vs. 4.7months, p<.001, respectively 
41,42. The immunomodulatory effects previously alluded to in the thesis makes 
lenalidomide a useful maintenance agent for the purposes of immunotherapy 
35. Lenalidomide has also been shown to inhibit osteoclastogenesis in vitro, by 
down regulation of pERK and transcription factor PU.1. The secretion of 
RANKL from stromal cells in the microenvironment is also significantly 
reduced. These effects resulted in improvement of osteoprotegerin (OPG) 
levels in patients treated with lenalidomide 43. Pomalidomide has similar 
activity and inhibits osteoclastogenesis by down regulating PU.1 a 
transcription factor affecting lineage commitment, which translated to inhibition 
of bone resorption44.  
 
2.2.2 Proteasomal Inhibition 
Bortezomib a dipeptide boronic acid is a potent, highly selective, and 
reversible proteasome inhibitor that targets 26S proteasome complex and 
inhibits its function of intracellular degradation of ubiquitinated proteins. 
Accumulation of misfolded proteins causes heat shock protein activation and 





myeloma cells including induction of apoptosis by caspase 9 activation, 
inhibition of nuclear factor-κB activation, triggering of caspase-dependent 
cleavage of gp130, down regulation of adhesion molecule expression on 
myeloma cells 
45
.  Bortezomib also down regulates adhesion receptors on BM 
stromal cells, inhibits angiogenesis and decreases secretion of survival and 
proliferative cytokines. Up to one third of patient do not respond to bortezomib 
and a proportion of patients acquire resistance by exposure to the drug. 
Resistance to bortezomib is mediated through over expression of bcl-2 and 
Hsp27 46,47. There are other possible mechanisms suggested for bortezomib 
resistance such as MCL-1 activation, high levels of IL-6, proteolytic subunit B 
mutation and activation of aggresome pathway, which is the other pathway for 
protein degradation (Fig 6).  FDA approval was based on the results of the 
APEX study showed a highly significant difference between the Bortezomib 
and High dose Dexamethasone (Dex) arms in relapsed/refractory myeloma 
patients (p<0.001) for TTP, but this only amounted to 3 months difference in 
progression free survival (PFS) between the 2 arms 48. Bortezomib inhibits 
osteoclastic activity and therefore enhances plasma cell apoptosis by 
reduction in release of soluble factors49. Bortezomib also enhances osteoblast 
differentiation through activation of beta catenin/T cell factor signalling and 
leads to  alteration in  the tumour microenvironment of myeloma patients, 
observed in bone marrow biopsies of treated patients and elevation of serum 
markers of bone formation50 51. Bortezomib also regulates osteogenesis via 
the induction of BMP-2 expression, increasing Runx2 transcriptional activity 
and stabilization of Runx2 protein52. Carfilzomib a new irreversible 





myeloma cells, chymotrypsin like inhibition alone was sufficient to induce 
proapoptotic effect, including proteasome substrate accumulation, Noxa and 
caspase 3/7 induction, and phospho-eIF2alpha suppression53. Carfilzomib 
has shown significant activity in Phase I/II clinical trials in relapsed/refractory 
myeloma patients. 
Although the response rates of relapsed myeloma patients to these novel 
agents is much higher compared to historical data, patients are still not cured 
and eventually progress. These agents when used in frontline treatment of 
myeloma induce much higher response rates but whether this would translate 
into longer progression free survival remains to be seen. It has become 
obvious, that bone marrow microenvironment supports survival of myeloma 
plasma cells and therapies targeting the plasma cell clone and  the bone 
marrow stromal/MM interaction are effective in relapsed disease 54. Despite 
these effective new agents, there is still a clearly unmet medical need for 
















Fig 5: Effects of Thalidomide and thalidomide analogues (IMiDs) on the 
myeloma microenvironment. Thalidomide and thalidomide analogues apart 
from direct effects on tumour cell also modify the microenvironment by its 
effects on stromal cells and angiogenesis in the marrow. Adapted from Quach 
















Fig 6:  Mechanisms of bortezomib resistance. Bortezomib a proteasomal 
inhibitor is effective in a majority of myeloma patients. This cartoon depicts the 
intracellular changes leading to resistance to therapy. Adapted from Kumar, S. 
















2.3 Primary and acquired resistance in myeloma 
Primary resistance to therapy is exhibited as either lack of or suboptimal 
response to therapy. Patients relapsing from previous therapy also exhibit 
features of acquired resistance which determines long term survival in these 
patients. Therapy sensitivity is restored in some patients through synergistic 
drug combination with targeted action eg; bortezomib. Expression of drug 
resistance proteins such as P- glycoprotein, which plays an important role in 
leukaemia survival have been shown to play an important role in 
chemotherapy resistance observed in myeloma. Soluble mediators and 
accessory cells in the microenvironment mediate resistance particularly in the 
relapsed/refractory patients. 
 
2.3.1 Genomic aberrations and primary resistance 
Cytogenetic aberrations up regulate oncogenes or down regulate proapoptotic 
genes resulting in the resistant phenotype observed in some subsets of 
myeloma. Acquired genomic abnormalities have been identified both in MGUS 
and in MM patients. Up to 90% of patients have a cytogenetic abnormality in 
purified myeloma cells obtained from bone marrow FISH14. The commonly 
observed del 13 cytogenetic abnormality is detected in up to 50% of patients 
on interphase FISH. Detection of del 13 abnormalities can be made by 
conventional cytogenetics, metaphase FISH and interphase FISH. Presence 
of del 13 detected by conventional cytogenetics is clearly linked with poor 
prognosis but not by interphase FISH55. Prior to the availability of IMiDs and 
proteasomal inhibitors, patients treated with combination chemotherapy and 





survival if they lacked del 13 abnormality on cytogenetics56. In patients 
recruited in IFM99 trials, the presence of t (4:14), and del (17p) abnormalities 
on interphase FISH were independently associated with poor event free and 
overall survival
14
. In a sub analysis from the Bortezomib trials the drug 
appears to overcome the poor prognosis conferred by del 1357. Data now 
available on patients treated with bortezomib and lenalidomide and the 
combination in the form a Total Therapy 3 trial approach show responses in 
patients carrying high risk cytogenetic features
11
. But it still remains to be 
seen if these patients progress early after therapy. In patients with high risk 
cytogenetics58, transactivation of oncogenic kinases or oncogenes such as 
FGFR3, Myc, NRAS, KRAS and dysregulation of cyclin dependent kinases 
gives cell a proliferative advantage leading to poor response to therapy and 
early disease progression. It is also hypothesised that patients who progress 
after prior therapy continue to develop further genomic abnormalities due to 
survival benefit exhibited by the clone. But there is a school of thought that 
apart from TP53 deletion further genomic changes at disease relapses is rare. 
This will probably be better addressed by performing single nucleotide 
polymorphism arrays (SNP array) analysis in relapsed patients, to see if 
further genetic events are acquired with disease progression.  
 
2.3.2 Therapy induced resistance 
Expression of MDR1 and its 170-kDa protein product, P-glycoprotein (P-gp), 
also designated as adenosine triphosphate (ATP)-binding cassette (ABC) 
transporter B1 (ABCB1) modulates response to chemotherapy. P-gp is a 





for chemotherapeutic drugs. Recent data also shows that C3435T 
polymorphism of MDR1 influences response to treatment and hence overall 
survival in uniformly treated myeloma patients59.  Bortezomib sensitivity in 
cancer cell lines is regulated by P-gp and MDR1 as evidenced by greater 
inhibition of the proteasome when the proteins were downregulated with 
siRNA. Up to one-third of myeloma patients are resistant to up front 
bortezomib therapy. Although other mechanisms are reported in literature, 
MDR1 up regulation could be a significant factor in relapsed myeloma 
patients.  Expression of P-gp is significantly increased in relapsed myeloma 
patients and is associated with resistance to doxorubicin60.  Addition of 
verapamil and cyclosporin to modulate P-gp expression in patients on 
myeloma therapy has shown little clinical benefit, with potential additive 
toxicity61. Therapy resistance may also be mediated by other multidrug 
resistance proteins. Multidrug-resistance associated protein, also known as 
ATP-binding cassette, subfamily C, member 1 (MRP1, or ABCC1) is also 
expressed in myeloma cells.  LRP (lung resistance protein) is present in 
myeloma cells of newly diagnosed patients. Response to melphalan therapy is 
lower in myeloma patients with LRP expression compared to those who have 
no LRP expression62.  Taken together, expression of MRD1, MRP1 and LRP 
play an important role in mediating response to therapeutic agents. Newer 









2.3.3 Resistance to glucocorticoid therapy 
Glucocorticoids have been the mainstay of treatment for myeloma for a 
number of years. High dose dexamethasone remains a standard comparator 
in major phase III trials. Brisk early responses are seen with steroids which is 
particularly useful when patients present with cord compression or renal 
failure. Over the course of their disease, myeloma patients become resistant 
and refractory to glucocorticoids. Glucocorticoid resistance in myeloma has 
been shown to be due to post receptor defects in the downstream signalling 
pathways. Recent data also suggests that decrease in expression of isoform 
of glucocorticoid receptor, GR alpha can mediate resistance in myeloma cell 
lines 63.  A recent study investigated if epigenetic modification of DNA 
correlated with dexamethasone resistance in a human myeloma cell line  
OPM1.  Epigenetic inactivation of RASD1 which encodes a ras family protein 
was found to be correlated with dexamethasone resistance64. Although 
glucocorticoid induced changes within the plasma cell has been well studied, 
changes in the microenvironment is less well understood.  
 
2.3.4 Role of microenvironment in induction of drug resistance 
Homing of tumour cells to the bone marrow through the SDF-1/CXCR4 
signalling pathway plays an important role in creating protective niches for 
plasma cell survival within the bone marrow65. Bone marrow is a rich source 
of cytokines and growth factors required for survival and proliferation of 
progenitor haematopoietic cells, which is utilised by neoplastic tumour cells 





factor for multiple myeloma cells and induces STAT3 signalling that confers 
protection from Fas-mediated apoptosis by up-regulating the antiapoptotic 
protein Bcl-XL in myeloma cells66. Primary samples producing IL-6 were found 
to be resistant to both spontaneous and dexamethasone induced apoptosis, 
whereas non–IL-6 secreting clones were sensitive67. Monoclonal antibody 
CNTO-328 directed against IL-6 receptor showed blockage of IL-6 signalling 
in myeloma cell lines and increased their sensitivity to bortezomib68. This 
observation is currently being studied in a prospective randomised clinical 
trial. Bone marrow stromal cells produce high levels of IL-6 and paracrine 
interaction of myeloma cells with stromal cells through soluble intermediaries 
enhances the secretion of growth factors by both cell types. Primary myeloma 
cells also produce vascular endothelial growth factor and fibroblast growth 
factor which, in turn, stimulates IL-6 production by stromal cells. Adhesion of 
myeloma cells in the microenvironment also induces acquired resistance 
against chemotherapeutic agents. This is discussed in detail in section 2.4. 
Osteoclasts are activated by cytokines released by stromal cells and plasma 
cells. The role of osteoclasts in promoting the survival and proliferation of 
plasma cells in patient samples has been elegantly described by two groups. 
This effect requires cell-cell contact between plasma cells and osteoclasts 
49,69. These features put together demonstrate that there are multiple factors 
governing resistance in myeloma cells. Some of the factors are intrinsic to the 
property of tumour cells and modulated through exposure to drugs but 
resistance is also mediated by accessory cells in the marrow and soluble 





relapse of disease when patients are followed up, and the biological nature of 




























2.4 Myeloma cell adhesion and cell adhesion mediated drug resistance 
(CAM-DR) 
Tissue formation in normal physiology requires cell adhesion. There are two 
types of cell adhesion, cell-cell adhesion and cell – extra cellular matrix (ECM) 
adhesion. Tight junctions, Adherens junctions and desmosomes are the three 
types of junctions which mediate adhesion between epithelial cells. Cell 
adhesion involves membrane anchors, transmembrane receptors, 
extracellular ligands and cytoskeketal components. Cadherins, 
transmembrane receptors constitute a large family of glycoproteins comprising 
an extracellular domain responsible for cell-cell interactions, a transmembrane 
domain, and a cytoplasmic domain that frequently is linked to the actin 
cytoskeleton. Cadherins are found in both adherens junction and 
desmosomes and play a key role in calcium-dependent cell-cell interaction 70. 
Cell–matrix contacts are specialised zones at the cell surface, where activated 
or clustered adhesion receptors bind to their ECM ligands and link 
intracellularly to components of the cytoskeleton. Cell-matrix contacts can 
exist as focal complexes, podosomes, focal adhesions, fibrillar adhesions, 
three dimensional matrix adhesions and hemidesmosomes. Best 
characterised of these are the focal adhesions71. There are five classes of cell 
adhesion molecules (CAM) – integrins, cadherins, immunoglobulin-like CAMs, 
selectins and proteoglycans. They have all been shown to be deregulated in 
human cancer. Integrins and syndecan-1/CD138 are the principal myeloma 
receptor systems of extracellular matrix components, as well as of surface 
molecules of stromal cells. CD44 and receptor for hyaluronan-mediated 









Fig 7: Myeloma cell adhesion and signalling pathways. Myeloma cell 
interacts with the microenvironment through different sets of adhesion 
molecules as shown here leading to activation of intracellular pathways. 












2.4.1 Integrin mediated adhesion 
Integrin class of cell adhesion molecules are α/β heterodimeric glycoprotein 
receptors that regulate cellular processes such as cell migration, phagocytosis 
and growth and development. Integrins recognise extracellular matrix proteins 
and cognate receptors on other cells and following ligand binding can activate 
or contribute to the same cellular signalling pathways that are regulated by 
growth factor receptors. They are always composed of two subunits, α and β. 
To date 18 α and 8 β subunit isoforms forming 24 combinations have been 
identified. Each α β combination has its own binding specificity and signalling 
properties. A specific ECM molecule can nevertheless be bound by different 
types of integrins, and specific integrins can bind to different types of ECM 
molecules. Integrin-mediated adhesion to ECM ligands such as fibronectin, 
collagen, vitronectin, osteopontin and laminin is mediated by recognition of 
arginine – glycine - aspartic acid (RGD) motifs in these proteins 73. Integrins 
can signal bidirectionally; interaction with ligand/external stimuli to induce 
intracellular changes (outside-in signalling) and intracellular stimuli can also 
cause extracellular changes (inside-out signalling). Integrin activation 
increases the affinity of individual integrins for ECM ligands, to bind strongly to 
ECM requires increasing the avidity of the interaction by clustering integrins 
(Fig.8) 74. In myeloma, adhesion of plasma cells to extracellular matrix 
proteins such as fibronectin, laminin, collagen and oseopontin in the 
microenvironment is mediated by integrins. Integrins are also important in the 
tumour pathogenesis of myeloma and surface expression of cell adhesion 
molecules analysed by flow cytometry varies between progressive disease 





that CD49d and CD49f expression is significantly higher in plasma cells 
present in the bone marrow compared to being in a solitary bone location76.  
α5 β1 integrin (CD49e or VLA-5) and α4 β1 integrin (CD49d or VLA-4) interact 
with fibronectin. Both are expressed in both normal and malignant plasma 
cells 77. Cytokines such as TNFα, Hepatocyte growth factor (HGF), Insulin 
growth factor -1(IGF-1) increased in bone marrow plasma of these patients 
activate integrins. αEβ7 mediates adhesion of plasma cells on stromal cells 
interacting with E-cadherin 
78. αvβ3 integrin is over expressed in patient with 
skeletal disease and is thought to mediate osteoclast activation by interacting 
with vitronectin and fibronectin 79. Engagement of integrins with their ligands 
such as vascular cell adhesion molecule-1 induces signalling critical for the 
regulation of proliferation, migration, and survival of normal haematopoietic 
and epithelial cells. Talin a cytoskeletal protein plays a central role in integrin 
activation by interacting with β integrin tail. Members of kindlin family are also 
involved in activation of integrins 80.  Integrin activation leads to 
conformational change, clustering and recruitment of other cytoskeletal 
proteins such as paxillin and vinculin. Focal Adhesion Kinase (FAK) generates 
docking sites for SH2-domain-containing proteins; including Src kinases, 
which in turn become activated and phosphorylate FAK. This leads to 
downstream activation of Ras/Raf/MAPK signalling pathways. Taken together, 
integrins play an important role on adhesion of plasma cells to the 







Fig 8: Integrin affinity, clustering and LFA-1. Integrin state, level of affinity 
and activation leading to clustering is shown in panel A. Panel B shows 
structure of LFA-1 (lymphocyte function associated antigen -1 ) which is a 
dimer of α and β chains. ICAM – Intercellular adhesion molecule, RAPL – 
GTPase RAP1 effector). Adapted from Kinashi et al Nat Rev Immunol  5, 546-
















2.4.2 Heparan sulphate proteoglycans and CD44 mediated adhesion 
CD138, syndecan -1 is a specific marker for plasma cells. Syndecan is a 
transmembrane heparan sulphate proteoglycan (heavily glycosylated 
glycoprotein) which can be shed in the marrow microenvironment and also 
when cells are manipulated ex vivo. Syndecans act as receptors for ECM 
proteins and for growth factors. They engage through the large flexible 
glycosaminoglycan chains that make them ideal receptors for ligands that are 
distant from the membrane. The short cytoplasmic domains can be subdivided 
into two conserved regions  that bind Src/Fyn Tyr kinase complexes and PDZ-
domain-containing proteins, respectively, and a central variable region 83. 
Focal adhesion formation when cells are plated on fibronectin is dependent on 
integrin engagement and cooperation with a cell surface proteoglycan like 
syndecan. It is also thought that Syndecan -1 cooperates with αvβ3   integrin 
and causes pathological neovascularisation. This could be linked with the 
increased microvascular density observed in these patients with relapsed 
myeloma with significant bone marrow plasmacytosis. The presence of 
heparanase in the microenvironment cleaves and activates the shed heparan 
sulphate releasing sequestered growth factors and triggering clustering of 
syndecan (activation) and promoting tumour growth. Yang and colleagues 
tested three different methods to down regulate syndecan-1 (CD138) effects; 
by adding heparinase, down regulating heparanase and an antibody targeting 
syndecan-1. All these strategies down regulated syndecan expression and led 
to tumour regression in vivo in a mouse model 84. Antibodies against 
syndecan-1 expressed on myeloma cells by a conjugate of cytotoxic 





myeloma cells, and blocked adhesion of myeloma cells to marrow stromal 
cells and induced tumour regression in vivo in SCID–Hu mice. Heparanase 
expression can also be down regulated by Defibrotide a polydispersible 
oligonucleotide, which has very little cytotoxic activity on myeloma cell lines in 
vitro. But in mouse models, defibrotide sensitised myeloma cells to other 
cytotoxics, reduced adhesion and angiogenesis leading to tumour 
regression85.  
CD44 splice variants, RHAMM and CD168 are receptors for the abundant 
amount of hyaluronan present in the microenvironment produced by stromal 
cells and haematopoietic progenitors in myeloma patients. Normal CD44 
expression is down regulated in myeloma cells and higher expression of 
cytoplasmic RHAMM noted in myeloma cells is a marker of genomic 
instability. There are a number of publications correlating the presence of 
splice variants of CD44 in patients and their poor prognostic disease 86,87. IL-6 
which drives myeloma cell proliferation also up regulates CD44 gene 
expression and alternative splicing of CD44. This generates CD44 splice 
variants seen in neoplastic plasma cells 88. Adhesion through CD44 variants 
expressed on myeloma cell lines to hyaluronan induces resistance to drugs 
such as dexamethasone 89. Addition of Bivatuzumab a monoclonal antibody 
specifically targeting CD44v6 which is a splice variant, reduced adhesion of 
myeloma cells to stromal cells. This drug also shows promising in results in 
other solid tumours 90. Highly  immunogenic CD8(+) T-cell epitope peptide 
derived from RHAMM was used in a phase 1 peptide vaccination programme 
in patients with MDS and myeloma. This trial  has generated encouraging 





myeloma patients with higher expression of RHAMM. These drugs are 
currently in Phase I clinical trials. 
 
2.4.3 Cell adhesion mediated drug resistance (CAM –DR) 
Drug resistance induced by adhesion to ECM plays an important role in the 
pathological manifestations of myeloma. The term cell adhesion mediated 
drug resistance (CAM-DR) was coined in studies by Damiano and Dalton et al 
in MM cells, and is now extended to other types of cancer, as part of 
environment-mediated drug resistance 77,92. CAM-DR to a variety of drugs 
such as melphalan and steroids in myeloma cells can be induced by FN or 
BM stromal cells and is mediated by integrins, predominantly by α4 β1. 
Damiano et al also showed, selecting for drug resistant myeloma cells leads 
to the up-regulation of the integrins VLA-4 and VLA-5. Drug-sensitive 
myeloma cells when adhered to FN demonstrated a reversible de novo drug 
resistance phenotype that was not due to reduced drug accumulation in cells 
or up-regulation of bcl-2 family members 77. The same group demonstrated 
that upon adhesion on FN, cells are arrested in G1 phase with up regulation of 
p27kip1    , which reversed on disruption of adhesion with cells moving into S 
phase. p27kip1   antisense oligonucleotides did not affect adhesion on FN, but 
p27Kip1 protein levels were reduced and cells became chemosensitive 92. Heat 
Shock Protein 70 is also up-regulated in myeloma cells and may be 
associated with CAM-DR. NFkB pathway activation was also demonstrated to 
be when myeloma cells adhered to FN, and may possibly play a role in CAM-





associated with reduction in drug-induced DNA damage, but rather in 
protection from mitochondrial perturbations and caspase activation94.  
Myeloma cells when adhered to stromal cells are resistant to commonly used 





Targeting the integrins using monoclonal antibodies restored partial sensitivity 
to these agents. But targeting the HMG-CoA/GG-PP/Rho/Rho-kinase pathway 
using statins restored almost complete chemosensitivity when myeloma cells 
were plated on stromal cells
96
. Wnt signalling pathways, the Wnt/β-catenin 
pathway (canonical pathway) and the Wnt/RhoA pathway (non-canonical 
pathway), are implicated in plasma cell migration and bone disease. Wnt / 
RhoA / ROCK pathway has been shown to modulate CAM-DR of plasma cell 
adhesion on stromal cells through VLA-6 receptor97.  
Some of the integrin-mediated responses of MM cells are in fact the outcome 
of a convergence of biochemical signals originating from adhesion molecules 
and growth factor\cytokine receptors. Intracellularly, upon engagement of 
integrin with fibronectin, IL-6 mediated STAT3 phosphorylation, nuclear 
translocation, and DNA binding ensue. Fibronectin facilitates the association 
of STAT3 and gp130, a part of the IL-6 signalling complex. These form 
potential kinase targets which can be exploited by therapy. With disease 
progression myeloma cells activate integrins and interact with the matrix 
proteins and stromal cells within the microenvironment leading to poor 
response to therapies. Lymphocyte function-associated antigen 1 (LFA-1) an 
integrin receptor constitutively activates the FAK/PI3-K/Akt survival pathway in 
myeloma and  targeting  this pathway by LFA-1 inhibitors, inhibitors of the Src 





and primary myeloma cells 98. In summary, CAM-DR is a key mechanism by 
which myeloma cells exhibit inertness to current day therapy. CAM-DR has 
been subsequently demonstrated in other haematologic malignancies and 
solid tumours. It remains to be seen if non chemotherapeutic targeted agents 
























2.4.4 Therapeutic targets in the microenvironment 
Primary cells from patients cannot be maintained in long term cultures ex vivo. 
Direct and indirect interactions of plasma cells with other cells and the ECM 
within the BM microenvironment are key requirements for myeloma 
pathogenesis, cell growth, survival, migration and drug resistance (Fig 9). 
Cytokines and growth factors that are produced and secreted within BM 
microenvironment regulate both by autocrine as well as paracrine loops 
interaction between plasma cells and other cells.  IL-6 is a key growth and 
survival factor in myeloma, predominantly produced and secreted by stromal 
cells and osteoblasts. IL-6 triggers activation of MEK/MAPK-, JAK/STAT3, 
and PI3K/Akt-signalling pathways. Compounds targeting IL-6 signalling 
pathways include antibodies against IL-6 and IL-6 receptor, CNTO 328, IL-6 
antisense oligonucleotides and IL-6 super antagonist Sant799. VEGF is 
secreted by several myeloma cell lines and present in patient plasma. 
VEGFR-1 is highly expressed by MM cells, consistent with autocrine 
signalling. In addition to bevacizumab a VEGF-A antibody, a multitude of other 
VEGF-targeting compounds are under preclinical and clinical investigation in 
MM including pazopanib, sorafenib and sunitinib. CD40 is expressed by 
antigen-presenting cells, T cells, as well as myeloma cells. Functionally, it 
mediates p53-dependent increase in MM cell growth. Targeting CD40-
signalling in MM cells inhibits monoclonal Ig secretion and overcomes CAM-
DR. Tumour cells and stromal cells express high levels of BAFF (B cell 
activating factor) and APRIL (a proliferation inducing ligand), as well as their 
receptors. Preclinical data suggest therapeutic value of targeting 





therapeutic targets are being studied in the microenvironment particularly, 
soluble factors, growth receptor pathways and deregulated kinases using 
antibodies and small molecules.  Agents targeting adhesion of plasma cells 
will combine theoretically well with cytotoxic agents. Small molecule inhibitors 
to integrins have been developed and VLA-4 has been a target used more 
frequently in models of asthma. Ghobrial et al have shown this as a proof of 
principle in mouse models using CXCR4 inhibitor in combination with anti 
myeloma agents
95
. Reduction in the adhesion of so called resistant plasma 
cells would enhance remissions but these adhesion interactions also anchor 
stem cells and myeloid cells in the marrow101. Therefore haematological 
toxicity could be a major side effect with these agents. The enhanced 
understanding of the pathophysiology of myeloma, intracellular pathways, 
soluble mediators and interactions with microenvironment has thrown up 
multiple potential targets in the microenvironment. This has led to creation of a 
pipeline of prospective agents. It still remains a major task to simplify the 













Fig 9: Interactions of plasma cell with the microenvironment. A detailed 
schematic representation of myeloma plasma cell interaction, with its cellular 
partners in the bone marrow microenvironment. Adapted from Podar et al 














2.5 Src signalling pathways and its role in myeloma pathogenesis 
c-Src was the first identified proto oncogene and has been extensively 
studied. Src family of membrane non-receptor protein tyrosine kinases (SFK) 
play a key role by transducing signals from the extracellular environment to 
intracellular biochemical pathways that either activate nuclear factors resulting 
in transcriptional responses, or target cytoplasmic components resulting in a 
cytoskeletal reorganisation102. Src participates in the maintenance of normal 
cell homeostasis and in a vast range of physiological functions including cell 
proliferation and survival, regulation of the cytoskeleton, cell shape control, 
and maintenance of normal intercellular contacts, cell–matrix adhesion 
dynamics, motility and migration. The Src family includes nine mammalian 
members: c-Src, Yes, Fyn, and Fgr, forming the Src A subfamily, Lck, Hck, 
Blk, and Lyn in the Src B subfamily, and Frk in its own subfamily 102. c-Src is 
regulated in terms of both protein levels and levels of activity by a range of 
mechanisms. Inactivation of c-Src is controlled by c-Src tyrosine kinase 
(CSK), which phosphorylates a conserved tyrosine residue in the c-Src 
carboxy-terminal domain (Tyr530). This is reversed by phosphatases such as 
protein tyrosine phosphatase 1B (PTP1B), which leads to c-Src activation. 
When c-Src is activated it undergoes dephosphorylation of Tyr 530 and 
phosphorylation of 416103. This makes Tyr416 a useful surrogate marker for 
investigating Src phosphorylation in myeloma cells. In cases of overexpressed 
c-Src both Tyr 530 and Tyr 416 are phosphorylated. It is important to note that 
phosphorylation patterns in Src family members such as Lyn are different to c-
Src. Activation of growth-factor receptors such as PDGFR leads to their 





intramolecular interactions thereby promoting c-Src activation. Other proteins, 
such as CRK-associated substrate (CAS) and FAK, bind to the c-Src SH2 and 
SH3 domains to promote c-Src activation by a similar mechanism (Fig. 10). c-
Src when inactive is located in the perinuclear sites. Upon activation c-Src is 
translocated to sites of cell adhesion and interacts with the plasma membrane 























Fig 10: Regulation of c-Src. Mechanisms involved in regulation of c-Src 
activity shown. CSK- c-SRC tyrosine kinase, PTB1B - protein tyrosine 
phosphatase 1B, CAS- CRK-associated substrate. Adapted from T J. 













2.5.1 SFK activation and integrin signalling in myeloma cells 
Src family kinases are activated downstream of integrin signalling upon 
integrin engagement to ligands leading to integrin clustering. The interaction 
between c-Src SH3 domain and β3 integrin cytoplasmic domain is direct and 
other SFK bind more generally to β1, β2 and β3 integrins104. Formation of 
focal adhesions and adherens junctions are both regulated by c-Src. Focal 
adhesions form at the sites where integrins link the actin cytoskeleton to ECM 
proteins. In addition to their role as cell–matrix attachment structures, 
providing the structural and mechanical properties necessary for adhesion, 
and participate in cell-signalling processes that regulate proliferation and gene 
transcription. Numerous cytoskeletal proteins are recruited to focal adhesions 
to mediate cell migration. They are associated with cytoskeletal stress fibres, 
composed of actin and myosin, which control the shape and ultimately, the 
motility of the cell. In the context of myeloma, Src is phosphorylated in primary 
myeloma cells and human myeloma cell lines MM1S, MM1R, RPMI8226 and 
OPM1105. Integrin clustering results in cytoskeleton organisation followed by 
phosphorylation of pp60 Src and focal adhesion kinase. Src kinases also 
transduce signals downstream of the proteoglycan CD44. When myeloma 
cells adhere through CD44 variants on hyaluronan the cytoskeleton binding is 
intrinsically regulated by phosphorylation of Ser325. The cytoplasmic tail 
(Ser325) is constitutively associated with Src family protein kinases (SFK) like 
Lck, Fyn, and Lyn. Binding of hyaluronic acid to CD44 leads to cytoskeletal 
reorganization. Additionally, the Src family kinase Fyn may activate guanine 
exchange factor Vav1 that activates the Rho-family GTPase Rac1 and/or the 





comparison with newly diagnosed patients and those with MGUS 105.  Higher 
levels of c-Src protein available will therefore play a key role in integrin or 
CD44 mediated resistance along with downstream activation of FAK and 
MAPK pathways.  
 
2.5.2 Role of SFK in IL-6 signalling pathway 
IL-6 is a pleiotropic cytokine, which enhances myeloma proliferation both in 
vitro and in vivo. High levels of IL-6 in the serum are shown to induce 
resistance to bortezomib therapy. IL-6 signalling is mediated by Src family 
kinases. Only a proportion of CD138 + plasma cells express CD45, a protein 
tyrosine phosphatase. Kawano et al showed that CD45 expression along with 
SFK activation is a prerequisite for IL-6 dependent proliferation in myeloma 
cell lines. CD45 neg myeloma cells highly express IL-6 receptor alpha chain 
(IL-6Rα). IL-6Rα and IGF-I receptors exist on plasma membrane in close 
proximity, facilitating efficient assembly of two receptors in response to IL-6. 
The synergistic effects of IL-6Rα on IGF-I receptor-mediated signals provide a 
novel insight into a Jak-independent IL-6 signalling mechanism of receptor 
cross talk in human myeloma cells 107. Furthermore, IL-6 dependent myeloma 
cell line proliferation was shown to be effectively inhibited by an antisense 
oligonucleotide to Src kinase in vitro 108. Another group has shown the Src 
family kinase Hck is associated with the IL-6R β-chain, gp130, and IL-6 
signalling induces Hck activation making Hck a potential intracellular target for 
blocking IL-6 signalling. Peptides derived from the gp130, inhibited growth of 
IL-6 dependent cell lines by interfering with the association of Hck109. Lyn 





the enhanced activation of the phosphatidylinositol (PI) 3-kinase and Akt. The 
IL-6-induced phosphorylation of STAT3 and ERK1/2 was not up-regulated in 
the Lyn-over expressed cells, indicating that the Lyn-PI 3-kinase-Akt pathway 
is independent of these pathways
110
. These data confirm that Src is a 
potential druggable target in patients with high IL-6 levels driving the 
proliferation and survival of myeloma cells. 
 
2.5.3 c-Src and bone resorbing activity of osteoclast 
Src family kinases also play an important role in the motility and function of 
osteoclasts. Bone resorption function of osteoclasts is dependent on the 
integrity of the actin cytoskeleton. Depending on the substratum upon which 
the osteoclasts are spread, there are two different configuration of actin 
known as podosomes and the sealing zone (continuous ring of actin filaments 
along the cell periphery that arises from fusion of clustered podosomes). 
Formation of podosomes is a key event and is characterized by an F-actin 
conical core concentrating actin regulatory proteins such as WASP, Arp2/3, 
cortactin, and gelsolin (Fig 11). The actin core is surrounded by adhesion 
molecules such as integrins, adaptors (paxillin, SH3P2, Cbl, and others), 
kinases (c-Src, Pyk2), small GTPases (Rho and Rac), and endocytic 
regulators 111. Osteoclasts are dynamic and motile cells and if plated on a 
suitable substratum such as bone the actin cytoskeleton switches from the 
migrating podosome phenotype to sealing zone found in the bone resorbing 
phenotype. The sealing zone consists of a large ring of actin about 4 μm wide 
and 4 μm high, in contrast to 1 μm in height and 0.5 μm diameter for an 





apical membrane of polarised osteoclasts 112.  Moreover, in resorbing 
osteoclasts showing sealing zone organisation, phosphorylated c-Src was 
mainly found in the center of the ring, in a membrane-specific region called 
the ruffled border. Src Tyrosine phosphorylation regulates actin polymerisation 
and the activity of proteins surrounding the podosome core. Tyrosine kinase 
activity of c-Src is also implicated in the formation of a αvβ3 integrin, Pyk2, c-
Src, and Cbl complex which is regulates the resorption activity of osteoclasts. 
The deletion of the gene encoding the nonreceptor tyrosine kinase c-Src 
produces an osteopetrotic skeletal phenotype. Src–/– osteoclasts exhibit 
reduced motility and abnormal organization of the apical secretory domain 
(the ruffled border) and attachment-related cytoskeletal elements that are 
necessary for bone resorption. c-Src−/− mice are viable and fertile and do not 
immediately exhibit obvious phenotypes but develop osteopetrosis. Osteoclast 
differentiation was not affected in c-Src−/− osteoclasts but were unable to 
resorb bone in vitro. Under such conditions, the when Src−/− osteoclasts were 
cultured on cover slips, they exhibit focal adhesions but no podosomes and 
have a migration defect and a delayed ability to reorganise their cytoskeleton 
after detachment and spreading113.  Formation of podosomes could be 
rescued by expression of a kinase-dead version of c-Src, highlighting the 
importance of the adaptor function of Src rather that its kinase activity. 
Furthermore, the other members of the Src family cannot compensate the 
absence of c-Src in the specific context of the osteoclast.  Myeloma patients 
present with lytic lesions and high serum calcium levels which are hallmarks 
of osteoclast activation. Bisphosphonates down regulate osteoclast activation 





proteins in the podosome core such as WASp should be explored in these 
patients 114,115. Targeting Src family kinases with a small molecule has 
potential to induce plasma cell death by altering the response to IL-6, reduce 
adhesion of plasma cells to ECM proteins in the bone marrow and modify the 
























Fig 11: Podosome structure and formation of podosomes and sealing 
zones in osteoclast.  (A) Cluster of podosomes with core formed of F- actin. 
(B) Detailed structure of a podosome. Arp2/3 – actin related protein complex, 
WASP – Wiskott Aldrich syndrome protein, cdc42 – GTP binding protein. (C) 
Formation of podosome cluster, rings, belt and sealing zones on different 













2.5.4 Kinase inhibition and its role in myeloma therapy 
 
The success of Imatinib in chronic myeloid leukaemia (CML) has generated a 
huge interest in developing kinase targets for haematologic malignancies. 
Increasingly pharmaceutical companies are investing huge sums in identifying 
and blocking targets with small molecules. Myeloma therapy is going through 
the phase of identifying potential druggable targets which includes kinase 
domains either in the plasma cells or in the microenvironment.  Some  of the 
kinases in the propagation of myeloma cells have
 
been established; vascular 
endothelial-derived growth factor receptor (VEGFR) kinase, insulin-like growth 
factor 1 receptor, Janus kinase, AKT, protein kinase C, Cdk4/6, IκB kinase β, 
aurora kinases  and  fibroblast growth factor receptor 3 (FGFR3). Over 
expression of FGFR3 occur in a subset of multiple myeloma patients with t (4; 
14) translocation. The other potential advantages of kinase therapies in 
myeloma are that, they can potentially be combined with manageable 
toxicities with the major scaffold agents such as bortezomib, dexamethasone 
and IMiDs116. In relapsing myeloma patients with poor performance status and 
limited suitability for high dose therapy, targeted agents such as kinase 
inhibitors may be more clinically relevant. 
Tiedemann et al through high-throughput screening for kinase mutations in 
primary myeloma cell and cell lines did not detect any mutations in 31 kinases 
analysed except, FGFR3 117. The same group used a high-throughput 
systematic RNA interference (RNAi) approach to identify kinases that regulate 
myeloma cell proliferation or survival. KMS11 and INA6 human multiple 
myeloma cells were transfected separately with synthetic short interfering 





myeloma cells were used in secondary validation screens. These cell lines 
were chosen for their genetic heterogeneity and are representative of t (4;14) 
(KMS11), t(14;16) (KMS11 and JJN3), and t(11;14) (INA6) myeloma variants. 
Kinases targeted by 1 or more siRNAs lethal or
 
inhibitory to KMS11 or INA6 
during primary screening were implicated as candidate survival kinases. 88 
kinases (14%) were identified as candidate survival kinases in KMS11 cells 
and 59 (9%) were identified in INA6 cells with only 4% in both cell lines 
reflecting the heterogeneity. G protein–coupled receptor kinase, GRK6 was 
identified through this process making it a candidate for drug target in 
myeloma118. Significant myeloma cell cytotoxicity is seen with inhibitors in vitro 
and with some them in vivo. But clinical evaluations have not been carried out 
particularly with concerns of toxicity with many of these agents. Potentially 
some of these agents will be used in combination with licensed anti myeloma 
drugs 119,120. An example is AKT inhibitor Perifosine which inhibits constitutive 
and cytokine (IL-6, IGF-1) induced PI-3K/Akt activation in MM cells and, 
therefore, induces MM cell death even when the MM cells are adherent to 
stromal cells. Perifosine is now being trialled in combination with bortezomib 
and lenalidomide. FGFR3 kinase, aurora kinase, p38/MAPK, JAK1/2, protein 
kinase C and cyclin-dependent kinase inhibitors have been extensively 










Fig 12: Signalling pathways in a neoplastic plasma cell. Intracellular 
pathways involved in regulating key cellular processes within a myeloma 

















2.6 Myeloma bone disease 
Bone resorption and subsequently bone destruction in the form of lytic lesions 
and fractures is a characteristic feature of myeloma.  Although not all patients 
present with bone disease they could potentially develop it during the course 
of the disease. Abnormalities in skeletal radiography are observed in up to 
90% of patients with myeloma during the course of their disease121. In a 
population-based retrospective cohort study, 16 times more fractures were 
observed than expected in the year before diagnosis,
 
mostly pathologic 
fractures of the vertebrae and ribs. Patients with a pathological fracture had 
poor survival 122. Bone disease may be limited to radiolucencies on X-rays but 
not infrequently patients develop pathological fractures requiring surgical 
pinning and radiotherapy. Bone pain significantly limits mobility and underpins 
the quality of life of these patients. Imbalance between bone resorption 
caused by osteoclastic activation with decreased osteoblastogenesis primarily 
leads to these clinical manifestations. Bone histomorphometric studies clearly 
demonstrate increased osteoclast numbers and activation in both early and 
overt myeloma patients 123 together with reduction in osteoblast numbers over 
the course of the disease. Osteoclasts are a key cellular partner in the bone 
marrow microenvironment of myeloma patients and enhance survival and 










2.6.1 Osteoclast activation in myeloma 
Uncoupling of osteoblast and osteoclast activity in the bone of MM patients is 
primarily due to activation of the osteoclast and secretion of soluble factors by 
plasma cells and stromal cells (Fig 11). Osteoclasts are activated by secretion 
of cytokines, the receptor activator of nuclear factor (NF)- B (RANK) ligand 
(RANKL), the chemokines macrophage inflammatory protein (MIP)-1. A 
balanced RANKL/osteoprotegerin (OPG) ratio is essential for normal bone 
turnover. Myeloma cells lead to an imbalance in the RANKL – OPG system in 
the tumour microenvironment. RANKL has been characterized as the key 
mediator of osteoclast differentiation and activation. RANKL is a member of 
the tumour necrosis factor super family and is produced mainly by 
osteoblastic lineage cells and stromal
 
cells. The cellular receptor for RANKL, 
RANK, is expressed on the surface of osteoclast precursors and mature 
osteoclasts. RANKL induces differentiation, formation, fusion, and survival of 
pre osteoclasts.  Moreover, it has direct effects on mature osteoclasts, 
causing actin ring formation and cytoskeletal rearrangements that precede 
bone resorption, and activating mature osteoclasts to resorb bone. OPG acts 
as a decoy receptor antagonist for RANKL. It is secreted mainly by 
osteoblastic lineage and stromal cells124. MIP-1  is chemotactic for osteoclast 
precursors, and promotes osteoclast formation in bone marrow cultures. Both 
MIP-1  and MIP-1β are produced and secreted by myeloma cells. MIP-1  
and MIP-1β enhance RANKL expression in stromal cells. MIP-1  induced 
signalling involves activation of the PI3K /Akt and mitogen-activated protein 
kinase (MAPK) signalling pathways in myeloma cells, leading to increased 





produced by stromal cells and IL-3 and HGF, produced by myeloma cells 
activate osteoclasts. Stromal derived factor alpha (SDF-1α), chemokine 
expressed by marrow stromal cells and myeloma cells binds to its receptor 
CXCR4, expressed
 
on osteoclast precursors, inducing chemotaxis and matrix
 
metalloproteinase (MMP)-9 activity 125. Syndecan-1 produced by myeloma 
cells, along with heparanase, an enzyme involved in syndecan-1 shedding, 
regulates osteoclastogenesis by sequestering OPG and by concentrating 
factors (HGF, IL-6, IL-8, SDF-1) that promote osteoclastogenesis, 
angiogenesis and myeloma growth 126. Activated osteoclasts also provide 
protection and enhance proliferation of neoplastic plasma cells 49. Taken 
together, activation of osteoclasts in the bone marrow microenvironment of 
myeloma patients plays a key role in myeloma bone disease and provides 
several therapeutic targets, which can be exploited. 
 
2.6.2 Osteoblastogenesis in myeloma 
Suppression of osteoblastogenesis in myeloma through multiple pathways 
leads to suppression of bone production and promotes myeloma cell survival. 
Various regulatory pathways of osteoblastogenesis are altered in MM 
patients. Wnt pathway has been shown to be a critical signalling pathway in 
osteoblast differentiation. Wnt glycoproteins bind to the Wnt receptor and its 
co receptors low-density lipoprotein receptor-related protein (LRP) 5 /LRP6. 
This leads to stabilisation and cytoplasmic accumulation of β-catenin. β-
catenin translocates into the nucleus and stimulates expression of osteoblastic 
target genes. In the absence of a Wnt3a (Wnt glycoprotein) signal, β-catenin is 





Dickkopf 1 (DKK1) a soluble Wnt signalling antagonist secreted by plasma 
cells and stromal cells inhibits osteoblastogenesis127. Patients with myeloma 
who had high levels of serum DKK1 had significant bone disease. Inhibition of 
DKK1 using a monoclonal antibody in vivo induced osteoblast mediated bone 
formation in SCID-rab mice 128. Secreted Frizzled-related protein 2 (sFRP-2), 
a Wnt inhibitor is produced by RPMI8226 and U266 human myeloma cell lines 
and primary myeloma cells. sFRP-2 suppressed in vitro mineralization as well 
as alkaline phosphatase activity in osteoblasts induced by bone 
morphogenetic protein 2 (BMP-2). Decorin, a small leucine-rich proteoglycan 
that is produced by osteoblasts, inhibited the survival of myeloma cells and 
attenuated the stimulatory effects of osteoclasts on myeloma cells. They also 
demonstrated that blocking activity or expression of decorin reduced 
osteoblasts inhibitory effects on myeloma cell growth and survival, but over 
expression of decorin in mesenchymal stem cells (MSCs) lessened the ability 
of these cells to support myeloma cell survival129. Cell surface receptor EphB4 
and its ligand ephrinB2 mediate bidirectional signalling between osteoblasts 
and osteoclasts. Osteoblasts and their precursors, mesenchymal cells, 
express ephrinB2 and EphB4, whereas osteoclasts mainly express ephrinB2. 
Forward signalling (activation of ephrin receptors by ligands) in MSCs 
promotes osteogenic differentiation, and reverse signalling (activation of 
ligands by receptors) in osteoclast precursors inhibits their differentiation into 
multinucleated bone-resorbing osteoclasts130. EphrinB2 and EphB4 are 
underexpressed in MSCs from patients with MM.  In vitro, myeloma cells 
downregulated expression of these factors in normal mesenchymal cells and 





Drug therapeutic strategies against myeloma ideally should promote 
osteoblast metabolism as well. Cbfa1/Runx2 is a transcription factor essential 
for bone formation and osteoblast differentiation. Proteasomal inhibitor 
Bortezomib significantly increased the transcription factor Cbfa1/Runx2 
activity in human osteoblast progenitors and osteoblasts in vitro. This 
correlates with increased numbers of osteoblasts in the marrow of patients 






















Fig 13: Bone remodelling in myeloma. Mechanisms leading to disruption of 
bone homeostasis. Adapted from Yaccoby.S. Brit J of Haematology (2009) 




















2.6.3 Therapeutics for myeloma related bone disease 
Until recently, targeting osteoclast activation has been the mainstay of therapy 
for myeloma related bone disease. Frequently, orthopaedic intervention 
kyphoplasty, vertebroplasty and radiotherapy are used to improve structural 
integrity and alleviate pain. The aim of therapy is the reduction of skeletal-
related events such as fractures, bone pain and plasmacytomas in patients 
with myeloma bone disease. Phase III randomised, placebo-controlled clinical 
trials have proven the efficacy
 
of intravenous pamidronate or oral clodronate 
in the therapy of myeloma bone disease. Bisphosphonates inhibits osteoclast 
activation and induces osteoclast apoptosis. Zoledronic acid is superior to 
pamidronate in the treatment of hypercalcemia of malignancy, but a clinical 
efficacy comparable with that of pamidronate in myeloma in the prevention of 
skeletal-related events132. A recent Cochrane review showed bisphosphonate 
in comparison with placebo, demonstrated the beneficial effect on prevention 
of pathological vertebral fractures (RR= 0.74 (95% CI: 0.62 to 0.89), P = 
0.001), and skeletal related events (SREs) (RR= 0.80 (95%CI: 0.72 to 0.89), 
P < 0.0001). There was no significant improvement in OS or PFS. They did 
not find a significant difference in efficacy between the Bisphosphonates 133.  
Recently concluded myeloma IX trial showed superiority of zoledronic acid 
over oral sodium clodronate for OS and PFS with the overall survival 
independent of occurrence of SREs134. Osteonecrosis of the jaw (ONJ) is a 
rather uncommon, but potentially serious, complication of intravenous 
bisphosphonates, which is characterised by the presence of exposed bone in 
the mouth. Invasive dental procedures are a major risk factor for the 





incidence of ONJ in a recent meta analysis 135. Various alternative compounds 
that may target MM bone disease are under investigation. Recently, 
Denosumab a RANKL neutralizing antibody known to be effective in 
osteoporosis was trialled in phase II setting in patients with relapsed or 
plateau-phase myeloma. Some patients who were treated with RANKL-
neutralizing antibody denosumab experienced MM disease stabilisation136. A 
humanised DKK1-neutralizing antibody, BHQ880, which is currently being 
evaluated in clinical trials, has shown increased osteoblast numbers and bone 
mass and reduced osteoclast numbers in SCID-hu mice engrafted with the 
IL6-dependent myeloma cell line INA6137. Inhibition of the ubiquitin–
proteasome pathway induces osteoblast differentiation by increasing 
expression of bone morphogenetic protein and preventing proteolytic 
degradation of RUNX2. Bortezomib also promotes bone formation by 
inhibiting DKK1 expression in osteogenic cells52. Long term treatment with 
Imatinib (Abl kinase inhibitor) in CML patients increased bone formation by 
inhibiting osteoclastogenesis suggesting that chronic therapy with a kinase 
inhibitor has the capacity to help bone remodelling138,139. The effects are 
thought to be related to inhibition of PDGF, c-fms, and abl kinase.  Dasatinib 
showing promising activity in CML shows multi-target effects, including 
inhibition of the macrophage colony stimulating factor (M-CSF) receptor, c-
fms, c-Abl and c-Src. Dasatinib abrogates osteoclast formation and activity in 
vitro and in vivo in Sprague Dawley rats140. The increase in trabecular volume 
observed was comparable to zoledronic acid. This observation is primarily due 
to impaired osteoclast activation and it remains to be explored, whether 





osteoblastogenesis. In summary, to arrest the progression of bone disease in 
myeloma, the goal of therapy should focus on inhibiting osteoclast function 
and enhancing osteoblastogenesis (Fig 14). 
 
 
Fig14. Therapeutic targets in myeloma bone disease. Existing and 
potential druggable targets with potential to modify myeloma bone disease. 


















2.7 Dasatinib therapy for myeloma 
Dasatinib is an oral, multitargeted tyrosine kinase inhibitor of members of five 
tyrosine kinase families: SRC family kinases (SRC, LCK, YES, FYN), BCR-
ABL, KIT, EPHA2 and PDGFβ. It has been shown to be safe and effective in 
CML patients, who are resistant and intolerant to Imatinib mesylate. Dasatinib 
is the analog of parent compound 2-aminothiazole discovered as a novel Src 
family kinase inhibitor. Molecular modelling was used to construct a putative 
binding model for Lck inhibition by this class of compounds
141
. Dasatinib has a 
chemical name, N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-
piperazinyl]-2-methyl-4-pyrimidinyl] amino]-5-thiazolecarboxamide, 
monohydrate according to the IUPAC nomenclature (Fig 15). In vitro studies 
have demonstrated that Dasatinib is 150 fold more potent than Imatinib in 
inhibiting bcr-abl and in addition inhibits Src kinase in nanomolar 
concentrations. Safety and efficacy of Dasatinib has also been demonstrated 
in several Phase II and Phase III trials in CML patients in chronic, accelerated 
and blast crisis phase of disease142. Dasatinib is also being studied in 
Philadelphia positive ALL, prostate cancer and melanoma. Up to one third of 
patients in chronic phase CML develop resistance/sub optimal response to 
Imatinib therapy. There are also patients who are intolerant to Imatinib. In a 
phase III randomised study, 519 patients with newly diagnosed chronic-phase 
CML were randomly assigned to receive dasatinib at a dose of 100 mg once 
daily (259 patients) or imatinib at a dose of 400 mg once daily (260 patients). 
After a minimum follow-up of 12 months, complete cytogenetic response and 
molecular response was higher with Dasatinib than with Imatinib (77% vs. 





effect restricted to the dasatinib group was pleural effusion, reported only in 26 
patients (10%) and no grade 3-4 events. The tolerability to Dasatinib has 
significantly improved since the reduction dose from 70mg BD to 100mg OD 
143
. Direct comparison with Imatinib mesylate in a randomised fashion as first 
line therapy for chronic myeloid leukaemia patients in chronic phase shows 
superior complete cytogenetic response, which is a surrogate marker of long 




Fig 15: Chemical Structure of Dasatinib. Adapted from Simard et al Nature 















2.7.1 Potential targeting of microenvironment by Dasatinib: Inhibition of 
angiogenesis 
The most important molecule identified to date, that controls angiogenesis is 
vascular endothelial growth factor A (VEGF A) which belong to a family of 
potent angiogenic regulators. VEGF A binds to VEGFR1 (FLT1) or VEGFR2 
(KDR) which have tyrosine kinase activity. Notch receptor and its ligand DLL4 
and PDGFRβ and its ligand PDGF which are highly expressed in pericytes 
are also implicated both in physiological and tumoral angiogenesis 
145
. 
Dasatinib demonstrates antiproliferative activity in human umbilical vein 
endothelial cells (HUVEC) treated with VEGF or basic fibroblast growth factor 
(bFGF). IC50 values of 42 nM and 248 nM were obtained under conditions 
with VEGF-stimulated and bFGF-stimulated growth, respectively140. 
Additionally, Dasatinib attenuates VEGF and bFGF stimulated HUVEC 
endothelial cell migration in vitro (IC50<5 nM)140. This demonstrates that 
Dasatinib has an effect on neovascularisation, maturation and migration of 
endothelial cells. Vacca et al took plasma cells and endothelial cells form 
myeloma patients (MMEC). They studied PDGFRβ and pp60c-Src which are 
constitutively activated in both cells. They demonstrated PDGF-BB/PDGFRβ 
kinase-axis promoted MM tumour growth and vessel-sprouting by activating 
ERK1/2, AKT, upon treatment with VEGF, released by MMEC. They have 
also shown using siRNA experiments they have validated that pp60Src is key 
signalling effector molecule in VEGF loop induced angiogenesis in MMEC. 
Blocking PDGFRβ and pp60c-Src in vitro and in vivo using Dasatinib , they 
have shown reduction in angiogenesis and tumour growth 105. In a recent 





34 advanced non-small-cell lung cancer patients, significant reduction in 
plasma VEGF and bFGF were observed. The reductions in VEGF correlated 
with disease control146. As described in section 2.1.2 of this thesis, 
angiogenesis plays an important role in the progression of myeloma. But 
angiogenesis as potential therapeutic target still remains unclear because of 
modest responses to bevacizumab (VEGF inhibitor) and modest reduction of 
angiogenesis in patients responding to thalidomide. It still remains to be 
demonstrated that angiogenesis is an important facet in myeloma, particularly 
as extramedullary plasmacytomas develop in relatively avascular areas and 
angiogenesis in marrow of relapsed patients is thought to be a reflection of 
tumour load. 
 
2.7.2 Potential targeting of microenvironment by Dasatinib: Inhibition of 
bone resorption 
Osteoclast mediated bone resorption is a complex process, intricately 
involving  several steps coordinated by humoral factors, activation of 
signalling pathways in the osteoclast, engagement of podosomes on an 
appropriate substrate followed by release lytic enzymes.  Hormones such as 
testosterone, oestrogen, parathyroid hormone (PTH)-related peptide (PTHrP), 
Parathyroid hormone along with  TNF-α, IL-1β, 1,25(OH)2 vitamin D3 regulate 
bone resorption through RANKL expression. Five signalling pathways 
mediated by protein kinases are induced during osteoclast activation; inhibitor 
of NF-κB kinase (IKK), c-Jun N-terminal kinase (JNK), p38, extracellular 
signal-regulated kinase (ERK) and Src pathways. Src protein, required for 
osteoclast activation, binds TRAF6 and allows RANK-mediated signalling to 





kinase AKT. Once osteoclast forms a sealing zone on the substrate, 
acidification of this compartment by secretion of protons leads to the activation 
of tatrate resistant acid phosphatase and cathepsin K, the two main enzymes 
responsible for the degradation of bone mineral and collagen matrix
147
. In 
preclinical models, Dasatinib has shown potent Src inhibitory activity and c-
Src phosphorylation is downregulated at a serum concentration of 42nM140. 
Dasatinib dose-dependently inhibits PTH stimulated release of calcium into 
the medium by foetal rat long bones in vitro with an apparent IC50 of 2nM. At 
5nM Dasatinib completely blocked PTH-stimulated bone resorption in vitro. 
Moreover, Dasatinib blocked the normalisation of plasma calcium in the thyro-
parathyroidectomised rat model after PTH infusion 140. In a phase II study of 
chemotherapy naive 40 castration resistant prostate cancer patients, 
Dasatinib induced reduction in urinary N-telopeptide levels and bone specific 
alkaline phosphatase in at least half of them, confirming reduction in bone 
resorption148. There is conflicting evidence as to whether Dasatinib 
suppresses osteoblast proliferation and differentiation by down regulating c-
Src and c-Abl in the osteoblasts 149,150. In summary, Dasatinib demonstrates 
potent inhibition of bone resorption in preclinical models and patients without 
significant toxicity making it an exciting drug to use in myeloma patients who 
have activated osteoclast mediated bone resorption. 
2.7.3 Dasatinib as a therapeutic agent in myeloma 
Dasatinib significantly delayed MM tumour growth and angiogenesis in vitro 
and in vivo in SCID mouse models. Dasatinib also exhibited a synergistic 
cytotoxicity with chemotherapy drugs  and bortezomib 105. However, the 





single-arm, phase II, open-label study of Dasatinib in 21 myeloma patients 
with relapsed or plateau phase was performed. Dasatinib was administered 
continuously at an oral dose of 70 mg twice daily, on Days 1 through 28, with 
cycles repeated every 28 days. After the enrolment of 9 patients and no 
observed responses, the protocol was amended to allow dose escalation of 
Dasatinib in patients with stable disease after 8 weeks on therapy to 100 mg 
twice daily. The overall median duration of therapy was 51 days. The overall 
response rate was low at 4.8%. Significant toxicity was observed with Grade 3 
or more haematologic and non haematologic toxicity observed in up to one 
third of patients151. Hence, Dasatinib as a single agent lack potential as a 
therapy against MM despite the observed significant efficacy of this drug at 
blocking the activity of BM cells that may support MM viability in preclinical 
and some clinical studies. Some in vitro studies suggest synergy for direct MM 
killing of Dasatinib with other drugs. Deng et al have also shown in human 
myeloma cell lines there is differential sensitivity to Dasatinib and synergistic 
activity with steroids, bortezomib and lenalidomide152. In myeloma cell lines, 
Dasatinib activated caspase-8 and caspase-12, and sensitised myeloma cells 
to agents that activate caspase-9, such as dexamethasone and bortezomib. 
They were also able to overcome IL-6 mediated and stroma mediated 
resistance in myeloma cells 152. Imatinib inhibits bcr-abl, c-kit, and platelet-
derived growth factor beta (PDGFRβ).  Imatinib was trialled as monotherapy in 
Phase I/II setting involving 21 relapsed/refractory myeloma patients, no 
responses were observed153. This observation was remarkable as one third of 
myeloma patients express c-kit on the plasma cells.  I hypothesised; 





activity of protective BM microenvironment cells, may inhibit adhesion 
of MM cells to BM cells and extracellular matrix and impair osteoclast 
function. I propose Dasatinib would therefore sensitise the tumour clone 



















































3. Patients, Materials and methods 
3.1 Patients 
Myeloma and MGUS patients as part of routine clinical testing consented to 
bone marrow (BM) and peripheral blood (PB) research samples to be taken. 
Patients gave written informed consent on the LREC protocol No 02-044. The 
Kings College Hospital Research Ethics committee approved the LREC 
protocol. The primary samples once obtained from the clinical facility were 
anonymised and if the sample was not used immediately for laboratory 
experiments, the sample was banked according to protocol in the Human 
tissue authority approved local tissue bank. The clinical information on the 
myeloma and MGUS patients were procured from the data available in the 
tissue bank database. 
 
3.2 Obtaining Osteoclasts from Primary Samples 
BM and PB were diluted with Hank’s balanced salt solution, Sigma in a ratio of 
1:1. Bone marrow particles were sheared using 18G needle. Density gradient 
separation (Histopaque, Sigma) was used to isolate BM mononuclear cells 
and PB mononuclear cells from patient samples. Cells were counted using a 
Haemocytometer. In case of bone marrow mononuclear cells, cells were 
plated overnight at 3 X 10^5cells/ ml in DMEM + 10% FCS and 5ng/ml of 
CSF-1. The next day bone marrow cells in the supernatant (adherent 
fibroblasts in the flask) were taken and plate din 12 or 24 well plates. They 
were plated at a density of 1.5X10^5 cells per well in a 96 well plate or 5 
x10^5 cells per well in 24 well plate in DMEM +10%FCS with Human CSF-1 
(Peprotech, UK) 25ng/ml and 50ng/ml of OPG – Ligand (Peprotech, UK).  




Peripheral blood mononuclear cells were plate at a density of 3 x 10^6 cells/ 
ml in a 24 well plate and left to adhere for 3 hours. After 3 hours the 
supernatant with non adherent cells were discarded and the wells replenished 
with DMEM + 10% FCS fortified with CSF-1 (Peprotech, UK) 25ng/ml and 
OPG- Ligand (Peprotech, UK) at 50ng/ml. Cultures were aspirated and fed 
with fresh conditioning medium every 72 hours. Osteoclasts were fully grown 
by Day 17. 
 
3.3 Cell lines and Reagents 
MM1S and MM1R human myeloma cell lines were gifted by Dr.Tai (DFCI 
Boston, USA) and were cultured in RPMI1640 (Sigma) with L-Glutamine and 
10% FBS (Sigma), Penicillin G (500U/ml) and streptomycin (50mg/ml) 
(sigma). ARH77, RPMI 8226 and U266 obtained from the American Type 
culture collection (LGC Promochem, Middlesex, UK) were maintained in RPMI 
Dutch modification (Sigma) and 10% FBS (Sigma) except for U266 -15%, 
Penicillin G (500U/ml) and streptomycin (50mg/ml) (Sigma), L-glutamine 
200um (Sigma) and 1%Sodium Pyruvate (Sigma). 5T33 and 5T33 GFP cell 
lines were obtained from Dr. Sirac Dilber, Karolinska Institute, Sweden and 
maintained in Minimal Essential medium Eagle (Sigma) 10% FBS (Sigma), 
Penicillin G (500U/ml) and streptomycin (50mg/ml) (Sigma), L-glutamine 
2mM/L (Sigma) and 1% Sodium Pyruvate (sigma). All cell lines were cultured 








3.4 Methyl thiazolyl tetrazolium (MTT) colorimetric assay  
Using a growth curve was adequate density for plating in proliferation 
experiments for MM1R, RPMI8226, ARH 77 and U266 cell lines was 2X10^5 
cells/ml, whereas MM1S, 5T33 and 5T33 GFP pos proliferated well without a 
plateau at a density of 4X10^5 cells/ml over a 5 day period. Cell lines were 
plated at a density of 2X10^5 cells/ml in a 96 well plate in quadruplicate, either 
untreated or with drugs. On the days of assessment 15ul of MTT (5mg/ml) 
solution (Sigma) was added to the wells. Plate was incubated for 3 hours at 
370C  in an incubator at 5%CO2. The plate was then spun down at 625Gy and 
aspirated.  Stop solution (0.1N Hcl in Isopropanol) was added and plate read 
at 570nm wavelength using a plate reader.  
 
3.5 Flow cytometry for apoptosis measurement and cell cycle analysis 
Cell lines were plated at a density of 2X10^5 cells/ ml in 12 well plates. On the 
days of analysis, cells were spun down at 450Gy. Cells were resuspended in 
Annexin V binding buffer with Annexin V APC conjugated (BD Pharmingen, 
UK) at a working concentration of 10µl/106 cells for 15 minutes in the dark. 
Centrifuge at 300Gy. Cell pellet was resuspended in Annexin V binding buffer 
200uL. 5μl / tube of 7-AAD was added and the cells were incubate din dark for 
15 minutes prior to analysis. For cell cycle analysis, eGFP expressing MM 
cells were harvested and fixed in BD Cytofix/ Cytoperm™Fixation/ 
Permeabilization. Samples were washed twice (5 min, 450 × g) in PBS and 
resuspended in a PBS solution containing propidium iodide (50 μg/ml) (sigma) 
and RNase (75 U/ml) (sigma) for 30 min at room temperature in the dark. 
Fluorescence emitted per cell unit was measured by flow cytometry using 




appropriate filters using a BD FACSCanto II flow cytometer (BD Biosciences). 
All the experiments were repeated three times. 
 
3.6 Adhesion assays 
Adhesion on Integrin Ligands: 96 well plates were coated overnight with 
Polylysine (Sigma) 10ug/ml and Fibronectin (Sigma) 10ug/ml. Plates were 
washed with Phosphate buffered saline (Sigma) and 5% BSA was added for 
30 minutes to prevent non specific adhesion. Cell lines were seeded in 96 well 
plate in RPMI at density 1X10^5 cells per well. They were left either untreated 
or treated with drugs. The cells were left to adhere for 30 minutes. 
Supernatant was aspirated and wells washed with RPMI 1640 once prior to 
adding 25ul MTT solution. MTT assay was performed. 
 
Adhesion on Osteoclasts: Myeloma cell line ARH77 was labelled with CFSE 
(Vybrant CFDA SE Tracer kit, Invitrogen, UK) as per protocol. In the first 
experiment CFSE labelled ARH77 cells were added at a density of 1x10^5 to 
fully grown Osteoclasts in DMEM only with or without MgEGTA for 30 min, to 
activate integrins and thereby enhance adhesion. They were left either 
untreated or treated with Dasatinib, Dexamethasone or the combination. In 
the second experiment prior to plating the CFSE labelled ARH77 cells for 
30minutes, the plasma cells or osteoclasts were pre-treated for 60 minutes 
with drugs. After aspirating the supernatant the plates were read using Tecan 
Fluorescent plate reader. 
 
3.7 Western blot 




Cell lines were plated at a concentration of 4x 10^5 cells/ml in 24 well plates 
precoated with 10ug/ml of Poly-L-lysine (Sigma) or 10ug/ml of fibronectin 
(Sigma). After adhesion for 30 minutes the supernatant was aspirated and 
wells washed once with media. Then 100ul of Laemmli buffer 1X was added 
to the wells. Laemmli buffer 4X was made using 0.8 g SDS stock (Sigma), 4 
ml 100% glycerol (Sigma), 0.01% bromophenol blue. Final Concentration is 
.02% (Sigma), 1 ml ß-mercaptoethanol (electrophoresis grade) (Sigma) and 
2.8 ml water. This was further diluted in water 1in 4 parts to make up 1x 
buffer. Lysates were sheared using 1ml syringe and needle and heated to 
100C for 5 minutes and stored down at -20C until electrophoresed. 10% 
SDS PAGE resolving gel and 4% SDS PAGE stacking gel were prepared. 
10ul of Lysates were run with 5ul of Dual precision plus standards (Biorad, 
UK) in Biorad Power Pac Basic system. Once the standards had fully resolved 
the gel was transferred onto a Nitrocellulose membrane (Amersham, UK) over 
4 hours. The membrane was stained with Ponceau S solution (Sigma) to 
check adequate transfer. The membranes were blocked with BSA 5% in TBS-
T blotted with primary antibodies pSrc, c-Abl activity kit, C-Abl, AKT, pAKT, 
ERK, pERK (Cell signalling, UK) and c- Src clone GD11 (Upstate Biotech) & 
B-actin (Sigma) overnight at 4C. HRP linked secondary antibodies were 
added to these membranes for an hour. ECL or ECL Plus 
Chemiluminescence kit (Amersham, UK) was used to detect presence of the 
bands. Konica – Minolta SRX-101-A photo developer was used to develop X-
ray films obtained from Fujifilm. The films were scanned in HP scanner and 
edited using Adobe photoshop CS3.0 software. 
 





Once osteoclasts were fully formed they were left untreated for a further 72 
hours or treated with drugs. 100ul 4% PFA solution in PBS was added to fix 
the cells until Immunostaining was performed. Plated were washes with PBS 
the Osteoclasts on the cover slips were treated with Triton 0.05% (Sigma, UK) 
to enable intracellular staining. Cover slips were removed from the plate and 
blocked with BSA 5% in PBS for 45 minutes. Primary antibodies Beta 3 
integrin (serotec) and Vinculin (Sigma) were added at a concentration of 1:100 
for 60 minutes. Secondary Antibodies and Phalloidin Alexafluor 568 were 
added for 1 hour. Cover slips were washed and inverted onto a slide with a 
drop of Vectashield mounting medium with DAPI (Vector labs, UK). The slides 
were imaged using a Fluorescent microscope (Leica). 
 
3.9 Statistical Analysis 
Calcusyn software version 2.0 (Biosoft, Ferguson, MO, USA) was used to 
analyse whether drug effects were synergistic or additive. The software 
performs multiple drug dose-effect calculations using the Median Effect 
methods described by T-C Chou and P. Talalay.  The method for drug 
combination is based on the median-effect equation, derived from the mass-
action law principle, which is the unified theory that provides the common link 
between single entity and multiple entities, and first order and higher order 
dynamics. A Combination Index (CI) value of <1.0 indicates synergy and >1.0 
is additive. Significance of the drug effects on Proliferation and adhesion of 
myeloma cell lines were analysed using paired samples T-test 
 




3.10 Generation of eGFP expressing MM cell lines 
Lentiviral vector stocks were produced in 293T cells by co-transfecting the 
transfer vector pHR_SINcPPT-SFFV-eGFP-(SEW), the envelope plasmid 
pMD.G, and the packaging plasmid pCMVR8.91, as previously described 
154
. 
1.5 X 107 cells were seeded onto 150 cm2 flasks and transfected with 10 g 
DNA envelope, 30 g DNA packaging and 40 g DNA transfer vector by 
precomplexing with 0.125 M PEI (22 kDa) for 15 minutes at room 
temperature in OptiMEM. After 4 hours at 37°C the medium was replaced with 
fresh DMEM 10% FCS and virus were harvested 48 and 72 hours post 
transfection. After filtering through a 0.45 m-pore-size filter, the virus 
suspension was concentrated by centrifugation at 50,000 g for 2 hours at 4°C. 
The resulting pellet was resuspended in RPMI (Sigma, UK) and stored at –
80°C until use. The desired numbers of plasma cells were plated in complete 
culture medium as described above and lentivirus-containing supernatant was 
added to the cells at an MOI of 10 and incubated for 24 hours. Medium was 
replaced with complete culture medium after 24 hours and cells were cultured 
for a further 48 hours to allow maximal expression of lentiviral vectors. eGFP 
expressing MM cells were resuspended at a density of 4 cells per ml in 250 
l/well in 96 well plates. After a period of 3 weeks, clones of cells in multiple 
wells were harvested and expanded in a 6 well plate with fresh media. 
Expression of GFP was confirmed by flow cytometry 
 
3.11 Fluorimetry 
eGFP-MM1S and eGFP-MM1R Cell lines were plated at a density of 4 x 10
5
 
cell/ml and 2 x 105 cell/ml, respectively in a 96 well plate in quadruplicate, 




either untreated or with drugs. On the days of assessment, the fluorescence 
intensity (FI) per well was read at λex488nm/λem528nm using a FLx800 
multidetection microplate reader (Biotek Instruments, USA). FI data were 
collected using Gen5 1.07 software. 
 
3.12 Stromal cell co-cultures 
HS5 human stromal cell (SC) line was obtained from American tissue culture 
collection. HS5 cells were cultured at 37°C in a humidified atmosphere in the 
presence of 5% CO2 in DMEM supplemented with antibiotics (penicillin at 
100 U/ml, streptomycin at 100 μg/ml) and 10% FBS. For cell proliferation 
assays of MM cell lines in co-culture, SCs were plated at a density of 0.3 x 105 
cells per well in a 96 well plate overnight. Media was aspirated and eGFP 
positive MM cell lines were plated at a density of 4 x 105 cells/ml (eGFP-
MM1S) and 2 x 105 cell/ml (eGFP-MM1R) on the semi-confluent SCs. On the 
days of assessment, plates were read in FLx800 multidetection plate reader 
as described above. For FACS assays, SCs were plated at a density of 105 
cells/well overnight in a 24 well plate. GFP positive plasma cells were added 
at the above density with and without treatments. On the days of assessment, 
suspended cells (which corresponded mainly to PC) were collected and wells 
washed with PBS once to retrieve the remaining PC which were loosely 
adhered on SCs. We confirmed by flow cytometry that the remaining cells in 








3.13 Osteoclast co-cultures 
Osteoclasts were differentiated over 3 weeks from primary BM mononuclear 
cells obtained from MM patients as previously described44. GFP positive 
plasma cells were layered on fully grown osteoclasts in 96 well plates at 
densities described above. On the days of assessment, images were obtained 
using a Fluorescent microscope and fluorimetry performed using a multi 
detection plate reader FLx800. For flow cytometry analysis, GFP positive PC 
were plated on fully grown osteoclasts in 24 well plates at above densities and 
supernatant containing PC was collected on the days of assessment. Wells 
were washed with PBS once to collect the remaining plasma cells. We 
confirmed by flow cytometry that the remaining cells in the well were eGFP 
negative, corresponding to osteoclasts only. 
 
3.14 Image processing 
Images of eGFP-MM cells in co-culture with osteoclasts were captured using 
a Nikon inverted fluorescent microscope attached to a digital camera. Images 
were processed in Photoshop CS3 as described before 155 to transform the 
fluorescent image into a binary black and white image. Firstly, the image 
mode of the fluorescence image was transformed from RGB to greyscale. 
Then, the image was enhanced using the autolevels function to make the 
fluorescent signal sharper and more distinguishable from the background. 
Using the Threshold function, the cells outline is drawn so that the cells are 
shown in white pixels and the background in black pixels. Images were then 
processed using UTHSCSA ImageTool (IT) v3.0, a free image processing 
software for image analysis. Using IT we transformed the enhanced images 




into binary images using automatic threshold and calculated the percentage of 
the area occupied by white pixels corresponding to eGFP-MM cells.  
 
3.15 Bone resorption assay 
BM mononuclear cells and PB mononuclear cells from patient samples were 
separated using Histopaque as described in section 3.2. In case of bone 
marrow mononuclear cells, cells were plated overnight at 3 X 10^5 cells/ ml in 
DMEM + 10% FCS and 5ng/ml of CSF-1. Dentine discs (IDS ltd, Bolton, UK) 
were added in a sterile environment to the 96 well plates with graphite pencil 
marking to denote the surface opposite to the culture surface. The next day 
bone marrow cells in the supernatant (adherent fibroblasts in the flask) were 
taken and plated on dentine slices in 96 well plates. They were plated at a 
density of 1.5X10^5 per well in DMEM +10%FCS with Human CSF-1 
(Peprotech, UK) 25ng/ml and 50ng/ml of OPG – Ligand (Peprotech, UK).  In 
case of peripheral blood mononuclear cells, they were plate at a density of 1 x 
10^6 cells/ml in a 96 well plate with dentine slices in the base of the wells and 
left to adhere for 3 hours. After 3 hours the supernatant with non adherent 
cells were discarded and the wells replenished with DMEM + 10% FCS 
fortified with CSF-1 (Peprotech, UK) 25ng/ml and OPG- Ligand (Peprotech, 
UK) at 50ng/ml. On Day 12 drugs, dexamethasone 1uM, Dasatinib 150nM, 
the combination of dasatinib and dexamethasone were added to the cultures. 
After 5 days of drug treatment the dentine slices were taken out and washed 
with PBS. They were treated with 50μl of 1M NH4OH overnight to remove the 
adherent osteoclasts.  Sonication (Soniprep MSE 150, Wolf labs, UK) was 
carried out for 15 seconds thrice in 1 ml PBS to further rid the dentine slices of 




cell debris. The dentine slices were washed in PBS and dried. For staining, 
50μl of Toluidine blue 0.1M was added to the dentine slices for 30 seconds 
and washed off with PBS. The dentine slices were dried before imaged under 
the phase contrast settings on the microscope (Zeiss microscope) 
 
3.16 Cytokine ELISA 
MIP-1α ELISA: MM1S and MM1R cells were plated at a density of 2 x 10^5 
cells/ml in 96 well plates with and without drugs for 24 hours. Dasatinib 
150nM, Dexamethasone 1uM and combination of Dasatinib and 
dexamethasone were used. The supernatants were taken after 24 hours and 
a MTT assay was performed as described in the methods section 3.4. The 
culture supernatant were added to the Maxisorp® ELISA 96 well plates 
(Nunc)  to perform MIP1α ELISA using the human Duoset Human MIP-1α 
ELISA kit (R&D systems). Culture supernatants were added in doubling 
dilution after initial calibrations with neat and 1:10 , 1:50 and 1:100 dilutions. 
The 96 well plates were read at the end of the protocol with fluorescence 
intensity (FI) per well was read at λex488nm/λem528nm using a FLx800 
multidetection microplate reader (Biotek Instruments, USA). FI data were 
collected using Gen5 1.07 software. The concentrations of MIP-1α were 
estimated by reading off the standard curve. 
IL-6 ELISA: HS5 stromal cells were plated on the 96 well plates overnight at a 
density of 2 x 10^4 cells per well. Once the stromal cells were fully covering 
the base of the wells, MM1S and MM1R cells were plated at a density of 2 x 
10^5 cells ml in 96 well plates with and without drugs for 24 hours. Dasatinib 
150nM, Dexamethasone 1uM and combination of Dasatinib and 




dexamethasone were used. The supernatants were taken after 24 hours and 
stored in -20°C until experiments were performed. The supernatants were 
added to the Maxisorp® ELISA 96 well plates (Nunc) to perform IL-6 ELISA 
using the human Duoset Human IL-6 ELISA kit (R&D systems). Culture 
supernatants were added in doubling dilution after initial calibrations with neat 
and 1:10, 1:50 and 1:100 dilutions. The 96 well plates were read at the end of 
the protocol with fluorescence intensity (FI) per well was read at 
λex488nm/λem528nm using a FLx800 multidetection microplate reader 
(Biotek Instruments, USA). FI data were collected using Gen5 1.07 software. 



























EFFECT OF DRUGS ON 
PLASMA CELLS







4.1.1   Cell Lines and models 
 
Plasma cells are end stage differentiated B cells. Myeloma cells obtained from 
patients bone marrow separated by immunomagnetic separation fail to survive 
for long periods despite growth factors and fortified human serum. Therefore 
most of the laboratory work utilises human myeloma cell lines. Myeloma 
patients develop secondary plasma cell leukaemia during end stages of their 
disease and most of the cell lines developed have utilised this source to 
culture human myeloma cell lines in vitro. U266 and RPMI 8226 were the first 
human cell lines developed. To date 81 myeloma cell lines have been 
developed from 73 patients with terminal features.  Myeloma cell lines have a 
significant genomic heterogeneity as observed in patients156. Presence of high 
risk cytogenetic features such as t(4;14) and del 17p continue to remain 
prognostic in the era of novel agents. Some of these cell lines harbour these 
specific high risk genomic aberrations156. Therefore drugs and other 
therapeutic interventions should be tested on a panel of cell lines. They serve 
as a useful resource to study the effect of drug combinations and biological 
features of the disease. Human myeloma cell lines also differ in their 
requirement for growth factors to maintain these cells in long term cultures, 
such us IL-6 dependence in INA-6 and XG-1 cell lines. Caution has been 
raised by Drexler et al who have reported on so called “false” myeloma cell 
lines used in several publications over the years. He defines them as EBV 
transformed lymphoblastoid cell lines with immunophenotypic and genotypic 
characteristics of lymphoma cells 157. This underpins the importance of 




choosing a panel of cell lines and growing them in adequate conditions to 
ensure that they retain parental characteristics. Myeloma cell lines with 
differential response to steroids which is one of the backbone of myeloma 
therapies, is an extremely useful tool to study drug combinations. Greenstein 
et al have developed cell lines from a single MM patient. Three separate cell 
lines were established that parallel the progression of the disease. These 
three cell lines, designated MM1.S, MM1.RE, and MM1.RL, can be 
distinguished on the basis of their sensitivity to steroid hormones such as 
glucocorticoids158.  
Myeloma models have been developed over the years particularly to look at 
biological aspect of mutations driving the disease, bone disease, drug effects 
in immunocompromised mice injected with myeloma cell lines. 5T myeloma 
cells that arose spontaneously in aged, inbred C57BL/KaLwRij mice and are 
propagated by the inoculation of these myeloma cells into syngeneic mice 
have been developed. 5T33 myeloma cell lines have been generated 
characterised and maintained in syngeneic animals by Radl et al at Leiden159. 
More recently using lentiviral transduction eGFP expressing 5T33 cell line was 
developed and described by Alici et al. They used the fluorescent marker to 
map the homing and quantify tumour load in the mice160. 
 
Primary cells maintained in pooled plasma or in cultures fortified with IL-6 
have been used to study effects of the drugs in vitro. Efforts are on to improve 
the ex vivo cultures of myeloma cells to better understand the effects of drugs 
on primary myeloma cells from patients with relapsed disease. 
 
 




4.1.2   Drug Exposure 
The underlying principles of drug exposure are based on an understanding of 
the causal relationships between exposure and effect. When the cell lines are 
exposed to drug at varying concentration the classical dose response curve 
which is sigmoid shaped is generated.  The lowest dose at which there are no 
effects observed is called No Observable Effect Level (NOEL). The dose at 
which 50% of cells apoptose or die would be classified as IC 50, in other 
words, it is the half maximal (50%) inhibitory concentration (IC) of a 
substance. It is important the concentrations studied in the lab are clinically 
achievable. The main stumbling for drug therapy is toxicity and concentrations 
safely achieved in Phase I trials should guide these experiments 
When drug combinations are studied together, serial concentrations of drug 
are added to the cell lines and a dose response curve is generated. The 
combined effect of the drugs could either be additive, antagonistic or 
synergistic.  Calcusyn is the software employed in my thesis to study these 
effects. Calcusyn is a software which analyses effect of drug combinations 
and is able to automatically quantify phenomena such as synergism and 
inhibition. The software performs multiple drug dose-effect calculations using 
the Median Effect methods described by T-C Chou and P. Talalay.  A 
Combination Index (CI) value of <1.0 indicates synergy and >1.0 is additive. 
Effects of drugs on cell lines and primary cell should be validated in other 
systems with other read outs. For example in studying cell proliferation, 
employing MTT assays, cell counts and trypan blue estimation to look at 
viability. This will enhance the validity of the results. I have performed cell 
cycle analysis, expression of Annexin V and 7-AAD to look at proportion of 




early apoptotic cells, necrotic cells and also examine the number of cell in Sub 




























4.1.3 Soluble factors 
Myeloma cells secrete soluble factors which help autocrine growth along with 
paracrine effects on the accessory cells in the microenvironment. The tumour 
cells activate the stroma by producing and secreting cytokines and growth 
factors, matrix metalloproteinases (MMPs). Myeloma cells can produce and 
secrete a variety of cytokines and growth factors into the MM BM 
microenvironment, including: IL-6, IGF-1, VEGF, TNF-α, SDF-1α, TGF-β, 
bFGF, MIP-1α, SCF, HGF, IL-1β, IL-3, IL-10, IL-15, and IL-21, as well as Ang-
1 and matrix metalloproteinases (e.g. MMP-2 and MMP-9) 54. IL-6 is the major 
growth and survival factor in MM cells, and also confers drug resistance to 
dexamethasone. VEGF and IGF -1 also secreted by plasma cells induce both 
autocrine and paracrine effects in the microenvironment driving tumour 
resistance and angiogenesis. 
IL-6 and MIP 1α are the two key cytokines measured in the experiments 
described this chapter. IL-6 is a key cytokine with pleiotropic effects on the 
plasma cell clone. Serum levels of IL-6 reflect disease severity in multiple 
myeloma patients. The levels of IL-6 are low in patients with smouldering 
disease or MGUS161. MIP-1α plays an important role in mediating bone 
disease in myeloma patients162.  The serum level of MIP 1α is elevated in 










4.2   Aims 
The aim of the experiments reported in this section of thesis is to determine 
whether Dasatinib, dexamethasone and the combination inhibit cell 
proliferation. If the drugs inhibit myeloma cell proliferation the next set of 
experiments will be to determine whether their effect of the drug combination 
is additive, antagonistic or synergistic. The levels of key cytokines IL- 6 and 
MIP 1α will be measured to observe whether drug exposure inhibits secretion 
of these cytokines which provide autocrine growth and paracrine effects. 
Induction of apoptosis will be analysed by studying the expression of Annexin 
V.  Cell cycle analysis will be performed to confirm the induction of apoptosis 
































4.3   Effect of drugs on proliferation of human myeloma cell lines 
 
 
Human myeloma cell lines MM1S, MM1R, RPMI 8226, U266, ARH 77 and 
murine myeloma cell lines 5T33 and 5T33 GFP were chosen for studying the 
effect of drug exposure. To determine the actual cell numbers required to 
study the proliferation over a 96 hour period, a growth curve was performed 
using the MTT assay. 
 
4.3.1 Growth curve  
MM1S and MM1R cell lines were seeded in 96 well plates in the following cell 
numbers in media (Fig 1). Cell numbers 2 x104, 4 x104 and 8 x 104 per well in 
200ul of culture medium were seeded in 5 plates. These plates were analysed 
by MTT assay as described in the methods and materials section including a 
control well (blank) for control of the background of OD emission in empty 
wells. Optical density values presented in Graphs 1-3 are after subtraction 
from blank values (control). The optical density values were plotted in Y axis 
and the time period in X axis. MM1S cells plated at a concentration of more 
than 8 x 104 cells per well (4 x 105 cells/ml) showed a proliferative response 
and this was used as initial seeding concentration for further experiments. 
MM1R cells plated at a density of more than 2 x 104 cells/well (2 x 105 cells 
per ml) showed a serial growth over 5 days and was used as initial seeding 
density of cells when plated alone or in coculture in further experiments 
described in the thesis. ARH77 cells, RPMI 8226 and U266 were plated at the 
same densities as described above over a 5 day period (Fig 2). The initial cell 
density levels of 4 x104 cells per well of media was adequate to provide 
exponential growth in all three cell lines. A higher cell density of 8 x 104 cells 




per well media showed no growth in ARH77 and RPMI8226 cell lines. This is 
probably due to the media being depleted of nutrients within the first 24 hours 




































































Fig 2: Growth curve of ARH77, RPMI 8226 and U266 human myeloma cell 
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4.3.2   Proliferation of human myeloma cell lines 
 
 
Human MM1S, MM1R, RPMI8226, ARH 77 and U266 cells were either left 
untreated or treated with Dasatinib used at 2 different concentrations 100nM 
and 150 nM. Concentrations above this were not chosen as the maximum 
serum concentration achieved in phase I studies was 180nM164. Subsequent 
to these initial studies, clinical efficacy with tolerable side effects was 
observed at a lower dose compared to those used in Phase I studies 143. 
Dexamethasone was used at 2 concentrations 1uM and 2 uM as reported in 
other studies165. Combination of dasatinib and dexamethasone was used at 2 
dose levels, 100nM + 1uM and 150nM + 2uM to inhibit proliferation of 
myeloma cell lines. PP3 an inactive Src analogue (Calbiochem, UK) which 
serves as control for Src inhibitor PP2 (Calbiochem, UK). PP2 is a 
commercially available Src inhibitor with chemical name (4-amino-5-(4-chloro-
phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine was initially reported as highly 
selective for Src family kinase166. Subsequently it has been shown that PP2 
down regulates both c-kit and Abl kinase activity167. Cells were also treated 
with Imatinib mesylate, a tyrosine kinase inhibitor which down regulates abl 
kinase activity.  Cell lines left untreated continued to proliferate as evidenced 
by increased cell numbers on the MTT assay. Treatment with dexamethasone 
strongly inhibited proliferation of MM1S, RPMI8226 and U266 cells even at 
the lower concentration (Figure 3).  MM1R, ARH77 cells were resistant to 
dexamethasone. Dasatinib on its own even at the higher concentration of 
150nM had a more modest inhibition of proliferation in MM1S and RPMI 8226 
cells with almost no effect on the other human myeloma cell lines.  




Combination of dasatinib and dexamethasone inhibited proliferation of all 
human myeloma cell lines tested but clearly cells which were dexamethasone 
sensitive showed a more profound reduction in proliferation compared to 
dexamethasone resistant cells (Figure 3). This was observed at both levels of 
combined dose used. PP2, inhibitor of Src kinase inhibited proliferation of 
MM1S, RPMI 8226, U266 human myeloma cell lines. The differences 
observed between PP2 and dasatinib could be explained partly by 
concentration of dasatinib used in these experiments. The differences could 
also be due to the spectrum of different tyrosine kinases inhibited by both 
drugs. Imatinib mesylate showed almost no effect on proliferation in human 






















Figure 3: Growth inhibition of myeloma cell lines by combination of 
Dasatinib and dexamethasone. Cell numbers in myeloma cell line cultures 
were estimated using MTT assay at  6 hours    , day 1     and day 5          post-
plating. Cells were left untreated (U) or treated with 10uM PP3, 5uM &10 uM 
PP2, 10uM Imatinib ( IM) 100nM and 150 nM Dasatinib (Das100, Das150) , 
1uM and 2 uM Dexamethasone (Dx1 & Dx2)  and combination of 100nM 
Dasatinib and 1uM Dexamethasone (C1), combination of 150nM Dasatinib 
and 2uM Dexamethasone (C2) . Histograms A) MM1S B) MM1R C) ARH 77 
D) RPMI 8226 E) U266. Cell lines were Human derived (A-E). Histograms 
show Mean +SD. * p < 0.05 Student t- test versus control untreated ** p 
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4.3.3   Synergy Assay 
 
Dasatinib and dexamethasone combination inhibited proliferation of human 
myeloma cell lines tested. To establish whether these effects are additive, 
antagonistic or synergistic proliferation assay was performed at various drug 
concentrations of dexamethasone alone, dasatinib alone and the 
combinations. MM1S ( Dex sensitive)  and MM1R  (Dex resistant) cell lines 
were exposed to Dasatinib at concentrations of 50nM, 100nM, 150 nM and 
200nM with dexamethasone 0.5uM, 1uM, 1.5uM and 2uM respectively. Cell 
lines were also treated with paired combinations of dasatinib and 
dexamethasone at all four dose levels. MM plasma cells continued to 
proliferate in presence of Dasatinib concentrations between 50nM and 200nM. 
As expected MM1S failed to proliferate when treated with dexamethasone 
whereas only the highest concentration of dexamethasone inhibited 
proliferation of MM1R in modest amounts. The combination inhibited 

















Figure 4: Growth inhibition to varying combinations of Dasatinib, 
dexamethasone. Cell numbers in myeloma cell line cultures were estimated 
using MTT assay on day 1     , day 2     , day 3        and    day 4      , post-
plating. Cells were treated with 50nM, 100nM, 150 nM and 200nM Dasatinib 
(Das50, Das100, Das150, Das 200) or 0.5uM, 1uM, 1.5uM and 2 uM 
Dexamethasone (Dex 0.5, Dex1, Dex 1.5 & Dex2)  or combination of 50nM 
Dasatinib and 0.5uM Dexamethasone (D+D1),  100nM Dasatinib and 1uM 
Dexamethasone (D+D2), 150nM Dasatinib and 1.5uM Dexamethasone 
(D+D3), combination of 200nM Dasatinib and 2uM Dexamethasone (D+D4) . 
















The data obtained from the MTT assay were input into the Calcusyn software. 
The software is based on the Chou-Talalay method. The resulting 
combination index (CI) theorem of Chou-Talalay offers quantitative definition 
for additive effect (CI = 1), synergism (CI < 1), and antagonism (CI > 1) in 
drug combinations 168. The above OD data obtained with combinations of 
dasatinib (up to 150nM) and dexamethasone (up to 1.5uM) were analysed by 
Calcusyn 2.0 software (Fig 5). In both MM1S and MM1R myeloma cell lines, 
all the examined dose level combination s of Dasatinib and dexamethasone 





















Figure 5: Synergy assay:  Calcusyn software output for MM1S (A) and 
MM1R (B) cell lines showing 3 different combination dose levels 1- 50nM 
Dasatinib and 0.5uM Dexamethasone (D+D1), dose level  2 - 100nM 
Dasatinib and 1uM Dexamethasone (D+D2), dose level 3- 150nM Dasatinib 
and 1.5uM Dexamethasone (D+D3). The values are less than 1.0 confirming 




















































4.4 Apoptosis measurement and cell cycle analysis 
 
Exposure to the combination of dasatinib and dexamethasone inhibited the 
proliferation of the myeloma cell lines. To understand whether inhibition of cell 
proliferation was cytostatic or correlated with increased cell death, cell lines 
were plated at the same density in parallel to proliferation assays in 24 well 
plates with and without drugs. On the days of proliferation analysis, cells were 
stained for 7-AAD and Annexin V in parallel for flow cytometric analysis to 
determine the percentage of apoptotic and necrotic cells. Phosphatidylserine 
is translocated to surface of plasma membranes on myeloma cells and 
Annexin V, an early marker of apoptotic cells preferentially binds to negatively 
charged Phosphatidylserine in the presence of Calcium. 7-AAD expression is 
a marker of necrotic cell death and late apoptotic cells. 7-AAD is an analogue 
of actinomycin D and binds to DNA of late apoptotic cells (7- AAD positive 
Annexin V positive) and necrotic cells (7 –AAD positive and Annexin V 
negative). In MM1S cells,   there was 5- 10% apoptotic fraction in untreated 
cells at baseline. Upon treatment with Dasatinib 150nM after 4 days there was 
no significant increase in apoptosis or necrosis (Fig 6A). Treatment with 1uM 
dexamethasone induced high levels of apoptosis. The combination of 
dasatinib and dexamethasone induced significant apoptosis and cell death 
with up to 70% of cells staining for both 7-AAD and Annexin V and 25 % 
staining for Annexin V alone. In MM1R cells there was a small increase in 








Fig 6: Flow cytometric analysis of apoptotic and necrotic fraction in the 
presence of drugs. MM1S (A) and MM1R (B) cells left untreated (U), or 
treated with dexamethasone 1uM(Dex), Dasatinib 150nM (Das) and 
combination of dasatinib and dexamethasone (D+D). Flow cytometric analysis 
with Annexin V staining (FITC) in Y axis and 7-AAD staining (PerCP-Cy5.5A) 
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Cell cycle analysis: 
 
Determining the relative cellular DNA content can provide a great deal of 
information about the cell cycle, and consequently the effect on the cell cycle 
of added stimuli, e.g.  Drug treatment.  Four distinct phases can be 
recognised in proliferating cells: the G0/G1-, S- (DNA synthesis phase), G2- 
and M-phase (mitosis). However, G2- and M-phase, which both have an 
identical DNA content, cannot be differentiated based on their DNA content. 
The major limitation to this analysis is the presence of doublets and clumps in 
the cell suspension.  A doublet is formed when two cells with a G1-phase DNA 
content are recorded by the flow cytometer as one event with a cellular DNA 
content similar to a G2/M-phase cell. This could lead to a false overestimation 
of G2/M population. Reduced DNA content in the Sub G0/G1 cell population is 
a useful way of detecting very late stage apoptotic phenotype cells 169,170. The 
limitation of this use is a sizeable proportion of this SubG0/G1 fraction could 
include cell debris. Human myeloma cell lines were fixed with ethanol and 
treated with RNase before staining with propidium iodide. Cells were plated in 
parallel to proliferation assays in 24 well plates with and without drugs to 
perform cell cycle analysis. MM1S cells upon treatment with the drug 
combination stopped proliferating as evidenced by absence of G2/M fraction 
of cells with an increase in Sub G0/G1 fraction of cells (Fig 7, 8).  In the 
MM1R cells although there was a constant fraction of proliferating cells in 
G2/M phase (25%), an increase in Sub G0/G1 fraction on exposure to drug 
combination confirming cell death, was observed ( Fig 7,8). The proportion of 
cells in Sub G0/G1 fraction in both ARH77 and RPMI8226 cell lines increase 
with the combination drug treatment in comparison to dasatinib or 




dexamethasone alone. This is was associated with a reduction of proliferating 



























Figure 7: Cell cycle analysis.  Cell cycle analysis was performed by flow 
cytometry after fixation with ice-cold 70% ethanol and staining with propidium 
iodide. The FACS plots shown were performed after 5 days of treatment with 
dexamethasone or combination of Dasatinib 150nM and dexamethasone 2 
uM (Dex 2+ Das 150).  MM1S cells are shown on the left panel and MM1R on 














Figure 8:  Increased Sub G0 and reduced G2/M populations on treatment 
with Dasatinib and Dexamethasone. Cell cycle analysis in myeloma cell 
cultures were performed by flow cytometry after fixation with ice-cold 70% 
ethanol and staining with propidium iodide on Day 1           and Day 5      post 
plating. Histograms show proportions of nonviable (Sub G0) and proliferative 
(G2/M) populations of MM1S (A, B) and MM1R (C, D) cell lines in a 
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Figure 9: Cell cycle analysis was performed on ARH77 and RPMI 8226 
cells with and without drug treatment. Cell cycle analysis in myeloma cell 
cultures were performed by flow cytometry after fixation with ice-cold 70% 
ethanol and staining with propidium iodide on Day 1 (      )   and Day 5 (    ) 
post plating. Histograms show proportions of nonviable (Sub G0) and 
proliferative (G2/M) populations of ARH77 (A, B) and RPMI8226 (C, D) cell 
































































































































4.5   Effect of drugs on soluble myeloma growth factors 
 
 
In the in vivo setting when the myeloma cells are exposed to drugs there are 
key proliferation signals within the microenvironment particularly cytokines 
enhancing the proliferation and resistance as has been shown with Interleukin 
6 (IL-6). Dasatinib and dexamethasone combine to inhibit proliferation of both 
human and murine myeloma cell lines by inducing apoptosis in vitro as shown 
in the previous experiments. The aim of this set of experiments was to see if 
the level of the cytokines known to promote survival of myeloma cell, present 
in the suspension, changed with exposure to drugs. IL-6 is primarily secreted 
by stromal cells whereas Macrophage inhibitory protein -1 α (MIP -1α) is 
primarily secreted by the plasma cells. The first set of experiments was done 
to optimise the number of cells, duration of cultures with media added to blank 
wells as controls. MM1S and MM1R cells were initially plated at 1 x 106 
cells/ml with and without drug treatment for 48 hours. Under these conditions, 
the levels of IL-6 were too low for quantitation. As previously reported, 
myeloma cells at 5 x 105 cells/ml were plated on stromal cells overnight at 
density 1 x 105 cells/ml for 72 hours171. IL-6 levels were significantly reduced 
with dasatinib and dexamethasone combination with a more modest reduction 
in the cocultures with MM1R cells (Fig 10 A). The levels of MIP 1α dropped 
significantly with 48 h drug treatment in MM1S cells cultured alone but not in 
MM1.R cells (Fig 10 B). These decrease in levels of secreted IL-6 and MIP 1α 
in the supernatants correlated with reduction in cell numbers as previously 
shown in Figure 4 of this chapter (Fig 10 A). From these results it is not 
possible to determine if the reduced levels of extracellular IL-6 is due to an 
effect of the drug on the cells or just due to the decrease in cell numbers.  To 




study if drug exposure would inhibit release of cytokines from plasma and/or 
stromal cells, the culture was optimised to short term cultures for 24 hours at a 
cell density of 2 x 105 cells per ml. For IL-6 estimation these cells were plated 
on stromal cells plated overnight at density of 1 x 10
5 
cells per well in 1 ml 
culture medium. The myeloma cells were left to adhere for 24 hours on 
stromal cells in media either untreated or treated with dasatinib, 
dexamethasone or the combination. After 24 hours the supernatants were 
taken and plasma cell numbers were counted and also estimated using MTT 
assay. There were no significant differences in cell numbers with drug 
treatments after 24 hours in both MM1S and MM1R cell lines (Figure 11 A).  
IL-6 levels decreased with dexamethasone treatment alone and combination 
of dasatinib and dexamethasone. This was observed in both MM1S and 
MM1R cell lines (Figure 11 B). This confirms an inhibition in secretion of IL-6 
in cocultures of plasma cells and stromal cells by dexamethasone and the 
combination treatment. MIP-1α secretion by both MM1S and MM1R cells was 
unaffected by dexamethasone, dasatinib and the combination of both within 













Figure 10: Cytokine levels. IL-6 estimation in ng/ml from supernatants of 
MM1S and MM1R cells plated at density of 5 x 105 per ml on 1 x 105 per ml of 
stromal cells (SC) for 48 hours (A). MIP 1 alpha estimation in ug/ml from 
supernatants of MM1S and MM1R cells plate at a 1x106 cells per ml for 72 
hours. Dasatinib and Dexamethasone combination (D+D) reduced IL-6 and 


















Fig 11: IL-6 levels and cell numbers. Human stromal cells (HS-5) were 
plated at a density of 1X105 per ml overnight. MM1S and MM1R cells plated 
at 2 x 105 per ml for 24 hours on stromal cells and left to adhere in media 
either untreated or treated with Dasatinib ( Das), Dexamethasone (Dex) or the 
combination (D+D). Histograms show cell numbers (A) estimated by MTT 
assay and IL-6 levels in ug/ml (B) from supernatants after 24 hours. * p <0.05 
Student t - test 
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Fig 12: MIP-1α levels and cell numbers. MM1S and MM1R cells plated at 2 
x 105 per ml for 24 hours in media left either untreated or treated with 
Dasatinib ( Das), Dexamethasone ( Dex) or the combination ( D+D). 
Histograms show MIP-1α levels in ug/ml (B) from supernatants and cell 


















































































































































The reduction in IL-6 levels aids inhibition of proliferation of myeloma cell in 
vivo by drug treatments. This reduces the paracrine effects on stromal cells, 
osteoclasts within the microenvironment which is permissive and helps 
survival of plasma cells. The lack of reduction of MIP-1α in 24 hours shows 
that secretion remains uninhibited in cell suspensions but with reduction in 
tumour load induced by cell kill, the total levels of MIP-1α will fall resulting  in 
























Dexamethasone based therapies particularly in combination with alkylating 
agents was mainstay of treatment for myeloma. Although patients respond 
early they become resistant particularly due to presence of cells in the 
microenvironment which promote survival of plasma cells, enhance resistance 
and presence of soluble factors which enhance proliferation. In this section of 
the thesis, Dasatinib a multitargeted tyrosine kinase, particularly Src kinase 
was combined with dexamethasone and tested on human myeloma cell lines. 
The drug combination inhibited proliferation of all the cell lines to variable 
degrees. The effects were confirmed to be synergistic in both dexamethasone 
sensitive and resistant cell lines. These findings will be tested in the presence 
of stromal cells and osteoclast, key cellular partners in the microenvironment 
in further sections of this thesis. The concentration of dasatinib tested is 
clinically achievable and on its own has very little effect on the plasma cells. 
Vij et al showed that single Dasatinib has very little effect in relapsed / 
refractory myeloma patients 151. This is predictable based on the results of the 
experiments described in this section where as a single agent it had very little 
effect in  either  inhibiting proliferation of myeloma cells or the induction of cell 
death. Also the synergism exhibited by the drugs can be exploited clinically, 
as high doses of dexamethasone used as standard has high degree of non 
haematological toxicity. 
The levels of IL-6 but not MIP -1 alpha secretion fell with treatment using 
dexamethasone and the combination of dasatinib and dexamethasone. 
Although Dasatinib alone does not inhibit secretion of IL-6, it down regulates 
c-Src which is a key intracellular Tyr-kinase and adaptor protein in IL-6 




signalling pathway 172. Dexamethasone is used primarily as an anti-
inflammatory agent in clinical practice.  Glucocorticoids effectively 
downregulate tumour necrosis alpha induced cytokine production including IL-
6. In the context of myeloma dexamethasone has been shown to reduce IL-6 
production by stromal cells 173. Reduction in IL-6 levels observed was initially 
thought to be due to enhanced repression of NFκB, but was shown to be due 
to interference of the activated glucocorticoid receptor with the transactivation 
potential of the NF-kappaB p65 subunit
174
. Glucocorticoids also up regulate 
glucocorticoid induced leucine zipper gene in myeloma cells which inhibits 
NFκB and activated protein-1 (AP-1) stimulated IL-6 production More recently 
it has been shown that dexamethasone affects the redox state of myeloma 
cells and transcription  factor AP-1 binding activity and resultant IL-6 
expression, is dependent on the oxidative state of the cells175.  
 There are many possible mechanisms for the observed enhanced pro 
apoptotic effect of the combination of dasatinib and dexamethasone on 
plasma cells. Dexamethasone has been shown to induce cleavage of caspase 
9 and its activation, whereas dasatinib induced cleavage of caspase 8 and 
therefore combining well to induce caspase mediated apoptotic cell death 152. 
MM1R cells are resistant to dexamethasone because of a truncated 
glucocorticoid receptor (GR). Sharma et al showed that when cells were 
Lentiviral transduced with GR, they reversed to become dexamethasone 
sensitive. In these cells when NFkB is repressed, apoptosis is induced even in 
cells with truncated GR165. They also demonstrated that in non transduced 
cells upon dexamethasone exposure cells survived despite induction of Bim  
 




and RAFTK phosphorylation. This shows that the dexamethasone resistant 
cells can be treated with combination of dexamethasone and other agents to  
induced a response  in resistant cell lines. Vacca et al showed PDGFR β, c-
Src and VEGF down regulation by dasatinib plays a key role in inhibiting 
angiogenesis and tumour growth in vivo105. The inhibition of multiple tyrosine 
kinases in the plasma cells makes the cell more susceptible to 
dexamethasone treatment. This effect theoretically could be enhanced in vivo 
because of the effects on the marrow microenvironment with Dasatinib. This 
observation has major implications in vivo where plasma cells adhere to the 
cellular partners, extracellular matrix proteins and has a favourable soluble 
milieu along with enhanced angiogenesis in presence of activated osteoclasts. 
The drug combination could potentially produce significant responses in 
relapsed patients particularly with active bone disease.







eGFP TRANSDUCTION OF 
MYELOMA CELL LINES AND 
DEVELOPMENT OF NOVEL in vitro 
COCULTURE SYSTEM 









5.1 Introduction  
The development of permissive conditions in the BM microenvironment leads 
to MM-cell growth, survival, drug resistance and enhanced invasive capacity 
54,100,176-178
. Mounting evidence on the role of tumour microenvironment in 
supporting the growth and survival of myeloma cells makes testing of potential 
drug treatments in vitro in this setting almost obligatory. Recently developed 
strategies recreate the myeloma tumour microenvironment in vitro allowing for 
detection of myeloma cell proliferation or distribution in bone marrow 
compartments using cell imaging. However, there is still a need to develop 
self–contained co-culture methods to apply various laboratory technologies 
and differentiate the behaviour of myeloma plasma cells from the accessory 
cells in the tumour microenvironment. Currently, most of the studies evaluate 
the anti-myeloma potential of drugs on MM cells or different BM 
microenvironment cells cultured separately. However, in the BM these cells 
interact with each other and hence, in vitro evaluation of the possible anti-
myeloma effect of drugs would be performed more accurately using co-culture 
systems. Although some studies try to address this issue179-181, the key 
problem with currently available cell viability assays is its lack of applicability 
in co-cultures systems, as the signal is generated from all cell populations in 
culture. Although the luciferase reporter systems partly overcome this 
problem, by marking the cells of interest, this technique is still restrictive as it 
allows only evaluation of proliferation and viability of MM cells using 
luminescence readers 181.  
Human 181 and mouse 158 eGFP-MM cell lines have been generated before 
and used in in vitro and in vivo studies. The eGFP signal in MM cell lines has 




been used to physically separate MM cells in co-culture with stromal cells 
using FACS sorting for further gene expression profiling 181 as well as for in 
vivo BM homing studies of MM cells 95. In this chapter, we characterise eGFP-
MM cell lines that we have generated. Our data show that our system enables 
to determine cell numbers using fluorimetry or image analysis with the same 
sensitivity as standard MTT assay. eGFP expression also enables detection 
using flow cytometry of apoptotic plasma cell fraction (eGFP positive fraction 
of co-cultures) in co-cultures with microenvironment cells (eGFP negative 
fraction of co-cultures), cell cycle analysis and FACS-sorting to apply other 
techniques such as gene expression profiling 181. Additionally, the expression 
of eGFP would allow us to track and/or visualise the morphology of MM cells 
in co-culture with other BM cells using fluorescent microscopy or live video 
microscopy. Before embarking on a clinical trial with new agents, validation of 
the effect of these compounds in vitro using eGFP-MM cells lines in the 
presence of tumour microenvironment provides a self-contained experimental 
platform for identifying optimal drugs and drug combinations and targeting 














In this chapter, I discuss the generation and validation of eGFP-MM cell lines 
using colorimetry and fluorimetry. I have also developed an in vitro co-culture 
model with stromal cells and osteoclasts to distinguish the effect of drugs or 

























5.3 Characterisation of eGFP expressing MM1S and MM1R MM cell lines 
 
Infection with lentiviral vectors had 97% and 80% efficiency in transducing 
MM1S and MM1R cell lines respectively, with the lentivirus DNA coding for 
GFP. This was confirmed by measuring GFP expression on flow cytometry 
(Figure 1middle panels). Following clonal selection by limiting dilution assay 
as described in materials and methods, 4 clones of eGFP-MM1S cells and 5 
clones of eGFP-MM1R cells were selected. The clones were expressing 
eGFP homogenously in comparison with the initially transduced parental 
population (Figure 1 right panels), which supports their clonality. The 
expression of eGFP using lentivirus transduction and the cloning process 
using limiting dilutions may alter the growth potential of these cell lines. To 
confirm the growth potential, cell proliferation of 4 clones of eGFP-MM1S and 
5 clones of eGFP-MM1R was evaluated over 96 hours using an MTT assay. 
Cells were plated in parallel with the parental cell lines (Figure 2, 3). There 
were no major differences in the pattern of proliferation with respect to 
parental cell lines by MTT assay. Growth kinetics of eGFP-MM1S Clone 3 and 
MM1R Clone 2 GFP were almost identical to the parental cell lines and were 
used in all further experiments described in this thesis. Dual peaks of eGFP 
expression were observed by flow cytometry primarily in clonal cultures of 
eGFP expressing MM1S cells during the initial days of proliferation before 
entering exponential growth. It was also observed that the lower intensity 
eGFP signal corresponded to cells with smaller forward scatter and increased 
side scatter (Fig 4). Previous experiments with parental cell lines described in 
this thesis showed that an increase in this subpopulation of cells in non-
proliferative cultures which may correspond to senescent cells or cells 




entering apoptosis. Hence, I investigated whether these changes in eGFP 
levels were dependent on the phase of cell cycle or cell viability. Lower eGFP 
levels were predominantly expressed by eGFP-MM1S cells in the sub-G0 
phase of the cell cycle (Fig 5). Treatment of eGFP-MM1S cells with 
Dexamethasone resulted as expected in an increase in the percentage of 
cells in the sub-G0 population. This sub-G0 population corresponded to the 
population of eGFP-MM1S expressing low levels of eGFP. A proportion of low 
eGFP expressing cells were also in the G0 phase (non – proliferating 
fraction).  This confirms that the generated eGFP-MM1S cells are clonal and 
the observed population of low-expressing eGFP cells, which also display 
lower forward scatter and higher side scatter in the initial and final stages of 
the cultures correspond to non proliferating (G0) or predominantly to apoptotic 

















Figure 1.  eGFP transduction and clonal selection. eGFP levels detected 
by flow cytometry in MM1S (upper panels) and MM1R cells (lower panels) pre 





















Figure 2: Growth curve of parental and eGFP MM1S clones. Growth curve 
of MM1S, MM1S GFP clones 1 -4 analysed by MTT assay over 96 hours. 
Parental and eGFP-expressing cells proliferated at the same rate since we 
found no statistical differences between the rate of increase in number of cells 


















Figure 3: Growth curve of parental and eGFP MM1R clones. Growth curve 
of MM1R and MM1R GFP clones 1-5 analysed by MTT assay over 96 hours. 
Parental and eGFP-expressing cells proliferated at the same rate since we 



















Figure 4: Distinct populations of eGFP expressing cells. (A) Dot plot of 
forward and side scatter as detected by flow cytometry in MM1S cells left 
untreated showing two populations of cells (grey and black); ( B) Histogram 
showing levels of expression on eGFP in MM1S cells. Data show that the 
population with lower forward scatter and larger side scatter expressed lower 






















Figure 5: Cell cycle analysis of eGFP expressing cells. MM1S cells 
expressing eGFP were either left untreated or treated with dexamethasone for 
48 hours. Cells were fixed, permeabilised and stained with propidium iodide 
and cell cycle analysis was performed. Cells expressing lower levels of eGFP 


















5.4 Cross validation of use of fluorimetry for enumerating cell numbers 
and cell proliferation 
MTT assays are colorimetric assays which are based on mitochondrial activity of 
cells. They are widely used for cell number estimation by most laboratories. The 
intensity of fluorescence from the eGFP-MM cell lines can be measured as 
fluorescence intensity (FI) in arbitrary units using a fluorescent plate reader.  To 
establish if measuring FI emitted by MM cells was a sensitive method to estimate 
the number of cells in culture per well, with similar threshold of detection as 
commonly used methods such as MTT assay, I compared the sensitivity of 
detection of cell numbers by measuring FI before obtaining OD signal (MTT assay) 
in identical wells. eGFP-MM1S and eGFP-MM1R cells were plated at 1, 5, 10, 25 
and 50 x 104 per well which corresponds to a maximum density of 2.5 x 106 cells 
per ml. Both the OD signal and the FI measurement of eGFP-MM cell lines were 
equally proportional to the number of cells plated per well (Figure 6). There was 
good correlation between MTT assays and Fluorescence detection in both MM1S 
GFP and eGFP-MM1R cells with a coefficient of determination R2 = 0.99 (Figure 
7). This data supports the use of fluorescence detection by a fluorescence plate 
reader as a reliable substitute for cell number estimation in the place of 
colorimetric MTT assays, in GFP expressing cells. 
MM1S and MM1R cell lines differ in their sensitivity to Dexamethasone treatment. 
MM1R cells are resistant to Dexamethasone due to presence of truncated 
glucocorticoid receptor158,182. To test the experimental use of fluorimetry in 
comparison to standard MTT assay and to confirm that the eGFP-expressing cells 
retained the characteristics of the parental non-fluorescent cells, we studied the 
effect of Dexamethasone treatment on the cultures. Cells were left either untreated 




or treated with Dexamethasone for 4 days and both fluorimetry and 
spectrophotometry were performed to compare the methods. The eGFP-MM1S 
cells continued to be sensitive to Dexamethasone and eGFP-MM1R cells were 
resistant retaining the parental cell characteristics (Fig 8 A). The results obtained 
by fluorimetry were equivalent to the commonly used spectrophotometric detection 
(MTT assay) (Figure 8 B). Taken together the results show that measuring 
fluorescence intensity of eGFP-MM1S/MM1R cells is a valid method to estimate 
the numbers of cells in culture with the same sensitivity as standard methods such 




















Figure 6: Comparison between fluorimetry and MTT assay.  MM1S GFP 
(A, C) and MM1R GFP (B, D) were plated at  1, 5, 10, 25, 50 x 104 cells/ well 
in a 96 well plate and both fluorimetry, fluorescence emitted per well  eGFP in 



















Figure 7: Correlation curve. Correlation between OD and FI in MM1S GFP 






                                                         













 Figure 8: Drug sensitivity testing by fIourimetry and MTT assay. MM1S 
and MM1R GFP cells left untreated or treated with Dexamethasone over 4 
days and proliferation assessed by fluorimetry (A) and MTT assay (B). 
Differences in cell growth were statistically analysed by comparing the growth 





   
 
































































5.5: eGFP expressing MM cell proliferation and viability in the presence 
of BM stromal cells 
 
MTT assay is commonly used when testing sensitivity of agents on co-culture 
of plasma cells and stromal cells 179. But this method is fraught with problems 
as the signal generated is from mitochondrial activity of both cell types and it 
is not possible to differentiate between changes in cell numbers of plasma 
cells or the other cells in co-culture. In certain cases, the effect of certain 
drugs could have differential effects on the accessory cells in coculture with 
the plasma cell giving erroneous results. As shown in the previous section, the 
fluorescent signal from eGFP-MM1S and eGFP-MM1R cells correlates with 
cell numbers in culture. Hence, if co-cultured with other non-fluorescent cells, 
we could record the emission of fluorescence intensity over time and discern 
the growth of  eGFP-MM cell lines without interference of emission from the 
other cell types in co-culture.  
For cell proliferation assays of MM cell lines in co-culture, Human HS5 stromal 
cells (SC) were plated at a density of 0.3 x 10
5
 cells per well in a 96 well plate 
overnight. Media was aspirated and eGFP positive MM cell lines were plated 
at a density of 4 x 105 cell/ml (eGFP-MM1S) and 2 x 105 cell/ml (eGFP-
MM1R) on the semi-confluent SCs. On the days of assessment, plates were 
read in FLx800 multidetection plate reader as described in materials and 
methods. For FACS assays, HS5 SCs were plated at a density of 105 cell/ 
well overnight in a 24 well plate. GFP positive plasma cells were added at the 
above density with and without treatments. On the days of assessment, 
suspended cells (which corresponded mainly to PC) were collected and wells 
washed with PBS once to retrieve the remaining PC which were loosely 




adhered on SCs. We confirmed by flow cytometry that the remaining cells in 
the well were eGFP negative corresponding to SCs only (Figure 9). 
Using this method, we compared the effect of Dexamethasone on eGFP-
MM1S and eGFP-MM1R cells cultured alone or in the presence of the HS5 
SC. Co-culture of eGFP-MM1S cells with SCs blocked the anti-proliferative 
effect of Dexamethasone and MM plasma cells continued to proliferate 
(Figure 10 A). As expected, eGFP-MM1R cells cultured alone were resistant 
to Dexamethasone treatment and continued to proliferate in the presence of 
the drug independent of the presence of stromal cells (Figure 10 B). The 
proliferation data in the eGFP cell lines correlated with the levels of apoptosis 
detected by expression of Annexin V in plasma cells detected by FACS in the 
eGFP positive MM population. Treatment of eGFP-MM1S alone with 2 M 
Dexamethasone resulted in extensive apoptosis with 95% of eGFP-MM1S 
cells expressing Annexin V (Figure 11 A). However, when cells were co-
cultured with stromal cells, we detected that 60 % of eGFP-MM1S remained 
viable (Figure 11). As expected, eGFP-MM1R cells remained viable in the 
presence of Dexamethasone with very low levels of apoptosis independent of 
the presence of stromal cells (Figure 11 B). Taken together, our proliferation 
and apoptosis data indicate that stromal cells provide a protective 
environment for eGFP-MM1S cells, which would normally be sensitive to 
treatment with Dexamethasone. Our results also show confirmed that the 
genetic pool of eGFP-MM1R cells 158 make them resistant to Dexamethasone 
regardless of the presence of SCs. 
We also found that eGFP-MM1S cells failed to proliferate when cultured in 
serum free medium to remove all signals from soluble factors, whereas eGFP-




MM1R cells continued to proliferate (Figure 10) and remained largely viable in 
the absence of serum with only 25% of cells undergoing apoptosis, whereas 
87% of apoptotic cells were detected in eGFP-MM1S cultures in the absence 
of serum (Figure 11). Co-culture of eGFP-MM1R cells with stromal cells in 
serum free medium modestly promoted viability and proliferation of eGFP-
MM1R but not eGFP-MM1S cells (Figure 11). Taken together, our results 
indicate that eGFP-MM1R cells can induce autocrine stimulation leading to 
survival possibly by release of soluble factors. There is also a suggestion that 
eGFP-MM1R but not eGFP-MM1S cells have a higher potential of interaction 
with SCs leading to MM cell proliferation, in the absence of soluble factors 


















Fig 9: Flow cytometric determination of ability of extracting plasma cells 
from PC-SC cocultures. MM1S GFP and MM1R GFP cells were plated on 
HS5 stromal cells (SC) or grown alone in 96 well plate for 4 days either left 
untreated (UT), treated with Dexamethasone (Dex) or cultured in serum free 
medium (SF). After 4 days eGFP plasma cells were collected and stromal 




















Figure 10. Evaluation of proliferation and viability in eGFP expressing 
MM cells alone or in co-culture with human stromal cells. (A, B) MM1S 
GFP and MM1R GFP cells were plated on HS5 stromal cells (SC) or grown 
alone in 96 well plate for 4 days either left untreated (UT), treated with 
Dexamethasone (Dex) or cultured in serum free medium (SF) and 
fluorescence emission per well was determined using a fluorescence plate 
reader. Differences in cell growth were statistically analysed by comparing the 
growth index with respect to the number of cells at day 0 (Student’s t-test. ** 
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Figure 11: Flow cytometric evaluation of apoptotic fraction in eGFP 
positive cells in cocultures with stromal cells with and without 
treatment. Annexin V expression of MM1S (A) and MM1R GFP cells (B) 
plated on HS5 stromal cells or cultured alone for 4 days determined by flow 
cytometry. Flow cytometry scatter plots show expression of eGFP in the Y 
axis and expression of Annexin V-APC in the X axis of the eGFP positive 
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5.6 Proliferation and viability in eGFP expressing MM cells alone or in 
co-culture with osteoclasts. 
Osteoclasts play a key role in proliferation and survival of myeloma cells. 
Osteoclasts are activated in the microenvironment of myeloma patients and 
hence the effect of therapeutic interventions should be studied in the 
presence of osteoclasts. These have been detailed earlier in section 2.6.1. 
The key problems with using an MTT assay in cocultures have been 
discussed in the last section. Anderson et al studied effects of myeloma drugs 
on osteoclastogenesis and 2 key problems were observed when the 
experiments were performed. Cell doublets are formed in osteoclast cultures 
and they have to be gated out during analysis of FACS plots. The drug treated 
wells demonstrate mononuclear cells which are arrested in pre lineage 
commitment phase and therefore use of cell size or expression of surface 
proteins for gating in or out can be challenging. Clone hybrid cells are 
generated in osteoclast- plasma cell cocultures. These cells are thought to be 
resultant of a fusion between myeloma cells and osteoclasts183. These 
experimental observations underpin the importance of developing a myeloma 
coculture system to study the effects on plasma cells.  
Osteoclasts were differentiated over 3 weeks from primary BM mononuclear 
cells obtained from MM patients as previously described44. GFP positive 
plasma cells were layered on fully grown osteoclasts in 96 well plates. On the 
days of assessment, images were obtained using a fluorescence microscope 
and fluorimetry performed using a multi detection plate reader FLx800. For 
flow cytometry analysis, GFP positive PC were plated on fully grown 
osteoclasts in 24 well plates and supernatant containing PC was collected on 




the days of assessment. Wells were washed with PBS once to collect the 
remaining plasma cells. We confirmed by flow cytometry that the remaining 
cells in the well were eGFP negative; corresponding to osteoclasts only prior 
to determining apoptotic fraction in the eGFP positive plasma cells (Figure 
12). 
eGFP-MM1S cells treated with Dexamethasone alone or in co-culture with 
osteoclasts failed to proliferate as detected by fluorimetry (Fig 13 A). As 
expected, eGFP-MM1R cells were able to proliferate and were resistant to 
Dexamethasone independent of the presence of osteoclasts (Figure 13 B). . 
Although treatment with Dexamethasone inhibited proliferation of eGFP-
MM1S cells despite the presence of osteoclasts, using flow cytometry we 
observed that osteoclasts significantly reduced the pro-apoptotic effect of 
Dexamethasone on eGFP-MM1S cells (Figure 14 A). Additionally, osteoclasts 
protected eGFP-MM1S and eGFP-MM1R cells from serum starvation as 
observed by decreased Annexin V expression in PC co-cultured with 
osteoclasts compared to PC grown alone (Fig 14). This supports data 
previously published 49,69. However, neither eGFP-MM1S nor eGFP-MM1R 
cells proliferated in co-culture with osteoclasts in serum-free medium (Fig 12). 
This data confirms that osteoclasts provide prosurvival effects in serum free 









Fig 12: Flow cytometric determination of ability of extracting plasma 
cells from PC-SC cocultures. MM1S GFP and MM1R GFP cells were plated 
on osteoclasts (OC) or grown alone in 96 well plate for 4 days either  left 
untreated (UT), treated with Dexamethasone (Dex) or cultured in serum free 
medium (SF). After 4 days eGFP expressing plasma cells were extracted and 


















Figure 13: Evaluation of proliferation and viability in eGFP expressing 
MM cells alone or in co-culture with osteoclasts. (A, B) MM1S GFP and 
MM1R GFP cells were plated on osteoclasts (OC) or grown alone in 96 well 
plate for 4 days either  left untreated (UT), treated with Dexamethasone (Dex) 
or cultured in serum free medium (SF) and fluorescence emission per well 
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Figure 14: Flow cytometric evaluation of apoptotic fraction in eGFP 
positive cells in cocultures with osteoclasts with and without treatment. 
MM1S GFP and MM1R GFP cells were plated on osteoclasts (OC) or grown 
alone in 96 well plate for 4 days either  left untreated (UT), treated with 
Dexamethasone (Dex) or cultured in serum free medium (SF) Annexin V 
expression of MM1S (A) and MM1R GFP cells (B) plated on osteoclasts or 
cultured alone for 4 days determined by flow cytometry. Scatter plots show 
expression of eGFP in the Y axis and expression of Annexin V-APC in the X 



































5.7 Image-based analysis of eGFP-MM cells proliferation 
 
Using eGFP-MM cells, proliferation can also be determined by image 
analysis. Images of cultured cells can be obtained using a fluorescent 
microscope (Fig 15 A) and quantification of the area occupied by  these cells 
can be performed similarly as previously described 184. Images of eGFP cells 
were captured in co-culture with osteoclasts (Figure 15). We processed the 
obtained images using Photoshop to generate a black and white image as 
described in materials and methods (Figure 15 B). Image Tool software was 
used to quantify the percentage of white pixels per image, which 
corresponded to the area occupied by MM cells (Figure 15 C).  Our data show 
that by estimating the area occupied by MM cells (Figure 15C), we can 
determine proliferation with comparable sensitivity to fluorimetry (Figure 12 A, 
B). Hence, both methods (measurement of FI using a plate reader or image 
analysis of micrographs) can be used to determine the number of eGFP-MM 














Figure 15: Determination of cell proliferation using image analysis of 
micrographs eGFP-MM cell. eGFP-MM1S and eGFP-MM1R cells were 
plated in co-culture with osteoclasts and left untreated or treated with 2 M 
Dexamethasone (Dex). Image processing and quantification of micrographs of 
eGFP-MM cells in co-culture with osteoclasts (A) Micrographs of eGFP cells 
in co-culture with osteoclasts. Images only show the presence of MM cells 
with no interference of the other cells in co-culture. Bar 50 m (B) Binary 
images were obtained from the original fluorescent micrographs after 
processing using Adobe Photoshop CS4 as described in materials and 
methods. (C) Using UTHSCSA Image Tool processing software we quantified 
the percentage of white pixels per micrograph, which correspond to the 
percentage of the area of the well occupied by eGFP-MM cells (n = 10 fields 
for group of analysis). Differences in cell growth were statistically analysed by 
comparing the growth index with respect to the area occupied by cells at day 
0 (Student’s t-test. *** p,0.005). Our results show that measuring the 
percentage of the area occupied by eGFP-MM1S cells using image analysis is 
as effective to determine cell numbers in culture as measuring fluorescence 
per well using a fluorescence plate reader.                                                                                                     
      
   




















5.9   Discussion 
MM remains incurable partly because of presumed permissive cellular 
microenvironmental niches and the presence of soluble factors and 
extracellular matrix proteins that create a BM milieu that renders relative 
resistance to myeloma cells against therapeutic agents. A great amount of 
evidence supports a key role of the tumour microenvironment in sustaining 
survival and proliferation of MM plasma cells within the BM 54. It is plausible 
that the in-vivo effect of any drug would be only partially captured by treatment 
of MM cells and BM cells separately. The impact of drug treatments should 
therefore be studied under experimental conditions that bear the closest 
similarity to that of the real tumour microenvironment. This requires the 
development of new co-culture systems to allow discrimination of the effects 
of drugs on the MM cells from that on other BM cells. Several groups have 
already developed strategies to recreate a tumour microenvironment in vitro to 
study anti myeloma efficacy of drugs 180,185 but their settings are laborious and 
technically challenging. Additionally, commonly used in vitro assays are not 
applicable in co-culture settings to discriminate the effect of drugs on MM cells 
from the rest of BM cells in co-culture as the detected signal is produced by all 
cells in the culture. Recent work by McMillin et al proposed the use of tumour 
cells stably expressing luciferase to address these issues and showed they 
can analyse and distinguish the effect of therapeutic drugs on viability and 
proliferation of tumour cells in co-culture with SC 181. Our work shows that 
expression of eGFP in MM cell lines equally allows analysis of proliferation 
and viability of MM cells in co-culture with other BM cells. Compared to the 
previously described method using bioluminescence, the use of fluorescent 




cells is much simpler and less expensive because substrate is not required 
and the fluorescence emitted per well by the eGFP in MM cells is read directly 
in a fluorescence plate reader. Expression of eGFP in the two MM cell lines 
tested did not interfere with their normal rate of proliferation or their intrinsic 
properties such as sensitivity to Dexamethasone. Our data expand the 
applicability of eGFP-MM cells so that they can be used for proliferation 
assays in co-culture with other BM cells as well as in vivo for previously 
described applications such as tracking of engraftment of MM cells in mice 
95,158 or for further gene expression profiling after FACS sorting 181. Detection 
of apoptotic MM cells in co-culture with other BM cells by flow cytometry is 
currently based on harvesting of co-cultured cells and staining with anti-
CD138 antibodies to detect the presence of plasma cells and anti-Annexin V 
to detect MM apoptotic cells. However, CD138 expression in MM plasma cells 
can be lost in long term co-cultures with osteoclasts186. We propose the use of 
eGFP-expressing MM cell lines as a more consistent method to measure the 
levels of MM cell death by apoptosis in co-culture with other BM cells. By 
harvesting co-cultures and using FACS, we can reliably detect apoptotic cells 
(Annexin V positive) in eGFP expressing cells (MM cells). The combination of 
the data obtained using fluorimetry (cell proliferation) and FACS (cell 
apoptosis) are essential to understand the real effect of the microenvironment 
or drugs on MM cells in co-culture.  
Using our method, we have shown that in the absence of soluble factors 
provided by foetal bovine serum used in in vitro culture, both eGFP-MM1R 
(resistant to Dexamethasone) and eGFP-MM1S cells (sensitive to 
Dexamethasone) failed to proliferate as shown using fluorimetry. However, 




using flow cytometry, we were able to show that a high percentage of eGFP-
MM1R cells remained viable in serum-free medium whereas eGFP-MM1S 
cells apoptosed in the absence of serum. When co-cultured with SC in serum-
free medium, MM1S cells in the presence or absence of SC failed to 
proliferate and underwent apoptosis, whereas SC promoted eGFP-MM1R 
cells proliferation. However, when co-cultured with osteoclasts in serum-free 
medium, although viability of both cell types increased as shown before 69, 
neither eGFP-MM1S nor eGFP-MM1R cells were able to proliferate. Taken 
together our results show that eGFP-MM1R cells are able to survive 
independent of the presence of the BM microenvironment suggesting that 
these cells are able to secrete or favour the pathway of pro-survival factors, 
which may account for their acquired Dexamethasone-resistant phenotype. 
This is supported by previous characterisation of MM1S and MM1R cell lines, 
which showed that various pro-survival signalling proteins, transcription 
factors and receptors for transcription factors are up regulated in MM1R cells 
158. Additionally, in the absence of serum, MM1R but not MM1S cells 
proliferated in co-culture with SC. This suggests that MM1R cells can induce 
or respond to SC factors more efficiently than MM1S cells. For example, 
MM1R have the potential to more readily respond to SC-secreted IL-6 since 
the IL-6 pathway is enhanced by upregulation of IL-6 signal transducer gp130 
158. This model is ideal to precisely understand the mechanisms of resistance 
to therapeutic drugs as we are able to study various aspects of eGFP-MM 
cells in co-culture with other cells in the BM microenvironment.  
Our results confirmed as expected that Dexamethasone treated eGFP-MM1R 
cells proliferated and remained viable independent of the presence of SC or 




osteoclasts. In the case of eGFP-MM1S cells, both SC and osteoclasts 
promoted eGFP-MM1S cells viability but only SC sustained eGFP-MM1S 
proliferation.  These results suggest that fibroblastic SCs promote MM cell 
proliferation more efficiently than OCs. Taken together, these results suggest 
that eGFP-MM1R cells can secrete autocrine pro-survival factors that may 
account for their Dexamethasone-resistant phenotype independently of the 
tumour microenvironment. Additionally, although eGFP-MM1S cells are 
sensitive to treatment with Dexamethasone on their own, they are able to 
resist the treatment with Dexamethasone through the protection provided by 
osteoclasts and SC. Our data suggest that the microenvironment provided by 
SC or osteoclasts in the BM promotes resistance to Dexamethasone in vivo to 
MM plasma cells that otherwise would be sensitive to treatment as they lack a 
resistant phenotype supported by their own gene expression. It is likely that 
adhesion of eGFP-MM cells may promote secretion of soluble factors like IL-6 
by SC 187 or osteoclasts 69, which not only blocks Dexamethasone-induced 
apoptosis but also promotes MM cell proliferation 188,189. 
These experiments demonstrate the potential use of eGFP-MM cell lines to 
increase our understanding of MM tumour biology. Stromal cells derived from 
long term cultures of CD138 negative fraction from BMs of MM patients can 
be used in the place of stromal cell line described in these experiments 181,190. 
Like in the case of the recently described luciferase-based experimental 
platform 181, the advantage of our system with respect to other previously 
taken approaches is that it allows us to discriminate the effect of drugs on MM 
cells from the effect on other BM microenvironment cells. Since detection of 
eGFP signal in eGFP-MM cells allow determination of viable cell numbers, 




detection using a fluorescent plate reader would also allow determining the 
adhesion efficiency of eGFP-MM on different substrata including the surface 
of BM cells. Given that cells can be cultured in multiwell plates, our method is 
also useful for high throughput screening of drugs and drug combinations 
against myeloma in the presence of the BM microenvironment. The use of 
eGFP-MM cells allows application of additional analysis of various parameters 
of cell function such as cell cycle using FACS. We have also shown that using 
image based analysis of eGFP-MM cells in co-culture with other BM cells we 
can estimate proliferation of MM cells. Using currently available microscopy 
systems that allow high throughput image-based analysis it will be possible to 
screen various drugs and drug combinations in a short period of time. The use 
of eGFP-MM cells would also allow us to track MM cells using live video 
microscopy, which is essential to further understand the adhesion and 
migration properties of MM cells in the BM microenvironment.  
 



























Cell adhesion in neoplasia is gradually gaining more significance and despite 
well understood mechanisms of cell adhesion, under normal physiological 
conditions the exact regulation of adhesion in the tumour microenvironment 
remains largely unknown. Plasma cell adhesion to the microenvironment is 
one of the key properties by which the disease is maintained before eventually 
relapsing in almost all patients. Persistence of plasma cells in patients who 
have aplastic bone marrow following chemotherapy could indicate its location 
in well preserved niches. Adhesion of plasma cells is regulated through 
receptors on the cells and ligands in the microenvironment. Plasma cells and 
the marrow microenvironment are coupled by a complex network of 
interactions mediated by soluble factors and adhesion molecules. Signalling 
responses in plasma cells are activated by adhesive interactions, which 
critically regulate proliferation, migration and survival of these cells. Integrins 
and syndecan-1/CD138 are the major myeloma receptor systems of 
extracellular matrix, as well as of surface molecules of stromal cells. CD44 
and RHAMM are the chief hyaluronan receptors of multiple myeloma cells. 
The SDF-1/CXCR4 axis has been shown to mediate BM stromal cell mediated 
drug resistance and homing of multiple myeloma cells to the bone marrow65. 
The levels of expression and activity of these adhesion molecules are 
controlled by signalling mechanisms, as well as by extracellular stimuli 
including growth factors and micro environmental conditions. But the 
microenvironment of myeloma patients is continually modified over time. 
Changes within both the cellular and extracellular components of myeloma 
bone marrow microenvironment are detected over a period of time. This is 




critical for maintenance of disease. For example, laminin 
immunohistochemistry performed on the bone marrow of myeloma patients 
demonstrated no significant differences between the groups tested. The levels 
of fibronectin and collagen I were reduced in marrow of patients with high 
plasma cell percentage. Expression of collagen IV in the marrow of MGUS 
and MM patients was higher than in the marrow from normal donors191.  
The well studied system of integrin activation upon binding to it ligands 
collagen or fibronectin leading to cell adhesion has been described in 
myeloma. The expression of sets of integrin receptors in different stages of 
disease such as MGUS, solitary plasmacytomas, early myeloma and relapsed 
myeloma has been studied. There is no conclusive pattern which has 
emerged in these studies76,192. There appears to be a specific patterning in 
integrin receptors present in plasma cells isolated from various sites such as 
marrow, blood and tonsil. These studies have to be interpreted in the light of 
the fact that isolated plasma cells do not survive for longer periods and it is 
not clear whether expression of integrin receptors vary with inside out 
signalling or with external stimuli. This is also substantiated by the fact that 
survival of plasma cells ex vivo is dependent on a combination of external 
stimuli, some of which are adhesion dependent193. Dalton et al have shown 
adhesion of myeloma cells to fibronectin induces G0/G1 cell cycle arrest and 
are resistant to doxorubicin92. In their recent work they showed presence of 
IL-6 although enhances plasma cell proliferation but they do not reverse 
doxorubicin resistance. Also presence of IL-6 enhanced STAT3 
phosphorylation and recruitment of gp130194.  




Bone marrow stromal cells produce and incorporate several types of 
glycosaminoglycans, which are incorporated in the extracellular matrix. 
Glycosaminoglycans are part of the molecular structure of proteoglycans such 
as heparan sulphate, chondroitin sulphate and dermatan sulphate, as well as 
hyaluronan. Adhesion on stromal cells provides survival benefit for myeloma 
cells and has been shown to increase IL-6 secretion187. Recent work has 
shown that stromal cells derived from myeloma patients are able to support 
growth and proliferation of side population cells (possible stem cells) and this 






















Plasma cells   adhere to cells in the microenvironment, matrix proteins which 
leads to activation of signalling pathways and enhanced proliferation and 
resistance to therapy. The aim of these experiments is to study the adhesion 
of plasma cells to matrix proteins, particularly fibronectin which is a ligand for 
alpha 4 beta 1 integrin receptors expressed on plasma cells. Activation of the 
integrins using divalent cations mimics inside- out integrin activation resulting 
in the active conformation of integrins and leading to enhanced adhesion. In 
these experiments drugs were added to determine whether they can 
overcome integrin activation initiated by the cations. Plasma cells were also 
left to adhere on human bone marrow stromal cells and osteoclasts derived 
from primary cell through long term cultures. The effect of drugs on adhesion 
of plasma cells on the cellular substrata was analysed. Integrin activation 
upon adhesion in the plasma cells leads to activation of downstream signalling 
pathways. Western blot analysis of cells left to adhere with or without drugs 
were performed to analyse the pathways involved in adhesion and also 













6.3   Adhesion on extracellular matrix protein fibronectin 
Fibronectin an extracellular matrix protein is secreted in soluble dimer form by   
myofibroblasts in the bone marrow. Upon activation by engagement with 
integrin receptors on the cell surface they are converted to insoluble 
multimeric fibrils. Fibronectin apart from binding integrins also binds collagen, 
glycosaminoglycans, fibrin and fibronectin itself196. Plasma cells were plated 
on fibronectin where the adhesion of plasma cells is dependent on integrins 
and also on polylysine where the adhesion is non integrin mediated. This was 
performed to study if the possible enhanced adhesion to the coated wells in 
the plate in response to integrin activation was non specific or integrin 
dependent. Integrins were fully activated on plasma cells by addition of 
magnesium EGTA to the cell suspension. 
 
Adhesion assay calibration: 
To standardise the adhesion assay, 2 human myeloma cell lines ARH77 and 
MM1R were taken. The wells in a 96-well plate were coated with polylysine, 
fibronectin and osteopontin. Myeloma cell lines were plated on precoated 
plates in media alone without serum. Equal volumes of cells were added in 
the experiment and control wells. Cells were left to adhere for either 30 
minutes or 4 hours at 37°C in an incubator. After the period of adhesion, cells 
in suspension were removed and the plates were washed with phosphate 
buffered saline either once or twice whereas the control wells (whose values 
will correspond to the initial numbers of seeded cells) were left undisturbed. 
MTT analysis was performed as described before in methods section. The 
results showed that the plasma cell adhered to the substrata by the 30 minute 




time period and level of adhesion was largely sustained only minor changes 
by the 4 hour time point (Figure 1). The 30 minute time point was the best 
time point to determine the level of adhesion. This is particularly important 
when drugs were added to the media during adhesion to pick up significant 
differences in levels of adhesion.  
The number of washes required to remove the loosely adherent cells was also 
analysed. In MM1R cell lines no significant difference was observed between 
2 washes and 1 wash with PBS. Although in ARH77 cell line the loosely 
adherent cells were further removed by an extra wash with PBS was 
significant the proportionate differences between the integrin activated wells 
and different substrata were retained (Fig 1). Due to the observed weak 
adherent nature of MM cells in short time periods (hours) one wash was 
chosen for further experiments. To standardise the readings obtained across 
all cell lines with and without drugs, 30 min adhesion time period with 1 wash 















Fig 1: Adhesion calibration of Human Myeloma cell lines. Cells were 
plated on wells pre coated with 10ug/ml poly-L-lysine (PLL), Fibronectin (FN) 
and 10ug/ml osteopontin (OP) overnight. Plasma cells were left in serum free 
media to adhere for 30min or 4 hours. Loosely adherent cells were aspirated 
and washed once or twice with PBS and the adhered cells measured using a 
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Human myeloma cell lines MM1S, MM1R, RPMI 8226 adhered more on 
polylysine than on fibronectin. The level of cell adhesion on polylysine ranged 
between 30-80% of cells plated (Figure 2). Binding on polylysine is due to the 
electrostatic interaction between the negative charge of the cell membrane 
and the positive charge of Lys, which makes it a very suitable substrate to 
induce high levels of cell adhesion on supports for culture without specific 
mediation of cell adhesion molecules. As expected, apart from ARH77 and 
murine myeloma cell lines, there was no significant enhancement of HMCL 
adhesion with addition of magnesium EGTA on polylysine.  Although the 
reasons are not clear ARH77 is an adherent cell line with EBV infection which 
could explain the difference in adhesion observed on polylysine. The basal 
level of adhesion of all human myeloma cell lines on fibronectin was between 
5 and 20% except for ARH77 cells where adhesion was between 40% and 
80%. The percentage of adhesion of all human myeloma cell lines on 
fibronectin increased with the addition of magnesium EGTA (Figure 2 B, D, F, 
H). This is expected as EGTA chelates the calcium in the cells and 
magnesium binds the integrin and activates its affinity and subsequently 
avidity. Dexamethasone had no significant or very modest impact on adhesion 
on the human myeloma cell lines tested. Dasatinib and combination of 
dasatinib and dexamethasone inhibited the adhesion of the plasma cells on 
FN in all human myeloma cell lines except for MM1.R. Activation of integrins 
with divalent cations enhanced adhesion of these cells on FN but the levels of 
adhesion remained significantly lower in the dasatinib and dasatinib and 
dexamethasone combination treatment wells. Blockade of adhesion by 
Dasatinib was sustained even in the presence of dexamethasone. Activation 




of integrins in MM1R, a dexamethasone resistant cell line was able to 
overcome the adhesion inhibition effects of drug combination (Fig 2). 
Adhesion inhibition observed in dasatinib was significantly higher than 
observed in PP2 and AZD0530, which are Src inhibitors. Imatinib also 
inhibited adhesion of MM1S cells on FN. This observation indicates that the 
effects of dasatinib on adhesion are mediated in part through multiple 





















Fig 2: Effect of Drug treatments on Adhesion of Human Myeloma cell 
lines. Cells were plated on wells pre coated with poly-L-lysine and Fibronectin 
overnight, in serum free media with drugs for 30min. Loosely adherent cells 
were aspirated and the adhered cells measured using a MTT assay.  ARH77 
(A,B), RPMI8226 (C,D), MM1S (E,F) and MM1R (G,H). Histograms show 
Mean +SD. Drug Treatments -  10uM  PP3, 10uM PP2, 0.1uM AZD0530  Src 
inhibitor (530), 0.5uM AZD0644 ERK inhibitor (644), COM and COM1 
represent a combination of 150nM Dasatinib and 2uM Dexamethasone and 
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6.4 Adhesion of plasma cells on HS5 Stromal cells 
Plasma cells adhere to stromal cells in vivo and this interaction will enhance 
the protection rendered by the stromal cells and leads to drug resistance. The 
interaction between stromal cells and plasma cells increases the secretion of 
IL-6 in a paracrine fashion. Adhesion assay protocol used for adhesion of 
myeloma cells on fibronectin is not applicable as the signal generated by MTT 
assay will be from both cell groups. As described in chapter 5, the eGFP 
positive myeloma cells were used in the adhesion assays on HS5 stromal 
cells with or without drugs to assess response. 
HS-5 cells were added to 96 well plate and left to spread and proliferate 
overnight adequate enough to cover more than 90% of the base of the wells. 
Plasma cells were layered on the stromal cells in serum free media with and 
without drugs for an hour. Supernatants were aspirated and the fluorescence 
intensity of the adherent plasma cells was measured relative to unaspirated 
wells using a fluorescent plate reader.  The plasma cells alone were pre-
treated before layering on to the stromal cells and compared with adding 
drugs to the coculture or plasma cells and stromal cells during adhesion. 
Treatment with Dasatinib (150nm), dexamethasone (1uM) and the drug 
combination significantly reduced the adhesion of plasma cells on HS5 
stromal cells.  There was up to 60% reduction in adhesion in both MM1S and 
MM1R cell lines (Fig 3).  There were no significant differences between the 
results obtained when the plasma cells were treated alone before the 
adhesion assay or treatment of the cocultures during adhesion. This confirms 
that the reduction in adhesion observed is due to the effect of the drugs 
dexamethasone and dasatinib on the plasma cells.  




Fig 3: Treatment with Dexamethasone and Dasatinib directly impairs the 
adhesion of MM cells on stromal cells. Histograms showing the percentage 
of adhesion of MM cells on stromal cells in the presence or drugs. Cells were 
left untreated (U) or treated for the period of adhesion of an hour with 1 uM 
Dexamethasone (Dex), 150 nM Dasatinib (Das) or the combination of these 2 
drugs (DD). In the plasma cells only treated group the cells were pre-treated 
with the drugs before the period of adhesion. (A) MM1S and (B) MM1R. The 
assay was repeated at least 4 times and results were reproducible.  






























































6.5 Adhesion of plasma cells on osteoclasts 
The presence of osteoclastic activation in bone marrows of myeloma patients 
is fairly universal. Osteoclast mediated plasma cell survival has been shown 
to be mediated through direct cell - cell contact.  As described in the methods 
section primary bone marrow cultures from myeloma patients were treated 
with colony stimulating factor and RANK ligand for 3 weeks to form 
osteoclasts. Plasma cells were added on to fully formed osteoclasts and left to 
adhere for 60 minutes in serum free media. The plasma cells were either pre-
treated with drugs or the drugs were added to the coculture during the period 
of adhesion. Short term adhesion experiments were chosen as osteoclast 
being cells of macrophage lineage will phagocytose dying plasma cells and 
also form fusion nuclei with plasma cells as has been described before. As in 
the case of adhesion assay on stromal cells a fluorescent marker is required 
to measure the level of adhesion as MTT assays will calculate the signal 
produced from the whole coculture.  
The initial assays were performed by CFSE labelling of plasma cells as 
described in the methods section of the thesis. When the plasma cells labelled 
with CFSE were analysed by flow cytometry a uniform peak in the FITC 
channel was observed (Fig 4). Cells were washed twice to remove any 
additional dye. CFSE labelled plasma cells were added to the osteoclast 
cultures and fluorescence intensity was measured after the loosely adherent 
cells were removed by aspiration and wash with PBS. The experiments were 
reproducible and fluorescence intensity emitted by the CFSE labelled plasma 
cells were markedly higher than the background fluorescence emitted by the 
osteoclasts in the base of the wells.  




Fig 4: CFSE labelling of plasma cells for adhesion experiments.  
Myeloma cell line MM1S was labelled with CFSE (Vybrant CFDA SE Tracer 
kit, Invitrogen, UK) as per protocol. Flow cytometry was performed to confirm 



















Fig 5: Dasatinib and Dexamethasone reduce adhesion of plasma cells on 
Osteoclasts. CFSE labelled MM1.S plasma cells alone or osteoclasts alone 
were preincubated with drugs for 60 minutes prior to plating on osteoclasts 
and adhesion was measured using fluorescent plate reader. Histograms show 





































To understand if the reduction in adhesion observed with the drug treatments 
is due an effect on the osteoclasts or the plasma cells, pre-treatment with 
drugs of both osteoclasts and plasma cells were carried out in parallel. 
Adhesion of MM1S plasma cells pre-treated with dexamethasone, dasatinib or 
the combination was significantly lower compared to plasma cells not exposed 
to drugs. Treatment of osteoclasts with did not affect the adhesion of plasma 
cells in the short term adhesion assay. Treatment with both dasatinib and 
dexamethasone had an equivalent reduction in adhesion of plasma cells by 
about 50% in comparison with cells left untreated. The short term combination 
pre-treatment with dasatinib and dexamethasone did not further decrease 
adhesion of plasma cells on osteoclasts than either of the drugs alone (Fig 5).   
 
As described in chapter 5 of this thesis eGFP transduced plasma cell clone of 
MM1S, MM1R and ARH77 cells were generated.  Osteoclasts derived from 
primary samples were grown in 96 well plates. Previously it was observed with 
CFSE labelled plasma cells, that there was very little effect on adhesion of 
plasma cells when osteoclasts were treated alone ( Fig 6). In this experiment 
either the plasma cells only were pre-treated before adhesion, or both the 
osteoclasts, plasma cells coculture were treated during the period of 
adhesion. The adhesion efficiency of MM1S, MM1R and ARH77 human 
myeloma cells significantly decreased upon treatment with dasatinib and 
dexamethasone.  Treatment of both plasma cells and the osteoclasts during 
the period of adhesion did not further reduce the level of adhesion. This 
shows that the drug treatment decreased the adhesion efficiency of plasma 
cells but the mechanisms mediating this are not clear from this experiment. 




The combined treatment of dasatinib and dexamethasone in a short period did 
not further reduce the percentage of adhesion than either of the drugs alone. 
This was also observed when plasma cells were left to adhere on stromal 
cells. ARH77 cell line was chosen for adhesion experiments as it showed high 
efficiency of adhesion on fibronectin in comparison to other myeloma cell lines 
tested. It was striking to see that the adhesion efficiency of these cells were 
no higher than MM1S and MM1R cell lines. The level of short adhesion across 
stromal cells, ECM protein fibronectin and osteoclasts was inefficient, 
particularly fibronectin. What is not clear is whether in the in vivo setting where 
humoral factors also play a role, and there is abundance of these cells and 
matrix proteins it is possible that plasma cells and its multiple receptors 

















Figure 6. Cell adhesion efficiency of MM cells on osteoclasts in 
response to treatment with Dexamethasone and Dasatinib. eGFP 
expressing plasma cells were left untreated (UT) or were treated with 1 uM 
Dexamethasone (Dex), 150 nM Dasatinib (Das) or the combination of these 2 
drugs for 1 h during the course of the adhesion assay (PC + OC treated) or 
alternatively, pre-treated with drugs for 3 hours prior the adhesion assay (PC 
only treated). Using a fluorescent plate reader, the number adhered cells was 
estimated by measuring the average of fluorescent intensity per well after 
adhesion. Histograms show the percentage of adhered MM cells after one h 
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6.6 Adhesion signalling pathways 
Integrins are the major class of receptor systems involved in the adhesion of 
plasma cells on the ECM. The receptors involved in the adhesion of plasma 
cells on stromal cells and osteoclasts are less clear, although integrins do play 
a role. The adhesion on ECM protein is much better defined particularly the 
interaction with ligands which use integrins to adhere, stimulate and 
coordinate other intracellular processes. For the purpose of my thesis I was 
interested in studying the downstream signalling pathways involved during 
integrin activation upon adhesion to ECM protein fibronectin. Treatment with 
drugs and resultant changes in the signalling pathways with drug exposure 
has been studied. 
Integrin activation by ligand binding, results in the oligomerisation of FAK 
(Focal adhesion kinase), which is mediated by Talin. Autophosphorylation of 
FAK at residue Tyr397 results in the binding of SH2 domain of Src and Fyn 
which phosphorylates a number of FAK-associated proteins including paxillin. 
Phosphorylation of Tyr397 also leads to the recruitment of other SH2-
containing proteins; including the PI3K (Phosphatidyl Inositol-3Kinase). Src 
can also phosphorylate FAK at tyrosine residue 925, creating a binding site for 
the growth-factor-receptor-bound protein complex, the GRB2-SOS complex 
and activate another small GTPase, Ras. Activated Src also phosphorylates 
CAS (Crk-Associated Substrate), enabling it to bind Crk leading to an increase 
in the affinity of the membranes for Rac 197. This underlines the importance of 
Src as a downstream signalling protein in integrin activation.  c-Abl kinase is 
also activated downstream upon engagement of  ligand such as fibronectin 




with  the integrins resulting  in  activation of MAPK. C-Abl also phosphorylates 
the cytoskeletal protein paxillin, a component of focal adhesion. In neutrophils,   
c-Abl kinase is activated after β2 integrin engagement. β2 integrin engagement
 
induces recruitment of c-Abl kinase to β2 integrin cytoplasmic
 
domain via talin 
head, a cytoskeletal protein.  c-Abl kinase also regulates signalling protein  
Vav activity 198. In these experiments the activation of c-Abl and Src kinase 
activity downstream of integrin receptor activation has been studied in the 
plasma cells adhering to fibronectin. 
Plasma cells upon short term adhesion to fibronectin were lysed and western 
blots were performed to analyse the signalling pathways in these cells upon 
integrin activation with magnesium and EGTA. Plasma cells were also treated 
with the drugs dasatinib and dexamethasone alone or in combination during 
the period of adhesion. The expression and activation of proteins downstream 
of integrin activation was compared with cells left untreated.  
Src and c-Abl phosphorylation was observed when the plasma cells adhered 
to polylysine in the wells. Crk like protein (Crkl) phosphorylation which is a 
surrogate marker for Abl tyrosine kinase activity was also up regulated with 
adhesion (Fig 7). This shows that even on surfaces lacking integrin, there is 
an activation of Src and Abl.  Treatment with src inhibitor PP2, downregulated 
the phosphorylation of Src in contrast with cells left untreated and treated with 
Mg EGTA. Dasatinib also inhibited the phosphorylation of Src   comparable to 
PP2. Although when integrins were fully activated MgEGTA in MM cells both 
Dasatinib and PP2 inhibited Src and c-Abl signalling, the net Src/c-Abl active 
signal was higher compared with drug-treated but not MgEGTA activated 




cells. Dexamethasone induced a minor decrease in the phosphorylation of c-
Src but the combination of dasatinib and dexamethasone were able to very 
effectively down-regulate integrin activation as evidenced by the lower levels 
of phosphorylation of Src and c-Abl on the immunoblot despite activation of 
integrins by Mg EGTA (Fig 7 A). C-Abl phosphorylation increased when cells 
were treated with MgEGTA. But dexamethasone and dasatinib both 
downregulated C-Abl activity and the combination almost completely inhibited 
phosphorylation of the Abl protein (Fig 7). This was supported by a reduction 
in levels of phosphorylated Crkl Protein. These results were quantified by the 
measurement of the intensity of the bands over the respective loading controls 














Fig 7: Effect of Dasatinib on integrin signalling in ARH 77 Myeloma cell 
line. Lysates obtained from ARH77 cells plated on PLL (A) +/- integrin 
activation with Mg EGTA, after drug treatment for 30 minutes. 10uM PP3, 
10uM PP2, 10uM 150nM Dasatinib (Das), 2uM Dexamethasone, 150nM 
+2uM Dasatinib + Dexamethasone (D+D). Membranes were immunoblotted 
for pSrc, Phospho c-Abl, Src and ß actin as loading control. C- Abl activity 
immunoblot kit containing Phospho c-Abl, pCrkl and e14AE as positive control 
was used. Figures B represents Intensity of Band / Loading control ratio in 






























On Fibronectin, where plasma cell adhesion is integrin dependent in the 
untreated cells there was clear evidence of Src, Abl phosphorylation, AKT 
phosphorylation and pCrkl observed on the immunoblots (Fig 8). Upon 
treatment with PP2 there was reduction in Src, Abl and Crkl phosphorylation 
which was not observed with PP3, a PP2 analogue without the inhibitory 
activity. Treatment with dexamethasone reduced the levels of phosphorylated 
Abl and Crkl without any effect on the levels of phosphorylated AKT. With 
Dasatinib treatment the levels of phosphorylation of Src, c-Abl and Crkl were 
almost undetectable with no effect on the AKT pathway (Fig 8). The 
combination of Dasatinib and dexamethasone completely inhibited the Abl 
and Src kinase pathways. In the figure 8 C the ratio of the phosphorylated 
proteins to the loading control shows objectively the significant reduction in 
Src and Abl kinase activation with Dasatinib on its own and with the 












Figure 8: Effect of Dasatinib on integrin signalling in ARH 77 Myeloma 
cell line. Lysates obtained from ARH77 cells plated on FN (A),(B) +/- integrin 
activation with Mg EGTA, after drug treatment for 30 minutes. 10uM PP3, 
10uM PP2, 10uM 150nM Dasatinib (Das), 2uM Dexamethasone, 150nM 
+2uM Dasatinib + Dexamethasone (D+D). Membranes were immunoblotted 
for pSrc, Phospho c-Abl, Src and ß actin as loading control. C- Abl activity 
immunoblot kit containing Phospho c-Abl, p Crkl and e14AE as positive 
control was used (Fig A). Figures C represents Intensity of Band / Loading 















                 
 
                
                   
                  
             
 

























Plasma cell adhesion to the extracellular matrix proteins and cells in the bone 
marrow microenvironment plays an important role in survival of plasma cells 
and slow relapse following therapy. Plasma cell adhesion on stromal cells and 
bidirectional interaction leads to disease growth and progression. Although the 
changes in the plasma cell compartment growing in the presence of the 
stromal cells have been well studied, the changes in the stromal cell 
compartment still remains poorly understood. Although myeloma cell lines 
have been shown to proliferate with stromal cell cultured medium, Plasma cell 
lines exclusively dependent on cell-cell contact with bone marrow stromal 
cells have been described199,200. I observed that level of adhesion on 
fibronectin; an extracellular matrix protein present in abundance in the marrow 
was variable between the different cell lines. This could be explained by the 
variability in expression of integrin receptors as has been described in primary 
cells when the disease evolves75. Integrins can also be activated in the 
presence of soluble mediators and there is preferential use of sets of dimeric 
integrin receptors depending on the extracellular matrix protein in context 201-
203. Also, local concentration of cytokines could be different in the bone 
marrow. These factors have to be taken into consideration when interpreting 
in vitro results and how they correlate with what maybe happening in vivo. 
Dasatinib down regulated the adhesion of plasma cells on fibronectin. The 
effect was more obvious on myeloma cells at basal level of integrin activation. 
Inhibition of adhesion by Dasatinib was not observed in all the cell lines. 
Various factors can explain the heterogeneity of response to dasatinib 
between the myeloma cell lines. Genomic changes in the plasma cells may 




lead to heterogeneity in adhesion to fibronectin as described before204. 
Additionally, adhesion on extracellular matrix protein such as fibronectin is 
also mediated by syndecan-1, CD44 variants and RHAMM which mediate 
interactions with hyaluronan, and the SDF-1/CXCR4 axis. The expression and 
activity of these molecules are regulated by cytokines within the bone marrow 
microenvironment. It is not clear at present as to which of these sets of 
adhesion processes is key for survival of plasma cells, although adhesion of 
plasma cells on fibronectin does lead to drug resistance as shown by Dalton 
et al. More recently, this group have shown that Notch activation during 
adhesion of myeloma cells on stromal cells leads to arrest of myeloma cells in 
G0/G1 phase of cell cycle with upregulation of p21205. In my experiments 
dasatinib at nanomolar concentrations inhibited both c-Src and c-Abl 
signalling pathways downstream of integrins when plasma cells were adhered 
on to fibronectin. Src is a key tyrosine kinase and adaptor protein downstream 
in the integrin signalling pathway. It functions as a non receptor tyrosine 
kinase which is can bind Grb2 and activate MAPK kinase during integrin 
activation, a process that can be inhibited by dasatinib. In my experiments, 
downregulation of both c-Src and c-Abl mediates the reduction in adhesion of 
MM cells. It is well known that Src can activate c-Abl  and they also interact 
downstream of integrin signalling pathways in cancer cells 206. The 
downregulation of c-Abl activity seen in our experiments with PP2 a Src 
kinase inhibitor could be explained by this interaction. The inhibition of integrin 
activity by Dasatinib is further supported by a recent study looking at non 
invasive photon emission tomography (PET) monitoring of αvβ3 activity in 
tumours using cyclic pentapeptides containing the RGD peptide sequence. 




When mice containing αvβ3  positive tumours were treated with dasatinib, PET 
activity significantly decreased within 72 hours suggesting integrin inactivation 
and prolonged therapy led to tumour reduction207.   
Multiple mechanisms have been described for Dexamethasone resistance 
myeloma patients. One of the mechanisms is adhesion of myeloma cells to 
stromal cells though expression of VLA-4 or CD44 engagement 89. 
Bortezomib had been shown to overcome the resistance mediated through 
CD49d
208
 . My findings show that Dasatinib can overcome Dexamethasone 
CAM-DR mediated by the interaction of MM cells with the cellular and non-
cellular components of the BM microenvironment. My data suggest that 
Dasatinib would form an useful adjunct in treating myeloma patients exhibiting 




















EFFECT OF DASATINIB ON 
OSTEOCLASTS AND INTERACTION 
OF PLASMA CELLS WITH THE 
MICROENVIRONMENT





Bone disease is a major cause of morbidity in myeloma. Clinical 
manifestations of osteoclast activation occur in up to 80% of patients with 
myeloma. Although treatment with antimyeloma agents induces stringent 
remission based on currently available clinical criteria, the effects of bone 
morbidity significantly impairs patient’s quality of life. Osteoclasts are highly 
dependent on the intact cytoskeleton to be able to perform the function of 
bone resorption. Also osteoclasts within the bone marrow are under the 
effects of soluble factors and cellular components T cells and plasma cells. 
The interaction between plasma cells and osteoclasts has been described 
extensively in the literature. There are recent reports indicating that the 
immune system of the patient may cooperate with osteoclasts to enhance 
bone resorption in myeloma patients 209,210. Soluble factors such DKK1 
produced both by stromal cells and plasma cells inhibit osteoblastogenesis 
and activate osteoclasts. Recently, soluble decoy receptor 3 (DcR3) of the 
Tumour necrosis factor super receptor family has been described to activate 
osteoclasts. DcR3 transgenic mice have low bone mass and high osteoclast 
numbers with activated phenotype. Myeloma patients have high levels of 
DCR3 and both plasma cells and T lymphocytes produce DCR3. This results 
in an increase in the numbers of osteoclasts in the blood and marrow of 
patients211. It is critical to disrupt the osteoclasts cytoskeleton and interaction 
between plasma cells and osteoclasts to enhance the therapeutic effects of 
treating this condition. In this chapter, the effects of Dasatinib, 
dexamethasone on the osteoclast cytoskeleton, function and interaction with 
cells of the microenvironment have been studied. 




During the course of disease stroma induced resistance plays a key role in 
determining response to therapy. Bone marrow stromal cell proliferation in 
response to addition of Dexamethasone has been demonstrate in vitro 212. We 
wanted to analyse the effects of Dasatinib of myeloma cells cocultured with 
bone marrow stroma in the presence of Dexamethasone. We have developed 
a model to look at the differential effects of drugs on both the stromal cells and 
the myeloma cells in coculture with eGFP positive myeloma cells and 
mCherry- HS5 cells. 
During the course of the experimental work for my thesis, another member of 
the laboratory developed mCherry-labelled-HS5 BM fibroblastic stromal cells. 
As in the case of eGFP-MM cells, the number of mCherry-HS5 cells can be 
evaluated by measuring the fluorescence intensity emitted by the cells (ex = 
587; em = 610). By employing mCherry-labelled-HS5 BM fibroblastic stromal 
cells co-cultured in direct contact with eGFP-labelled MM cell lines we were 
enabled to accurate study the heterotypic cell interactions in both cell 
compartments. This fluorescent-based platform can assess the impact of 
drugs on stromal and tumour cell proliferation and viability. This experimental 
model provides a significant improvement on previous methodologies by 
allowing for the concomitant assessment of tumour and BM stromal 











Osteoclasts derived from the primary bone marrow cells of patients as 
described in the methods section were analysed by microscopy and their 
function was assessed on rabbit dentine slices. Src is a key protein involved in 
osteoclast motility and function. Dasatinib was used in parallel with 
dexamethasone to study a) the effects on the cytoskeleton and function of 
osteoclasts. b) the effect of drugs on fibroblastic stromal cells c) the effect of 
drugs on plasma cells and BM microenvironmental cells in coculture. I wanted 
to validate the findings using the novel coculture system. The effects of the 
drugs on the viability of plasma cells when they were in the presence of 



















7.3 Effects on osteoclastogenesis and the cytoskeleton 
Primary bone marrow mononuclear cells from myeloma patients were 
differentiated into osteoclasts. By day 17, the mature osteoclasts are fully 
differentiated with capability to resorb bone. Osteoclasts were exposed to 
drugs from day 12 or left untreated. Using Immunofluoroscence, the 
morphological features of osteoclast cytoskeletal structure were analysed. In 
the cells left untreated large multinucleated osteoclasts were formed with actin 
ring in the periphery of the cell (Fig 1 Panel A). On higher magnification, the 
podosome assembly forming actin rings in the periphery of the osteoclast was 
seen (Fig 1 Panel E). Treatment with dexamethasone had no significant effect 
on the size of the osteoclast, actin ring formation or podosome assembly (Fig 
1 Panel C). Dasatinib at 150nM concentration resulted in formation of small 
clusters of actin at the periphery of the cell, with the absence of uniform ring 
formation (Fig 1 Panel B, F). Treatment of the osteoclasts with the 
combination of dasatinib and dexamethasone showed impaired actin ring 
formation and clustering of actin in the cells (Fig 1 Panel D). In order to 
quantify the observed changes in size and nuclearity the osteoclasts grown on 
the cover slip were counted in a 10X field in triplicate and a mean number was 
plotted as a histogram (Fig 2 Panel A). The average size of osteoclast is 
about 340 microns in diameter and the size of the osteoclast increases after 
11 days of plating213.  
On Day 12 when the cultures were untreated the number of osteoclasts per 
field equal between the experiment wells. The cultures left untreated by day 
17, had lesser number of osteoclasts per field because of the increase in size 
of the cells (Fig 2 Panel A). The dexamethasone treated cells also continue to 




increase in size in contrast with Dasatinib treatment which inhibited further 
increase in size of osteoclasts. Dasatinib also caused arrest of osteoclast 
fusion as evidenced by most cells having less than 4 nuclei (Fig 2 B). Cultures 
left untreated and treated with dexamethasone showed multinucleated 
osteoclasts (Fig 2 B). Treatment with the combination of dasatinib and 
dexamethasone inhibited osteoclast fusion and increase in size of the 
osteoclast. The effect on the osteoclasts was identical to those observed with 
Dasatinib alone (Fig 2 Panel A, B), which also prevented fusion of 
mononucleated immature osteoclasts forming multinucleate larger well 
differentiated and mature cells. This effect was reversible when cultures were 
fed with fresh media in the absence of drugs for 3 days (Fig 3) 
To study the function of these osteoclasts differentiated from mononuclear 
cells obtained from myeloma patients, cultures were established on rabbit 
dentine slices. Osteoclasts resorb bone by forming sealing zones and ruffled 
border on the dentine surface. Once the osteoclasts form these membrane 
domains the proteolytic enzymes and collagenase are secreted on the bone 
surface to resorb the bone. We hypothesised that by the observed inhibition of 
osteoclast maturation and cytoskeletal integrity with Dasatinib and the 
combination of Dasatinib and dexamethasone there will be a significant 
reduction in bone resorption. The numbers of pits on the dentine slices were 
counted under 10X objective showing inhibition of bone resorption by 
Dasatinib (Fig 4 Panel E).  In the untreated cultures, osteoclasts resorbed the 
dentine slices, as observed on phase contract microscopy (Fig 3 Panel A). In 
the dexamethasone treated cultures the osteoclasts resorbed the dentine 
slices evidenced by formation of resorption pits (Fig 4 Panel B). Treatment 




with Dasatinib and the combination of Dasatinib and dexamethasone inhibited 
bone resorption evidenced by the lack of presence of resorption pits (Fig 4 



























Fig 1:  Dasatinib reduces the size of the osteoclast and disrupts actin 
cytoskeletal architecture. Osteoclasts were seeded on glass cover slips and 
at the time of interest they were fixed with 1% PFA, permeabilised with 0.05% 
Triton X-100 and stained with Alexa568-Phalloidin to detect the distribution of 
actin filaments (red) and DAPI to detect nuclei (blue). Osteoclasts were left  
Untreated (A) or treated with 150nM Dasatinib (B),  1uM Dexamethasone (C), 
combination of 150nM Dasatinib and 1uM Dexamethasone (D) Structure of 
actin ring with clustered podosomes in an Untreated Osteoclast (E) , 
Disrupted actin aggregates in Osteoclasts treated with 150nM Dasatinib and 































Fig 2: Dexamethasone does not affect osteoclast integrity and function 
whereas Dasatinib blocks osteoclastogenesis. Osteoclasts were seeded 
on glass cover slips and at the time of interest they were fixed with 1% PFA, 
permeabilised with 0.05% Triton X-100 and stained with Alexa568-Phalloidin 
to detect the distribution of actin filaments (red) and DAPI to detect nuclei 
(blue). (A) Histograms show the average of number of osteoclasts per field 
using a 10X lens magnification at day 12 and day 17 of differentiation in vitro. 
As osteoclasts differentiate they fuse and increase in size so that the number 
of osteoclasts per field decreases. Cultures were left untreated or were 
treated with 1 uM Dexamethasone (Dex), 150 nM Dasatinib (Das) or the 
combination of these 2 drugs. (B) Histograms showing the average of the 
number of nuclei per osteoclast at day 12 and day 17 of culture. As 
osteoclasts differentiate they fuse and the number of nuclei per cell increases. 



















         
 










Figure 3: Effects of Dasatinib on osteoclasts is reversible. Primary 
osteoclasts  were left  Untreated (A) or treated with 150nM Dasatinib (B),  
1uM Dexamethasone (C), combination of 150nM Dasatinib and 1uM 
Dexamethasone (D) for 3 days . Media with drugs were removed after Day 3 
and plated in fresh media for another 72 hours (3 days post treatment), 
showing recovery of osteoclasts in dasatinib and dasatinib and 




































Fig 4: Dasatinib inhibits the resorptive function of osteoclasts.  
Osteoclasts were cultured on dentine discs for 17 days. Cultures were left 
untreated (A) or were treated with 1 uM Dexamethasone (Dex) (B) , 150 nM 
Dasatinib (Das) (C)  or the combination of these 2 drugs (D) .  At day 17 
osteoclasts were lysed and dentine discs were sonicated to remove cell 
debris. The discs were stained with Toluidine to visualise the pits of resorption 
generated by osteoclasts.  Bars (A -D) 20um. The number of pits were 
analysed by phase contrast microscopy and Histograms show the average 



























                                                                                                 










7.4 Effect on plasma cells in coculture with osteoclasts 
Yaccoby et al showed that the protection from cell death mediated by 
osteoclasts on plasma cells is cell – cell contact dependent. In chapter 4 of 
this thesis, I showed   the combination of Dasatinib and dexamethasone was 
effective in inhibiting proliferation of both Human and murine myeloma cell 
lines to varying degree. I have also shown in chapter 5 that osteoclasts can 
protect myeloma cells from dexamethasone induced apoptosis. In this chapter 
I will test whether Dasatinib may overcome such protection of MM cells 
against dexamethasone by osteoclasts. In the novel coculture system eGFP 
expressing plasma cells and osteoclasts were left either untreated or treated 
with drugs. Both plasma cell proliferation by measuring the fluorescence 
intensity and the expression of Annexin V as a marker of apoptosis were 
analysed. MM1S cells which are sensitive to steroids were co cultured with 
osteoclasts in the presence or absence of drugs. Untreated eGFP labelled 
MM1S cells either alone or in the presence of osteoclasts proliferated well as 
evidenced by increased fluorescence intensity and small percentage of cells 
expressing Annexin V on the cell surface (Fig 5 Panel A, B). The presence of 
osteoclasts in coculture did not enhance further proliferation in this short term 
culture (Fig 5 Panel A, B). Treatment with Dasatinib of eGFP MM1S cells 
alone or in cocultures with osteoclasts did not inhibit proliferation of plasma 
cells and the level of proliferation and cell death was comparable to untreated 
cultures (Fig 5 Panel A, B). As expected treatment with dexamethasone 
inhibited proliferation of plasma cells left alone by inducing cell death through 
apoptosis observed by higher expression of Annexin V. The presence of 
osteoclasts in coculture did not enhance or sustain  plasma cell proliferation in 




Dex treated wells but partially protected plasma cells from apoptosis (64.6% 
of apoptotic plasma cells in cocultures with OC’s vs. 82.1% of apoptotic cells 
in cell treated alone) (Fig 5 Panel A, B). The combination of dasatinib and 
dexamethasone was able to inhibit proliferation as well as induce apoptosis of 
plasma cells to similar extent in both, plasma cells cultured alone or in 
coculture with osteoclasts. The drug combination induced 88% of apoptotic 
fraction of plasma cells when they were in coculture with osteoclasts (Fig 5 
Panel A, B). This confirms that the drug combination is able to overcome the 
protective effect of the osteoclasts observed in dexamethasone alone 
treatment wells. 
MM1R cells are resistant to dexamethasone treatment due to presence of 
truncated glucocorticoid receptor in these cells. The eGFP labelled MM1R 
cells   left untreated either alone or in the presence of osteoclasts proliferated 
well as evidenced by increased fluorescence intensity and small percentage 
of cells expressing Annexin V on the cell surface (Fig .6 Panel A, B). The 
presence of osteoclasts in coculture did not enhance further proliferation of 
MM1R cells in the short term cultures. Treatment with Dasatinib of eGFP 
MM1R cells alone or in cocultures with osteoclasts did not inhibit proliferation 
of plasma cells. Treatment with Dexamethasone resulted in a minor increase 
in apoptosis of eGFP-MM1.R cells grown alone (Figure 6 A). However, this 
reduced viability failed to have an impact on eGFP-MM1.R cell proliferation. 
Although the apoptotic fraction of plasma cells cultured alone increased with 
Dasatinib and dexamethasone treatment, cell cycle analysis previously 
described in Chapter 4 showed an intact proliferative fraction (Fig 6 Panel A, 
B). Plasma cells in coculture with osteoclasts and treated with dasatinib and 




dexamethasone continued to proliferate and remained viable as shown by no 
increase in Annexin V expressing cells (Fig 6 Panel A, B). Combination of 
dasatinib and dexamethasone did not significantly affect the proliferation of 

























Figure 5. Viability and cell proliferation of MM1S cells on osteoclasts in 
response to treatment with Dexamethasone and Dasatinib. Histograms 
showing the levels of staining of Annexin V as detected by flow cytometry in 
eGFP-MM1.S (A) cultured alone or in co-culture with osteoclasts. To generate 
the histograms of the corresponding cells in co-culture, we acquired 10,000 
events in the gated eGFP positive subpopulation. Cultures were left untreated 
(UT) or were treated with 1 uM Dexamethasone (Dex), 150 nM Dasatinib 
(Das) or the combination of these 2 drugs for 72 h. Using a fluorescent plate 
reader, proliferation of eGFP-MM1.S cells (B) cultured alone or in the 
presence of osteoclasts was estimated by measuring the average of 
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Figure 6. Viability and cell proliferation of MM1R cells on osteoclasts in 
response to treatment with Dexamethasone and Dasatinib. Histograms 
showing the levels of staining of Annexin V as detected by flow cytometry in 
eGFP-MM1.R (A) cultured alone or in co-culture with osteoclasts. To generate 
the histograms of the corresponding cells in co-culture, we acquired 10,000 
events in the gated eGFP positive subpopulation. Cultures were left untreated 
(UT) or were treated with 1 uM Dexamethasone (Dex), 150 nM Dasatinib 
(Das) or the combination of these 2 drugs for 72 h. Using a fluorescent plate 
reader, proliferation of eGFP-MM1.R cells (B) cultured alone or in the 
presence of osteoclasts was estimated by measuring the average of 
fluorescent intensity per well at day 0 and day 4 after plating. 
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7.5 Effect on plasma cells in coculture with stromal cells 
Bone marrow stroma protects plasma cell from apoptosis by providing a 
cellular surface for adhesion and secreting soluble cytokines such as IL-6. 
Bone marrow stromal cells also induce proliferation of plasma cells. 
Osteoclasts protected plasma cells from apoptotic cell death when treated 
with dexamethasone. We wanted to study in the novel in vitro coculture 
system of plasma cells and stromal cells, whether the drugs dexamethasone, 
dasatinib and the combination have proapoptotic effects. Stromal cells HS5   
is a human fibroblastic stromal cell line which is commonly used in cocultures 
with myeloma cells as it offers protection against therapeutic agents 181. The 
eGFP MM1S cells were plated on stromal cells and fluorescence intensity and 
Annexin V expression of was studied after 72 hours, with or without drug 
treatment. In the untreated cells there was no enhanced proliferation in the 
presence of stroma at the cell density described in the methods section. (Fig 7 
B). In Dexamethasone treated cultures, the percentage of apoptotic eGFP 
MM1S cells decreased in the presence of stromal cells, confirming protection 
(Fig 7A). In the presence of dexamethasone, proliferation of eGFP MM1S 
cells plated alone fell significantly, but plasma cells in coculture with stromal 
cells continued to proliferate (Fig 7 B). This was due to the antiapoptotic effect 
and protective effect of stromal cells in coculture with eGFP MM1S cells (Fig 7 
A). Treatment with Dasatinib did not significantly alter cell proliferation or 
induce apoptosis of eGFP MM1S cells either in the presence or absence of 
stromal cells. The combination of Dasatinib and dexamethasone induced 
significant inhibition of proliferation of eGFP MM1S cell line either in the 
presence or absence of HS5 stromal cells. 




This was also evidenced by almost 100% apoptotic eGFP MM1S cells by 72 
hours of combined treatment with Dasatinib and dexamethasone. 
Combination of Dasatinib with Dexamethasone enhanced the percentage of 
apoptotic eGFP-MM1.S cells in the presence of stromal cells by 3.5-fold in 
comparison with co-cultures treated with Dexamethasone alone (Fig 7 A). 
The eGFP MM1R cells are resistant to Dasatinib and dexamethasone at the 
current concentrations described which are clinically achievable. eGFP-MM1R 
plasma cells continued to proliferate in the presence of drugs (Fig7 Panel B). 
Flow cytometric analysis confirmed the findings on the proliferation assay with 
no increase in apoptotic eGFP MM1R cells cultures alone or in cocultures with 
either dasatinib, dexamethasone (Fig 8 A). The combination of dasatinib and 
dexamethasone had no significant effect on proliferation of eGFP MM1R cells. 
But expression of Annexin V was modestly increased when myeloma cells 
were grown alone with some reduction of apoptotic eGFP MM1R cells in 
coculture with HS5 stromal cells (Fig 8 A). Dexamethasone enhanced the 
proliferation of mCherry-HS5 cells in co-culture with either MM1S or MM1R 
cells. 150 nM Dasatinib significantly reversed dexamethasone-enhanced 
proliferation of mCherry-HS5 cells co-cultured with MM cells (Figure 7 C). The 
effect of drugs on the stromal cells was also studied by flow cytometry alone 
and in coculture with stromal cells. The eGFP expression of plasma cells were 
used to gate out the myeloma cells in coculture. Treatment with Dasatinib, 
dexamethasone or the combination had no significant proapoptotic effect in 
the stromal cells at the drug concentrations used for up to 72 hours (Fig 8 B). 
Similar effect was observed when stromal cells were co cultured with eGFP 
MM1S cells and treated with the same drug treatments (Fig 8 Panel B).This 




confirms that these drugs are unlikely to  induce stromal cell death in vivo 



























Figure 7. Sensitisation of eGFP-MM1.S cells to Dexamethasone in the 
presence of stromal cells by combined treatment with Dasatinib.  
(A) Histograms showing the levels of staining of Annexin V as detected by 
flow cytometry in eGFP-MM1.S cells alone or in co-culture with HS.5 cells. 
The eGFP-MM1.S myeloma cells and the cocultures were left untreated or 
treated with 1 uM Dexamethasone (Dex), 150 nM Dasatinib (Das) or the 
combination of these 2 drugs To generate the histograms of the 
corresponding cells in co-culture, 10,000 events in the gated subpopulation of 
interest was acquired. (B) Histograms showing the fold increase in 
proliferation of mCherry HS 5 stromal cells cultured alone in the presence and 
absence of drugs and in co culture with eGFP-MM1.S and eGFP-MM1.R 
plasma cells.  (C) Histograms showing the fold increase in proliferation of 
eGFP-MM1.S and eGFP-MM1.R cells in co-culture with stromal cells in the 





























Figure 8: Effect of drugs on HS5 stromal cells and steroid resistant 
eGFP MM1R cells cultured alone or in coculture with stromal cells 
(A) Histograms showing the levels of staining of Annexin V as detected by 
flow cytometry in eGFP-MM1.R cells alone or in co-culture with HS.5 cells. 
The eGFP-MM1.Rmyeloma cells and the cocultures were left untreated or 
treated with 1 uM Dexamethasone (Dex), 150 nM Dasatinib (Das) or the 
combination of these 2 drugs To generate the histograms of the 
corresponding cells in co-culture, 10,000 events in the gated subpopulation of 
interest was acquired. (B) Histograms showing the levels of staining of 
Annexin V as detected by flow cytometry in HS5 cells alone or in co-culture 
with eGFP MM1S cells. To generate the histograms of the corresponding cells 
in co-culture, up to 10,000 events were acquired in the gated subpopulation of 
















































































7.6 Discussion:  
I have shown in this chapter that Dasatinib at clinically achievable 
concentrations significantly inhibits osteoclastogenesis. Presence of dasatinib 
also inhibits osteoclast function. My data show that dasatinib causes major 
disruption of the osteoclast cytoskeleton, which correlates with inhibition of 
bore resorption and cell fusion. The correlation between abnormal 
organisation of the osteoclast cytoskeleton and impairment of osteoclast cell 
fusion and bone resorption is expected as they require an intact organisation 
and adequate dynamics of F-actin. Dasatinib is a potent c-Src inhibitor and at 
1nM concentrations it also inhibits c-fms and its downstream signalling 
significantly in the presence of M-CSF, a key cytokine involved in 
osteoclastogenesis 214. The crucial role of c-Src in osteoclast function through 
the organisation of the actin cytoskeleton has been confirmed in vitro and in 
vivo215,216. There is also evidence suggesting the c-Abl could be involved in 
osteoclast function. For example, Imatinib has been shown to block 
osteoclastogenesis138. Imatinib promotes osteoblast differentiation by 
inhibiting PDGFR signalling and inhibits osteoclastogenesis by both direct and 
stromal cell-dependent mechanisms and long term Imatinib therapy 
administered in chronic myeloid leukaemia patients showed evidence of 
impairment in bone remodelling139. In vitro data indicate that dasatinib block 
osteoclast function and this is further supported by several in vivo studies. 
Dasatinib treated sprague-dawley rats exhibited evidence of osteoclast 
inhibition which was comparable to rats treated with zoledronic acid. No 
significant increase in osteoblastic activity was observed217. Dasatinib has 
also been previously shown to inhibit osteoclast activity in vitro and in vivo and 




in the presence of prostate cancer cells217,218. Long term dexamethasone 
administration in patients causes osteoporosis. In my experiments, 
Dexamethasone did not affect osteoclastogenesis or osteoclast function. 
Dexamethasone promotes osteoclastogenesis with help of marrow adipocytes 
and also works synergistically with TGFβ which has been shown to be 
increased in sera of myeloma patients219,220. These results suggest that 
treatment of MM patients with dexamethasone would not resolve bone 
disease. Our data may imply that through the inhibition of osteoclast function, 
dasatinib would be a beneficial drug to target bone disease while promoting 
the pro-apoptotic efficacy of dexamethasone. Autologous and allogeneic 
osteoclasts have been shown to protect plasma cell from apoptosis through 
cell-cell contact 49.In the above experiments although osteoclast protected 
plasma cells from apoptosis on exposure to dexamethasone, the combination 
of dasatinib and dexamethasone overcame this protection. This effect could 
partly be mediated through reduced plasma cell adhesion to osteoclasts and 
also reduction in available osteoclast surface for plasma cells to interact, due 
to the effect of dasatinib on the osteoclast size. Although Dasatinib affects 
osteoclastogenesis, removal of drug and regrowing cells in presence fresh 
media was able to recover osteoclast formation and function. This is critical to 
maintain the bone homeostasis in myeloma patients, particularly because of 
the chronic nature of the disease. Due to the role of osteoclasts in 
haematopoiesis, recovery of osteoclast function could facilitate the 
repopulation of the BM after drug treatment. Bone marrow stroma protection 
of myeloma plasma cells in the presence of drugs has been frequently 
demonstrated in vitro. We were able to reliably demonstrate the effects on 




plasma cells in the presence of BM cells (HS5 BM fibroblastic cells and 
osteoclasts) with the help of the validated eGFP labelled plasma cell coculture 
system. In my experiments HS5 stromal cells protected myeloma cell lines 
from pro apoptotic effects of dexamethasone. But combination of dasatinib 
and dexamethasone was able to overcome these effects. This effect of 
dasatinib is not mediated through inhibition of stromal cell viability, but by 
inhibition of adhesion and secretion of IL-6. Both Dasatinib and 
dexamethasone or the combination does not induce apoptosis in HS5 stromal 
cells during short term cultures. This has clinical relevance as bone marrow 
stroma is required to support haematopoiesis to prevent toxicity in patients 
receiving therapy. I also found that Dexamethasone treatment enhanced the 
proliferation of mCherry-HS5 cells in the presence of eGFP-MM cells. This 
could be reversed by co-treatment of dexamethasone with dasatinib and 
correlated with sensitisation of MM cells to dexamethasone-induced 
apoptosis.  This can be explained by the dependence of proliferation of 
stromal cells on Src and c-Abl kinases 221,222.  
In this chapter, the effects of Dasatinib on both osteoclasts and SCs have 
been demonstrated. Dexamethasone promotes osteoclastogenesis and 
stromal cells are able to protect myeloma cells from apoptosis. Dasatinib 
overcomes these effects and in combination induces significant apoptosis in 
myeloma cell lines. Also by targeting adhesion of MM cells to SCs by 
Dasatinib and dexamethasone combination could decrease bone disease by 
interfering with the physical contact required to induce secretion of DKK1 and 
RANKL by SC leading to osteoclast activation. The effects of soluble and 
cellular components of the  microenvironment  on myeloma tumour cells is 




diverse 54. Drugs which have specific targets in the microenvironment are 
unlikely to have significant impact because the microenvironment will support 
early tumour regrowth. Multitargeted agents such as Dasatinib, with effects on 
plasma cell adhesion, osteoclastogenesis, overcoming stromal protection and 
sensitising myeloma plasma cells to dexamethasone, may offer hope to 

































8.0 Discussion and Future work 
MM remains an incurable disease with a relapsing remitting course until 
disease becomes resistant to all therapies. Intramedullary myeloma growth is 
closely linked to development of bone damage which is a key clinical feature 
leading to morbidity in this disease. In a majority of patients relapses occur 
with further evidence of new bone damage.  This also partly explains the 
improved survival observed in the myeloma IX trial in the cohort of patients 
randomised to receive Zoledronic acid an amino bisphosphonate which 
significantly inhibits osteoclastic activity.  
CAM-DR promotes resistance in myeloma and to study these processes 
better, in vitro models are required to recreate the in vivo setting. I have 
developed a new experimental model combined with the work of other people 
in the group (mCherry-HS5 cells). Using this model I demonstrated that 
fibroblastic stromal cells and OC protect MM cells against Dex and this can be 
overcome with Dasatinib. The data confirmed the importance of analysing 
both plasma cell proliferation and viability (apoptosis/necrosis) to fully 
determine the effect of drugs in coculture experiments. The data showed the 
protection against Dex when plasma cells were grown in coculture with OCs. 
In the presence of OCs, Dex still blocks MM cells proliferation but I was still 
able to detect a small viable population of cells which is not present when the 
cells are treated alone. It is quite likely that this viable population could 
emerge as a resistant clone and would continue to proliferate after drug 
withdrawal. 
My data indicates sensitisation of MM cells to Dexamethasone by Dasatinib in 
the presence of HS5 stromal cells was achieved through: a) inhibition of MM 




cell adhesion; b) inhibition of IL-6 secretion; c) synergy of the effect of Das 
and Dex to induce apoptosis in MM cells. This could be attributed to the role 
of Src family kinases in transduction of Dex-signalling. Inhibition of Lck 
enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in 
chronic lymphocytic leukemia223, d) Inhibition of Dexamethasone-induced 
fibroblastic stromal cell proliferation. Dexamethasone has been shown to 
induce stromal proliferation in prostatic and adipose tissues both in vitro and 
in vivo
221,224
. Activation of Src signalling underlies dexamethasone induced 
stromal cell proliferation. In the treatment of myeloma dexamethasone has 
been shown to be a useful adjunct in increasing responses to both IMiDs and 
Proteasomal inhibitors. Although direct anti myeloma effects are more 
pronounced by the addition of dexamethasone, potential niches of resistance 
can be simultaneously induced.   
 Addition of Dasatinib resulted in sensitisation of MM cells to Dexamethasone 
in the presence of OCs through inhibition of adhesion of MM cells. Dasatinib 
therapy could be effective in blocking MM bone disease as it inhibits bone 
resorption activity of mature OCs through disruption of the actin cytoskeleton. 
These data indicate that targeting the OC cytoskeleton is a possible strategy 
to block bone disease in MM. Mouse Knockouts of proteins involved in the 
organisation of the OC cytoskeleton such as Src itself, WASP and gelsolin 
results in alteration of osteoclast function in vivo114,225. Dasatinib also by 
inhibiting c-Src expression aids differentiation of mesenchymal stromal cells 
into osteoblasts resulting in bone formation226,227. Bortezomib is the only 
currently available agent which has shown this effect in myeloma patients in 
vivo52. 




I have also demonstrated that stromal cells have the capacity to induce 
proliferation of myeloma cells in coculture, which is not observed when 
myeloma cells are coculture with osteoclasts. Osteoclasts both autologous 
and allogeneic have been previously shown to enhance myeloma survival in 
cocultures 49. The observation of increased proliferation of myeloma cells in 
stromal cocultures could be due to presence of higher levels of IL-6 in these 
cocultures. 
This data suggest the combination of Dasatinib and dexamethasone would be 
synergistic in enhancing responses in myeloma patients. More recently a 
similar approach has been taken with use of plerixafor, a CXCR4 inhibitor 
which overcomes the protection from the stromal environment 95. A Phase I 
trial has been initiated with the combination of bortezomib and plerixafor in 
relapsed refractory myeloma patients.  
Myeloma patients continue to relapse despite previous response to therapy. It 
is currently thought that both intrinsic genetic changes in plasma cells and 
microenvironmental changes account for this. The potential interest in 
exploring this combination in myeloma patients is the little or no direct 
antimyeloma activity of Dasatinib in this combination136. This would be one of 
the first combinations with an anti-microenvironmental agent to be trialled in 
myeloma patients apart from plerixafor. As all MM patients would have 
previously been exposed to dexamethasone, it would be easier to observe 
synergistic in vivo combination of these two agents The prominent in vitro 
effect on osteoclasts is particularly advantageous in this combination as 
dexamethasone induces osteoporosis. As there are established frontline 
combinations in the treatment of myeloma inducing responses in the order of 




70 -80%, the role of this combination will be limited or more relevant in the 
relapsed refractory population, particularly in patients with active bone 
disease. Relapsed/ Refractory myeloma patients are heavily pre-treated and 
suffer from considerable comorbidities because of age and the disease per 
se. Although this is an oral combination they are not without significant side 
effects as shown in other trials. Higher doses of dexamethasone which will be 
relied upon as the anti MM agent has been shown to have adverse overall 
survival in this group of patients
228
. Dasatinib used in chronic myeloid 
leukaemia has also demonstrated manageable but some significant side 
effects in this group of patients 229.  A phase I/ II dose escalation study of 
Dasatinib with dexamethasone with escalating cohorts of Dasatinib would be 
the best design to explore this combination further. Based on the in vitro data 
patients with skeletal morbidity or with multiple skeletal plasmacytomas may 
benefit from this combination. This trial could also explore if drugs with strong 
anti micro environmental effect were added to treatment combination results 















1) Explore further combinations with dasatinib on the high throughput 
platform 
2) Little is known about the changes in the stromal cell compartment of 
myeloma patients. The in vitro model could be used to study the 
changes in the stromal cell compartment and osteoclasts, with drugs in 
myeloma patient samples. 
3) Intracellular pathways activated in adherent plasma cells on fibronectin 
and stromal cells. Using GEP and phosphoproteomics other key 
mediators in cell signalling pathways downstream of the integrin 
receptors could be identified and targeted.  
4) Dasatinib has been shown to reduce tumour load in SCID mouse 
models injected with myeloma cell lines. Profound changes in 
osteoclasts in presence of dasatinib were observed in vitro and 
reported in bone biopsies of CML patients on long term dasatinib. The 
in vivo effects on bone disease could be evaluated in C57/Bl KawlriJ 
syngeneic mouse myeloma model which develops bone disease within 
4 weeks after tumour injection160. 
5) Dasatinib is a standard therapy in chronic myeloid leukaemia patients. 
This would make it easier to develop a Phase I/II study to look at 
safety, tolerability of combination of dasatinib and dexamethasone in 
relapsed/ refractory myeloma patients. Tumour responses, toxicity and 
bone changes by PET activity and biochemistry would be the evaluable 
outcomes in this study. 
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